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ABSTRACT 
 Naproxen is a commonly used non-steroidal anti-inflammatory drug designed to 
relieve pain and inflammation. Due to potentially adverse effects on the gastrointestinal 
(GI) tract, cardiovascular and immune system, and renal function, naproxen may 
negatively affect thermoregulation, fluid and electrolyte balance, and performance during 
exercise, particularly in the heat. Therefore, the purpose of this study was to determine the 
effects of naproxen on core temperature (Tc), inflammation, hydration, GI distress, and 
performance during cycling in a hot environment. We utilized a double-blind, randomized 
and counterbalanced, cross-over design to determine the effects of naproxen (dose = 3 220 
mg naproxen sodium pills) or placebo (3 cellulose pills) on the dependent variables: Tc, 
interleukin-6 (IL-6), GI distress symptoms, fecal occult blood, plasma sodium and 
potassium concentration, plasma osmolality, urine osmolality, urine specific gravity, 
percent change in body mass, urine volume, fluid volume, heart rate, blood pressure, rate 
of perceived exertion, and distance during a 10 min time trial. Participants (n = 11, age = 
27.8 + 5.7 yrs, weight = 79.1 + 17.9 kg, and V̇O2max = 41.4 + 5.7 mL/kg) completed 4 
conditions: 1) placebo and ambient (Control); 2) naproxen and ambient (Npx); 3) placebo 
and heat (Heat); and 4) naproxen and heat (NpxHeat) separated by a minimum of 7 days. 
Dependent measures were taken pre-, during, post-, and 3 hrs post- a 90 min cycling 
protocol. We found no statistically significant differences between experimental conditions 
for any dependent variable. Exercise induced significant overall increases pre- to post- for 
Tc, IL-6, plasma potassium, heart rate, blood pressure, perceived exertion, and GI distress.
vi 
Compared to placebo, naproxen generally led to higher fluid intake and lower urine 
volume. Mean distance traveled was highest during Npx (3.3 + 0.8 miles) and lowest in 
NpxHeat (2.8 + 0.8 miles). Participants experienced greater GI distress during Heat, 
especially day post-exercise. During exercise, GI symptom occurred in 64% of trials. 
Interestingly, dizziness and headache were only reported during placebo conditions, with 
generally less systemic symptoms during exercise with naproxen use. In conclusion, our 
results do not support our hypotheses that naproxen would increase Tc, IL-6, and GI 
distress, alter fluid-electrolyte balance, and decrease performance compared to placebos. 
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CHAPTER 1 
OVERALL INTRODUCTION 
Intense exercise places strain on multiple physiological systems that work to 
maintain core temperature (Tc), cardiovascular function, and fluid and electrolyte balance. 
When these systems become less efficient, individuals present with signs and symptoms 
associated with health and performance decrements. For example, when the body fails to 
thermoregulate, Tc increases. If this increase occurs beyond a certain point, typically above 
40°C, cells begin to die and a systemic inflammatory response (SIR) can ensue, leading to 
organ failure and death.1,2 Therefore, when thermal stress is added to intense exercise the 
demand on these systems increases.  
Importantly, the thermoregulatory, cardiovascular, and fluid-electrolyte systems 
work concurrently to maintain homeostasis. Changes in these three systems often depend 
on exercise intensity. In general, the cardiovascular system responds by shunting blood, 
approximately 80%, away from the gastrointestinal (GI) organs to working muscles.3 As 
exercise continues, the cardiovascular system will maintain blood pressure (BP) and 
cardiac output by increasing heart rate (HR). At the same time, working muscles are 
producing a large amount of metabolic heat, which increases Tc. To mitigate this, blood is 
shunted to peripheral vessels to dissipate heat through the skin.3 If an individual maintains 
hydration the cardiovascular system is more capable of keeping up with the exercise and/or 
thermal demands. However, when dehydration occurs plasma volume decreases, which
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 stimulates the renin-angiotensin-aldosterone system to release hormones (ie, aldosterone 
and vasopressin) that act on the kidneys and blood vessels. In the kidneys, aldosterone 
causes sodium reabsorption. As a powerful cation, sodium causes water to be reabsorbed, 
subsequently increasing plasma volume and BP.4 In a similar way, vasopressin, also known 
as anti-diuretic hormone, causes kidneys to reabsorb water.3 Finally, blood continues to be 
shunted from non-working muscles and the GI through vasoconstriction, which assists in 
increasing BP.1 As long as the body’s systems can maintain function, an individual can 
continue exercise until he/she voluntarily stops. When one or more of these systems begin 
to fail the person either continues exercise while experiencing signs and symptoms (eg, 
headache, tachycardia, fatigue, abdominal cramping) or the person involuntarily stops 
exercise (eg, loss of consciousness, cardiac failure). 
Indications for thermoregulatory failure may present as an exertional heat illness 
(EHI), such as heat syncope, heat exhaustion, or, in extreme cases, heat stroke (EHS). 
Milder symptoms, typically seen with syncope or exhaustion, include lightheadedness, 
dizziness, fatigue, nausea, and headache.5 Cardiovascular failure often accompanies EHS. 
Individuals present with more serious symptoms, such as central nervous system 
dysfunction (ie, loss of consciousness, irritability, or irrational behavior), multi-organ 
failure, or death.5  
Fluid-electrolyte imbalances during intense exercise and thermal strain include 
hypohydration, hyperkalemia (plasma potassium > 5 mmol/L),6 and hyponatremia (plasma 
sodium concentration < 135 mmol/L).7 One big concern for hypohydration is how it affects 
the other systems. Symptoms for hypohydration vary on severity (mild to extreme 
hypohydration), and are similar to those of EHIs (ie, dizziness, headache, fatigue). 
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Hypohydration, as little as 2% body mass loss, can perpetuate Tc increase because of 
increased cardiovascular strain.8,9 Elevated plasma potassium during exercise primarily 
comes from working skeletal muscle releasing potassium.6 When systems are functioning 
appropriately, particularly the kidneys, potassium can be cleared from the blood before 
detrimental effects occur. This additionally supports the need to maintain hydration in order 
to maintain renal function, since hyperkalemia can lead to extreme cardiac failure (ie, 
stroke and heart attack).6 Sodium is essential for many physiological functions. When 
plasma sodium levels are depleted an individual may experience many of the same 
symptoms of hypohydration and EHIs (ie, headache, dizziness, weakness, and nausea). 
During severe hyponatremia, the excessive water intake and dramatic drop in sodium can 
lead to cerebral and pulmonary edema, central nervous system dysfunction, seizure, and 
death.7 The primary etiology for hyponatremia is consuming hypotonic fluids in excess of 
fluid lost through sweat and respiration. Hyponatremia can also be induced from 
inappropriate release of vasopressin, causing water retention and diluting sodium, or 
excessive sodium loss through sweat.7   
 Together, the cardiovascular, thermoregulatory, and fluid-electrolyte systems are 
critical in maintaining health and performance during activity and can be influenced by 
two other important systems – the GI and immune. Major effects on the GI during intense 
exercise include hypoxia from shunted blood, disruption in epithelial barrier integrity,10 
and direct damage from mechanical vibrations and increased abdominal pressure.11 These 
can upregulate immune responses and lead to SIR. As previously mentioned, SIR is seen 
during EHS. The similarities between the two has led to a closer examination of EHS 
etiology, going beyond the early theory of cells simply becoming “too hot”, to what now 
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some consider a dual model for developing EHS.1 This model is highly based on influences 
from both the immune system and GI tract. The first model suggests hyperthermia is caused 
by exercise in the heat and exacerbated by GI ischemia, inflammatory cytokine release, 
and endotoxin release. Exercise continues until the body is overloaded by endotoxin and 
pyrogenic cytokines, which cause cell necrosis, decreased plasma volume, fever, and 
eventually SIR and EHS.1 The second model suggests that regardless of environment, 
prolong intense exercise suppresses the immune system. The individual, exercising with a 
blunted immune response and/or subclinical infection, exercises but can no longer handle 
the demands to maintain cardiac function and Tc. Inflammatory responses drive endotoxin 
release from the GI and, like the first model, SIR and EHS can occur.1 This latter model 
helps explain why some individuals can experience EHS in cooler environmental 
temperatures12 or with Tc below 40.5°C.  
 Presumably, any factor that can perpetuate cardiovascular failure, thermoregulatory 
failure, fluid-electrolyte imbalance, or increase immune and GI responses can predispose 
an individual to developing EHI. There are a number of known intrinsic and extrinsic risk 
factors for EHS. Extrinsic variables (ie, equipment, clothing, rest breaks, nutrition, water 
access)5 are more easily controlled. On the other hand, intrinsic variables are more difficult 
to understand and may be unknown to the individual or healthcare professionals working 
with physically active individuals. For instance, previous or current illness can elicit an 
immune response causing subclinical fever and inflammation, which would decrease 
thermal tolerance.  
Some medications stimulate metabolic heat production or alter cardiovascular 
function and subsequently fluid-electrolyte balance.5 Non-steroidal anti-inflammatory 
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drugs (NSAIDs) are not currently considered a risk factor for EHS. This is primarily 
attributed to their association with being anti-pyretic and anti-inflammatory. Another 
reason is that existing literature results are conflicting. It is difficult to make conclusions 
because of the wide variety of NSAIDs available and the doses used. In theory and despite 
their anti-pyretic and anti-inflammatory affects, NSAIDs may be a risk factor due to the 
adverse effects they have on the GI epithelial lining, cardiovascular system, and renal 
function. Regardless of the type of NSAID, research has established they directly damage 
the GI, causing ulcers, hemorrhaging, and increased barrier permeability.13,14 
Gastrointestinal damage causes an inflammatory response, upregulating cytokine release.15 
NSAIDs promote vasoconstriction in both the kidneys and peripheral blood vessels. Renal 
vasoconstriction decreases urine volume by retaining fluid, which dilutes plasma sodium. 
Peripheral vasoconstriction decreases the effectiveness to eliminate metabolic heat 
production, increasing Tc. Finally, both vasoconstriction and fluid retention increase 
BP.7,16 It can be presumed, through these adverse effects, NSAIDs have several pathways 
to promote either model of EHS.  
 The little research available and conflicting results makes it difficult to determine 
whether NSAIDs are risk factors for EHS. Some studies have found NSAIDs have no effect 
on Tc during exercise,17,18 while others have found they increase Tc.19 No research has 
examined naproxen’s effects on Tc. Presently very little research on NSAIDs using both 
males and females and comparing ambient and hot conditions exists. The purpose of this 
study was to contribute to the body of literature in this area by examining naproxen on 
thermoregulation, cardiovascular function, and fluid-electrolyte balance during exercise. 
Identifying and understanding potential risk factors for EHS may increase awareness and 
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improve prevention techniques for physically active persons and those working with these 
individuals 
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CHAPTER 2 
NAPROXEN EFFECTS ON CORE TEMPERATURE AND INFLAMMATION DURING EXERCISE IN 
THE HEAT1 
1Dawn M. Emerson, J. Mark Davis, Toni M. Torres-McGehee, Stephen CL Chen, J. 
Larry Durstine, Justin V. Stone, Joseph D. Bivona, Charles C. Emerson, Craig E. 
Pfeifer. To be submitted to Med Sci Sports Exerc. 
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ABSTRACT 
Purpose: Existing literature regarding non-steroidal anti-inflammatory drugs (NSAIDs) 
on core temperature (Tc) during exercise is limited and conflicting. Our aim was to 
determine the effects of naproxen, a common NSAID, on Tc and interleukin-6 (IL-6) in 
hydrated, exercising humans. Methods: We utilized a double-blind, randomized and 
counterbalanced, cross-over design to determine effects of a 24 hr naproxen dose (220 mg 
naproxen/dose) and placebo (0 mg naproxen/dose) on Tc and IL-6 during cycling in a hot 
or ambient environment. Participants (n = 11; 6 male, 5 female) completed 4 conditions: 
1) placebo and ambient (Control); 2) placebo and heat (Heat); 3) naproxen and ambient 
(Npx); and 4) naproxen and heat (NpxHeat). Participants cycled for 90 min then rested 3 
hrs in an ambient environment. Throughout exercise, participants drank water (3.5 ml/kg) 
every 15 min to maintain euhydration. Dependent measures were taken pre-, during, post- 
and 3 hrs post-cycling. Results: Overall Tc significantly increased pre- to post-cycling 
(37.1 + 0.4°C to 38.2 + 0.3°C, P < 0.001) and decreased during rest (P < 0.001), but neither 
rate of change or maximum Tc were significantly different between conditions. IL-6 
increased pre- to post-exercise (0.54 + 0.06 pg/ml to 2.46 + 0.28 pg/ml, P < 0.001), and 
remained significantly higher than pre- at 3 hrs post- (1.17 + 0.14 pg/ml, P = 0.001). No 
significant IL-6 differences were found between conditions. Conclusion: A 24 hr dose of 
over the counter strength naproxen did not significantly affect Tc or IL-6 among hydrated 
males and females cycling in hot and ambient conditions. Key Words: cytokine, exertional 
heat illness, NSAIDs, thermoregulation  
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INTRODUCTION 
Intense physical activity and/or thermal stress is known to induce gastrointestinal 
(GI) damage and a number of inflammatory responses.(8) Damage to the GI epithelial 
barrier lining increases GI permeability and causes inflammatory cytokine release.(6,8) 
Maintaining GI barrier integrity mitigates potentially toxic products, such as bacterial 
lipopolysaccharide (ie, endotoxin), from moving from the gut into blood circulation. When 
integrity is compromised these products can enter the blood and cause severe conditions, 
such as endotoxemia and systemic inflammatory response (SIR).(8)  
Symptoms associated with SIR are similar to those seen with exertional heat illness 
(EHI), particularly exertional heat stroke (EHS). For example, both EHS and SIR can 
present with vomiting, dehydration, cell necrosis, cardiovascular compromise, and multi-
organ failure.(7,8) Additionally, both conditions can be driven by GI distress or 
compromised immune function. An individual exercising with an underlying inflammatory 
response is at greater risk for EHI due to thermal intolerance.(8) 
Exertional heat stroke is identified by two key characteristics: 1) a Tc > 40.5°C and 
2) altered central nervous system function.(3) It is important to note that 40.5°C is not a 
“golden number”. It remains elusive why some individuals can participate in intense 
activity with Tc above 40.5°C without developing EHS, and other individuals experience 
EHS below this temperature. Extensive scientific literature has examined risk factors,(1,5) 
ways to prevent,(2,3) and ways to treat EHS.(4,9) However, preventable EHS deaths still 
occur. Individual variability among EHS cases suggests there are a number of less 
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understood intrinsic factors. Additional extrinsic variables, such as non-steroidal anti-
inflammatory drugs (NSAIDs), may also play a role. 
NSAIDs reduce fever, inflammation, and pain by inhibiting cyclooxygenase (COX) 
derived prostaglandins (PGs) that induce these responses. However, NSAIDs are also 
associated with a number of adverse effects on the GI and immune systems. These adverse 
events are closely associated with developing SIR and EHIs. Like intense exercise and 
thermal stress, NSAIDs increase GI permeability,(12,13,25) cause GI distress(6,14) and 
induce inflammatory cytokines.(17,28,32) Despite these similarities, limited research has 
evaluated NSAID effects on Tc during exercise, particularly during thermal stress. Older 
studies found sodium salicylate(11) and aspirin(7) had no effect on Tc compared to 
placebos. However, a more recent investigation using aspirin showed significant Tc 
increases due to blunted skin blood flow.(4) Our study sought to determine acute dose 
effects of a commonly used over the counter NSAID, naproxen, on Tc and the 
inflammatory cytokine interleukin-6 (IL-6). We hypothesized naproxen would increase Tc 
and plasma IL-6 levels significantly during exercise in the heat compared to placebo 
controls. 
METHODS 
Participants 
Eleven moderately trained, healthy, non-heat acclimatized participants (6 male, 5 
female) were recruited from the university and surrounding community to complete this 
study. Participant demographical information is presented in Table 2.1. Prior to 
participation, participants read and signed an Institutional Review Board approved 
informed consent form (Appendix A). Inclusion criteria was determined by a health and 
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injury history questionnaire (Appendix B) and V̇O2max test (Appendix E.2). Participants 
were free from cardiovascular, respiratory, and metabolic disorders; musculoskeletal 
disorders preventing cycling exercise; fluid and electrolyte balance disorders; and GI and 
swallowing disorders. Participants were also asked about current over the counter and 
prescription medication use to ensure no potentially harmful interactions. Any participant 
currently taking analgesic or anti-inflammatory medication was asked to cease the 
medication for the study duration. Participants were asked about previous EHI history, but 
this was not an exclusion criteria. Lastly, females completed questions regarding menstrual 
cycle. Participants completed a graded cycling V̇O2max test to ensure they were moderately 
trained (male V̇O2max between 35-40 mL/kg and female V̇O2max between 32-40 
mL/kg).(21)  
Experimental Conditions 
Four experimental conditions were completed in a randomized, counter-balanced 
order. A minimum of 7 days separated each trial. Prior to beginning exercise, participants 
took a 24 hr dose (3 capsules) of placebo or naproxen. Participants consumed 1 capsule at 
16 hrs, 8 hrs, and 0 hrs before data collection. All participants were given specific take 
home instructions to follow 24 hrs prior to data collection, including directions for taking 
each capsule with 1 8oz glass of water and not with food. All trials took place in an 
environmental chamber (hot = 35.7 + 1.3°C, 53.2 + 3.2% relative humidity [RH]) or 
laboratory (ambient = 22.7 + 1.8°C, 52.4 + 5.5% RH).  
Control. Participants in the Control condition were given 3 placebo capsules 
(cellulose) and exercised in an ambient environment.  
13 
 
Naproxen (Npx). Participants in the Npx condition were given 3 naproxen capsules 
(220 mg naproxen sodium/dose) and exercised in a hot environment. 
Placebo and Heat (Heat). Participants in the Heat condition were given 3 placebo 
capsules (cellulose) and exercised in a hot environment. 
Naproxen and Heat (NpxHeat). Participants in the NpxHeat condition were given 
3 naproxen capsules (220 mg naproxen sodium/dose) and exercised in a hot environment.  
Instruments and Protocols 
Anthropometric Measures. Weight and body fat percentage was measured using 
a bioelectrical impedance analysis scale (Tanita SC-331S Body Composition Monitor, 
Tanita Co., Tokyo, Japan). Height was self-reported. 
Health and Injury History Questionnaire (Appendix B). Details in Chapter 3. 
Cycle Exercise Protocol. Participants completed a 90 min cycle protocol on a 
stationary bike (Monark Ergomedic 828E, Monark Exercise AB, Vansbro, Sweden). 
Before starting a 3 min warm-up, participants were provided their target heart rate (HR) 
corresponding to 70% V̇O2max to maintain during 80 min of cycling.(29) Heart rate was 
monitored using Polar HR monitors (Polar Electro Inc., Lake Success, NY). Monitors were 
within the participant’s visual and researchers provided verbal cues to assist participants in 
maintaining HR throughout. Following 80 min, participants cycled 10 min at maximum 
effort. Research assistants gave each participant verbal encouragement. The exercise 
protocol ended with a 5 min cool down. 
  Inflammatory Cytokines. We collected blood from a cubital vein pre-, post-, and 
3 hrs post-exercise. Two 6 ml vials were collected into a vacutainer tube and inverted 
several times to mix. We assessed IL-6 using enzyme linked immunosorbent assay high 
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sensitivity kits (R&D Systems human IL-6 Quantikine ELISA kit, R&D Systems, Inc., 
Minneapolis, MN). 
Core Temperature. Core temperature was measured using rectal thermometry 
(Doric 450 Series digital thermometer, VAS Engineering, Inc., San Diego, CA). 
Participants were instructed to insert the probe 10 cm past the anal sphincter. During 
exercise, Tc was continuously monitored and recorded every 5 min. Participants were not 
allowed to exceed a Tc > 40°C. During the 3 hr rest period, Tc was recorded at 5 and 10 
min post-exercise, then every 15 min until the participant reached baseline (pre-exercise 
Tc) or the rest period concluded.  
Hydration. Participants were required to be euhydrated prior to beginning exercise. 
To maintain hydration during exercise, participants were provided 3.5 ml/kg of water to 
consume every 15 minutes. Hydration status was measured using urine specific gravity 
(Usg) by a handheld clinical refractometer (model REF 312, Atago Company Ltd., Tokyo, 
Japan). Euhydration was defined as Usg < 1.020.(26) A clean catch method was used in 
which the participant was instructed to urinate a small amount before placing the specimen 
cup in midstream to collect a minimum of 1 ounce of urine. Hydration measures were taken 
pre-, post-, and 3 hrs post-exercise. 
Diet and Activity Logs. To control for pre-data collection dietary and physical 
activity influences, participants were asked to track diet and physical activity for 3 days 
prior and 1 day after data collection using an online nutrition software FoodProdigyTM 
(ESHA Research, Salem, OR). Participants were encouraged to maintain similar diet and 
physical activity habits during the 24 hrs prior to each data collection session.  
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Experimental Procedures  
Information Session. After all inclusion criteria were met, participants were 
randomly assigned to experimental conditions by a research assistant. Participants, primary 
investigators, and primary research assistants were blinded to which condition (naproxen 
or placebo) participants were completing. Participants were familiarized with the online 
diet and activity log. The V̇O2max test was used to familiarize participants with the 
stationary cycle. Seat and handle bar position were noted to maintain consistency 
throughout trials.  
Pre-Data Collection. Seventy-two hrs prior to data collection, participants were 
sent an email with instructions for completing the diet and physical activity log. Logs 
included the 72 hrs before and 24 hrs after data collection. Participants were also instructed 
to refrain from intense, vigorous exercise for 48 hrs pre-trial.(22) Twenty-four hrs prior, 
participants received written take-home instructions and information was reviewed 
verbally by a research assistant. Instructions included when to take 2 capsules (placebo or 
naproxen), refrain from consuming alcohol and exercising, and to maintain normal sleep 
behaviors. Participants were also instructed to consume fluids, such as water, to ensure 
euhydration upon arriving for data collection. Lastly, participants were instructed to 
consume a small meal at least 2 hrs before arriving to ensure no food was in the stomach.  
Data Collection Session. Once at the laboratory, participants were verbally asked 
if they took the 2 pills before taking the 3rd pill. Baseline HR, Tc, and Usg were measured 
prior to blood collection. During the 90 min cycling, participants consumed water every 15 
min, and researchers continuously monitored Tc and HR. At the conclusion of the 10 min 
maximum effort, participants cooled down on the bike for 5 min. Participants then rested 
16 
 
for 5 min where post-blood was collected. Participants provided a urine sample for 
hydration assessment. During the 3 hr rest period, participants sat in a semi-reclined/seated 
position in an ambient environment (23°C and 56% RH). Each participant received a 
standardized non-sucrose snack based on individual weight and were allowed to consume 
water ad libitum. Throughout the rest, Tc was recorded every 15 min. Blood and urine 
measures were collected at the rest conclusion. Before leaving, take home instructions were 
reviewed with the participant regarding the 1 day post diet and activity log.  
Statistical Analysis 
IBM SPSS Statistics (version XXII; IBM Corporation, Armonk, NY) was used for 
all analyses. Descriptive statistics (mean and standard deviations) for all dependent 
variables were calculated. A one-way ANOVA assessed differences in demographics 
between conditions and gender (eg, age, height, weight, body fat %). Changes in Tc were 
assessed using regression models and two repeated measures ANOVAs: 1) 4 (condition) x 
20 (cycling) and 2) 4 (condition) x 9 (rest). A 4 (condition) x 3 (time) repeated measures 
ANOVA was used to determine differences in pre-, post-, and 3 hr post-cycling IL-6 and 
Usg. The same repeated measures ANOVAs were conducted to determine differences in 
Tc and IL-6 between conditions within genders. Differences for overall Tc between 
genders was assessed using 2 (gender) x 20 (cycling) and 9 (rest) repeated measures 
ANOVAs. A 2 (gender) x 3 (time) repeated measures ANOVA determined differences in 
IL-6. Assumptions of sphericity were verified to determine whether variance in the 
differences within experimental conditions were equal or significantly different. 
Greenhouse-Geisser corrections were used for Tc and IL-6 when sphericity was violated. 
Post hoc analysis was conducted on significant main effects with Bonferroni corrections. 
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Power calculations were conducted a priori using standard deviations for Tc and IL-6. A 
sample size of 8 was necessary to achieve a statistical power of 0.8. Our participant number 
(n =11) is consistent with previously published research.(9,11,12,25,29) Significance level 
was set at P < 0.05 for all analyses.  
RESULTS 
Sixteen participants began the study. Two participants dropped due to the intensity 
of the study and 3 dropped due to the time commitment, yielding 11 participants. We 
identified significant gender differences for height and body fat % (Table 2.1), but no other 
demographical measures were significantly different. Five of 6 female participants used 
oral contraceptives. Only one participant reported a previous history of EHI. All 
participants began experimental trials euhydrated (Usg = 1.012 + 0.005) and remained 
euhydrated to post- (Usg = 1.011 + 0.008) and 3 hr post-exercise (Usg = 1.007 + 0.006). 
No significant Usg differences existed between experimental conditions at any time point. 
Dietary analysis revealed no significant differences in calorie, carbohydrate, protein, 
sodium, or fat intake between conditions. Physical activity level 24 hrs before remained 
low to sedentary and was not significantly different between conditions. 
Core Temperature 
Figure 2.1 shows Tc changes throughout exercise and rest for each experimental 
condition. Overall, Tc significantly increased from pre- (37.1 + 0.4°C) to post-exercise 
(38.2 + 0.3°C, P < 0.001). During rest, Tc significantly decreased over time (P < 0.001) 
and reached pre-exercise by 75 min post-exercise. Starting at 60 min cycling, mean Tc was 
higher in heat trials compared to ambient (Figure 2.1) and remained higher throughout rest. 
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However, there were no statistically significant Tc differences between experimental 
conditions at any time point. 
 Figures 2.2.a-d illustrate individual participants’ Tc, overall mean, and regression 
statistics for each condition during exercise. During Control and Npx, Tc increased 
curvilinear during cycling, with a cubic regression model providing the best fit. Both Heat 
and NpxHeat followed a linear model with no difference in slope between conditions. 
Similar results were found for Tc during rest, with a curvilinear, cubic model providing the 
best fit for all conditions and no difference in slope between conditions. 
Regarding gender, a significant main effect was found for Tc change over time 
within males (P < 0.003) and females (P < 0.001). For males we found no significant Tc 
differences between conditions (Appendix F, Figure F.1); however, the main effect for Tc 
and condition during exercise approached significance (P = 0.075). Within females there 
was no significant differences between conditions at any time point (Appendix F, Figure 
F.2). When combined (Appendix F, Figure F.3.), pre-exercise mean female Tc was 
significantly higher (37.3 + 0.3°C) than males (37.0 + 0.4°C, P = 0.02). During cycling, 
females stayed significantly higher until 15 min. During rest, male Tc was significantly 
higher at 10 min post-cycling (38.3 + 0.5°C versus 38.0 + 0.4°C, P < 0.02). Females were 
significantly higher again at 75 post-cycling (37.3 + 0.3°C versus 37.1 + 0.4°C, P = 0.006) 
and remained higher until the end of rest (37.3 + 0.2°C versus 36.8 + 0.3°C, P < 0.001).  
Cytokines 
 Differences in IL-6 between pre-, post-, and 3 hrs post-exercise are presented in 
Figure 2.3. No significant differences were found between conditions at any time point. A 
significant change in mean IL-6 occurred over time (P < 0.001), with post-exercise IL-6 
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significantly higher than pre- and 3hrs post- for all conditions. At 3 hrs post-exercise, both 
Npx (1.06 + 0.73 pg/ml) and Heat (0.97 + 0.49 pg/ml) were significantly higher compared 
to pre- (Npx and Heat mean = 0.44 + 0.29 pg/ml, P < 0.04). 
 A significant main effect for IL-6 was found across time for gender (P = 0.001). 
Additional analysis found no significant difference between genders at any time point 
between conditions. Within males (Appendix F, Figure F.4) there was a significant main 
effect over time within each condition (P < 0.04). Post hoc analysis showed only Heat and 
NpxHeat were significantly greater post-exercise compared to pre-. No other significant 
differences were found for males. Significant main effects were found within Control and 
Npx for females (Appendix F, Figure F.5). Post-exercise IL-6 was significantly greater 
than pre- in the Npx condition. Though not statistically significant, mean post-exercise IL-
6 during NpxHeat was higher than all other conditions and remained elevated 3 hrs post-
exercise.  
DISCUSSION 
Due to anti-pyretic effects, NSAIDs have been theorized to decrease or blunt Tc 
rise during exercise. However, existing literature has been unable to find NSAIDs elicit 
this effect, instead finding they cause no change(7,11) or may increase Tc.(4) Our study 
sought to determine whether a 24 hr over the counter dose of naproxen would negatively 
affect thermoregulation and inflammation during moderate-intense cycling. Compared to 
a placebo, our results indicated naproxen did not significantly affect Tc or IL-6 in either an 
ambient or hot environment. These results are consistent with males walking in a hot 
environment using 7.8 g sodium salicylate(11) and in ambient conditions using aspirin 
acutely (1½ hrs pre-exercise) or chronically (daily doses for 2 and 7 days).(7) Sodium 
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salicylate is generally considered less effective than aspirin at inhibiting PGs and is not 
known for its antipyretic effects.(2) Therefore, it is not surprising taking sodium salicylate 
would not elicit significant Tc changes.  
Lack of significance in max Tc and rate of Tc increase between conditions may be 
attributed to our dosage. Using low dose aspirin (81 mg daily for 7 days) in older males 
and females who rested and then cycled 2 hrs at 60% V̇O2max significantly increased Tc 
after resting 30 min in a hot environment and remained significantly higher throughout 
exercise.(4) The mechanism for Tc increase is attributed to peripheral vasoconstriction,(4) 
which prevents temperature dissipation. This mechanism is understandable considering 
aspirin’s efficacy on the cardiovascular system, effectively reducing cardiac events (ie, 
stroke and heart attack).(18) Compared to aspirin, naproxen has greater selectivity toward 
COX 2, making naproxen highly effective at reducing pain and inflammation.(3) Unlike 
aspirin, naproxen reversibly inhibits platelet aggregation,(1) making naproxen less 
effective at reducing cardiac events. Because we did not measure skin blood flow we are 
unable to make a definitive statement whether naproxen elicited any effect through 
vasoconstriction, but based on our lack of Tc differences, we find it unlikely our naproxen 
dosage caused changes in skin blood flow. With higher dosages (ie, prescription strength) 
or longer use (ie, 7 days) the possibility exists that we would see similar responses as 
Bruning et al.(4)  
The significant increase in IL-6 pre- to post-exercise in our study was expected and 
similar to other moderate-intense cycling.(31) Like Tc, we found naproxen did not 
significantly affect IL-6. These results are consistent with other studies showing neither a 
1000 mg aspirin (20) or 400 mg ibuprofen(27) dose significantly increased plasma 
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inflammatory cytokine concentrations. Aspirin is more selective toward COX 1 than 2, 
meaning aspirin is less effective at relieving inflammation.(18) Considered equipotent 
against COX 1 and 2, results on ibuprofen’s effects on exercise driven inflammation is 
contradictory; though, dosage plays an important role. While 400 mg 2 hrs prior to ultra-
distance running made no difference in IL-6(27), 600 mg the afternoon prior and 1200 mg 
on the day of a ultra-distance race significantly increased post-race IL-6 compared to 
controls.(17) The 3 220 mg naproxen doses over 24 hrs prior to exercise in our study did 
not significantly increase or decrease IL-6 compared to placebos. If dosing was extended 
across multiple days there may be significant effects. 
Controlled laboratory exercise studies often do not measure NSAIDs, Tc, and 
inflammation together, and even fewer field studies are available. Among a group of ultra-
marathon runners (n = 19), 6 participants reported using NSAIDs or other anti-
inflammatory supplements (ie, fish oil).(10) Researchers found no correlation with NSAID 
use and IL-6. The researchers determined there was no effect on Tc; however, temperature 
was assessed aurally.(10) Aural temperature is known to be an inaccurate Tc assessment 
in exercising individuals.(5) The reported post-race temperatures (37.0 + 0.3°C)(10) may 
not have accurately reflected individuals’ Tc when one considers a person’s normal 
baseline Tc (37°C + 1°C)(16) and the environmental race conditions (30-40°C and 31-40% 
RH).(10)  
Individual Variability 
Knowing a number of factors play a role in thermoregulation during exercise, we 
attempted to control nutrition, hydration, medication, physical activity, clothing, and 
illness. Furthermore, our study participants were non-heat acclimatized and moderately 
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endurance trained. Despite our attempts, a number of factors cannot be controlled and 
explain some individual variability in existing EHS literature and in our results, particularly 
when examining genders.  
Though not statistically significant, the IL-6 increase in our male participants was 
greater than females. Also, these concentrations tended to stay elevated at 3 hrs post-
exercise. Lack of statistical significance likely comes from the large standard deviations 
post-exercise among males in all conditions. Timmons et al.(31) compared immune 
responses in males to females during different menstrual phases using and not using oral 
contraception. Result indicated no significant differences in IL-6 levels from pre- to post-
cycling.(31) Skeletal muscle contraction during exercise produces a high amount of IL-6, 
which increases plasma IL-6.(30) Our male participants did not weigh significantly more 
than females, but males had greater muscle mass, as indicated by their significantly lower 
body fat %. The higher mean IL-6 and large variations in male participants could be caused 
by muscle induced IL-6. Within the males, IL-6 means were lower post-exercise with 
naproxen, suggesting there may have been some effects, but this did not continue at 3 hrs. 
We identified some overall Tc differences. Both male and female Tc averaged 
38.2°C immediately post-cycling, but males continued to increase during the 5 min cool 
down, reaching 38.4°C and remaining significantly higher 10 min post-cycling. This 
elevation may be explained by a higher metabolic heat production,(8) less body fat and 
slightly higher V̇O2max. Female pre- and 3 hr post-exercise Tc was significantly higher than 
males. This is likely due to the naturally higher Tc during the luteal phase (~ 0.3°C 
higher).(23) We did not control for menstrual cycle, but we did not find significant 
differences in resting Tc based on the individual’s phase (follicular or luteal). Oral 
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contraceptives increase Tc during moderate-intense exercise in the heat(15) similar to that 
seen in non-oral contraceptive users. In our one participant who did not use birth control, 
we found during the luteal phase, which happened to be when she completed NpxHeat, she 
experienced her highest post-exercise Tc and IL-6. This was not found during the luteal 
phase in any other female participant. Further, this individual was the one participant who 
reported a previous EHI and had the highest body fat % and lowest V̇O2max among females. 
Another interesting consideration for individual confounding risk factors is in our 
failed trials. A female participant attempting to complete the NpxHeat trial began 
experiencing hypotension and reported severe nausea. Researchers ceased her trial for 
safety reasons. Though her pre-trial measures were within normal limits, upon inquiry, the 
participant reported previous GI illness within a few days of the trial and feeling tired. One 
male participant was unable to begin a data collection trial due to extreme GI symptoms 
and illness after initiating the naproxen. The individual withdrew after a later trial due to 
the intensity of the study. These two examples support the need to use a multifaceted 
approach to recognize and monitor individuals at-risk for adverse events. Additionally, it 
is important to inquire about NSAID use in persons who may present with signs and 
symptoms before or during exercise. 
Limitations and Future Research 
The primary limitation to this study was using a constant HR during 80 min of 
cycling rather than using the work rate corresponding to 70% V̇O2max. The purpose of a 
constant HR was to allow us to better determine the direct effects of naproxen on dependent 
measures. If work rate had been used we would expect an increased cardiovascular strain, 
particularly in the heat, which could increase Tc. However, by using a constant HR, the 
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cycling intensity during heat trials was inherently less than ambient due to cardiovascular 
alterations (increased HR and BP) in response to thermal stress. With the available data, 
we are unable to identify specific work rate differences between heat and ambient trials 
during the 80 min. We acknowledge using constant HR likely limited us from finding 
significant differences between experimental conditions. Additionally, we could have 
measured oxygen consumption to better control for work rate during each trial. Many 
exercise bouts are completed at a set intensity rather than focusing on a target HR; however, 
our results are useful for individuals who may use a set HR to pace themselves during 
endurance exercise and then “go all-out” at the finish.  Our second limitation is only 
measuring IL-6, which is a prominent pro-inflammatory cytokine that increases early 
during immune responses. Another prominent pro-inflammatory cytokine, tumor necrosis 
factor-alpha increases several hours after exercise.(19) Examining this cytokine at 3 hrs 
post-cycling and day-post would provide a better idea of naproxen’s effects. Third, diet 
and physical activity logs indicated participants followed pre-data collection guidelines for 
physical activity and nutrition. We assume participants were honest with following 
guidelines and completing the logs.  
Future research should examine naproxen and other non-aspirin NSAIDs in higher 
doses, particularly looking at prescription strength and/or long-term use (ie, 7 days, 14 
days, etc.). Research is warranted in hot environments using greater cycling intensity and 
other exercise modes. Running is known to add strain on the GI tract,(24) which may 
exacerbate responses. Field studies should be conducted in both long distance cycling and 
running, as well as field sports where there is alternating high intensity activity and rest 
periods. Considering GI barrier integrity and inflammation driven SIR closely resembles 
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models for EHS, research should examine plasma endotoxin concentration and GI 
permeability related to NSAID use and exercise. We also suggest additional research on 
potential gender differences. Examining females using and not using oral contraception is 
warranted as well as during different menstrual phases. Studies in individuals with 
musculoskeletal injuries or conditions potentially compromising the immune system are 
pertinent. Finally, future research is needed regarding confounding risk factors, such as 
sleep deprivation, nutrition, and especially hypohydration. Hypohydration places 
additional strain on the cardiovascular and thermoregulatory systems, which, if combined 
with NSAID effects, could promote Tc increase. 
Conclusion 
 Our results suggest hydrated males and females completing moderate-intense 
exercise in either ambient or hot environments taking a 24 hr naproxen dose do not 
experience increased Tc or IL-6. These results are important for both physically active 
individuals and those working with persons who may be taking naproxen. While we did 
not find negative impacts on thermoregulation or inflammation, we encourage individuals 
to be aware of the potential adverse effects that NSAID may have on the GI tract that could 
perpetuate thermal intolerance during exercise. This understanding is especially vital in 
individuals with other confounding risk factors (eg, previous illness, sleep deprivation, 
repeated intense exercise bouts, hypohydration, etc.). 
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Table 2.1. Participant Demographics (M + SD) 
 Aggregate 
(N = 11) 
Male 
(N = 6) 
Female 
(N = 5) 
Age (yrs) 27.8 + 5.7 28.7 + 5.3 26.8 + 6.5 
Weight (kg) 79.1 + 17.9 88.4 + 14.0 67.9 + 16.5 
Height (cm) 177.0 + 9.5 183.2 + 5.3 169.5 + 7.8a 
Body fat (%) 15.2 + 8.3 10.7 + 4.0 20.6 + 9.1a 
V̇O2max (mL/kg) 41.4 + 5.7 43.6 + 5.3 38.7 + 5.3 
aSignificantly different between genders (P < 0.04) 
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Figure 2.1. Mean Core Temperature during Cycling and Rest for Experimental Conditions 
Significant change in Tc during exercise (F1.7,67.3 = 150.5, P < 0.001) and rest (F2.0,81.5 = 201.6, P < 0.001)
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Figure 2.2.a. Regression and Participant Core Temperature during Cycling. 
Bold line represents mean Tc for condition. Shaded area indicates 10 min cycling at maximum effort. Final 5 
min is an active cool down. Cubic regression equation: ŷ = 0.03x + 37.3; r2 = 0.59; 95% CI = 37.1, 37.5; P = 
0.001. 
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Figure 2.2.b. Regression and Participant Core Temperature during Cycling. 
Bold line represents mean Tc for condition. Shaded area indicates 10 min cycling at maximum effort. Final 5 
min is an active cool down. Cubic regression equation: ŷ = 0.02x + 37.4; r2 = 0.58; 95% CI =37.2, 37.6; P = 
0.002. 
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Figure 2.2.c. Regression and Participant Core Temperature during Cycling. 
Bold line represents mean Tc for condition. Shaded area indicates 10 min cycling at maximum effort. Final 5 
min is an active cool down. Linear regression equation: ŷ = 0.01x + 37.4; r2 = 0.54; 95% CI =37.2, 37.6; P < 
0.001. 
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Figure 2.2.d. Regression and Participant Core Temperature during Cycling. 
Bold line represents mean Tc for condition. Shaded area indicates 10 min cycling at maximum effort. Final 5 
min is an active cool down. Linear regression equation: ŷ = 0.01x + 37.4; r2 = 0.56; 95% CI =37.2, 37.6; P < 
0.001.
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Figure 2.3. Mean IL-6 Pre-, Post-, and 3 Hrs Post-Cycling for Experimental Conditions 
N = 7. Significant change over time (F2, 48 = 41.8, P < 0.001). aSignificantly higher than pre- within condition (P < 
0.04). bSignificantly lower than post- within condition (P < 0.04). 
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CHAPTER 3 
NAPROXEN EFFECTS ON HYDRATION AND ELECTROLYTE MEASURES DURING CYCLING IN 
THE HEAT1 
1Dawn M. Emerson, Toni M. Torres-McGehee, Stephen CL Chen, J. Larry Durstine, J. 
Mark Davis, Craig E. Pfeifer, Charles C. Emerson, Justin V. Stone, Joseph D. Bivona. 
To be submitted to J Athl Train. 
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ABSTRACT 
Context: Non-steroidal anti-inflammatory drugs (NSAIDs) can cause a number of adverse 
effects, including impaired fluid-electrolyte balance. There is a lack of controlled 
laboratory studies examining NSAID effects on fluid and electrolyte regulation during 
exercise. 
Objective: To examine the effects of naproxen, a commonly used NSAID, on hydration 
and electrolyte measures in hydrated humans cycling in a hot environment.  
Design: Double-blind, randomized and counterbalanced, cross-over design. 
Setting: Laboratory. 
Patients or Other Participants: A total of 11 moderately endurance trained volunteers (6 
male and 5 female; age = 27.8 + 6.5 yrs, weight = 79.1 + 17.9 kg, height = 177 + 9.5 cm, 
V̇O2max = 41.4 + 5.7 mL/kg) completed this study. 
Intervention(s): Participants were randomly assigned to complete 4 trials: 1) placebo and 
ambient (Control); 2) placebo and heat (Heat); 3) naproxen and ambient (Npx); and 4) 
naproxen and heat (NpxHeat). 
Main Outcome Measure(s): Hydration (plasma osmolality, urine osmolality, urine 
specific gravity, and body mass change), electrolyte (plasma sodium and plasma potassium 
concentration), and cardiovascular (heart rate and blood pressures) measures were taken 
pre-, post- and 3 hrs post-90 min cycling. We also measured fluid volume (Fvol) and urine 
volume (Uvol).  
Results: We found no statistically significant differences between experimental conditions 
for hydration, electrolyte, or cardiovascular measures. All participants began hydrated and 
became more hydrated throughout trials. Mean aggregate plasma sodium was < 135 
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mmol/L at pre-, post-, and 3 hrs post-exercise, but did not significantly decrease over time. 
Overall plasma potassium significantly increased pre- to post-exercise (P = 0.02). Though 
not statistically significant, mean Fvol was greater and Uvol lower during naproxen trials 
compared to placebos.   
Conclusion: A 24 hr naproxen dose did not significantly alter hydration or electrolyte 
measures during 90 min cycling in either ambient or hot conditions. The trend for naproxen 
to increase Fvol and decrease Uvol suggests the start of fluid retention, which should be a 
concern for individuals at risk for hyponatremia or with pre-existing cardiovascular 
conditions (ie, hypertension). 
Key Words: NSAID, urine specific gravity, plasma osmolality, plasma sodium, urine 
osmolality 
INTRODUCTION 
 Non-steroidal anti-inflammatory drugs (NSAIDs) include a variety of prescription and 
non-prescription medications including aspirin, ibuprofen, indomethacin, and naproxen. 
An individual drug’s effectiveness and side effects are dependent on its chemical makeup 
and selectivity toward inhibiting cyclooxygenase (COX). In general, all NSAIDs work to 
relieve pain and inflammation by preventing COX from catalyzing the conversion of 
arachidonic acid (a fatty acid released from cell membranes during injury/inflammation) 
to prostaglandin (PG).1 There are numerous PG subsets that are responsible for not only 
promoting pain and inflammation, but also maintaining blood pressure (BP), plasma 
volume, and renal function. Although less imperative in normal healthy individuals, PGs 
are critical in maintaining homeostasis during altered cardiovascular states (eg, 
hypotension) or altered fluid regulation (eg, hypovolemia and sodium imbalance)2,3 – 
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common conditions experienced during physical activity. Inhibiting PGs can perpetuate 
altered cardiovascular and renal function, potentially leading to serious fluid and 
electrolyte imbalances (eg, hyponatremia, edema formation, and hypertension) or even 
acute renal failure.3,4   
Existing literature evaluating the relationship between NSAIDs and fluid regulation 
during physical activity is primarily centered on observational studies examining exertional 
hyponatremia (defined as a plasma sodium concentration [P[Na+]] < 135 mmol/L).4-6 The 
mechanism for NSAIDs to promote hyponatremia is due to their ability to decrease urine 
production and increase water retention, which dilutes P[Na+].7 To our knowledge, the only 
controlled study examining this relationship is by Dumke et al.,8 who found 600 mg of 
ibuprofen pre- and 1200 mg during an ultra-distance marathon did not significantly alter 
plasma electrolytes. Controlled laboratory studies examining NSAID effects on fluid-
electrolyte balance during exercise is lacking. Thus, as part of a larger study, we sought to 
determine acute dose effects of a commonly used over the counter NSAID, naproxen, on 
fluid and electrolyte measures during moderate-intense endurance exercise in a hot or 
ambient environment. We hypothesized naproxen would increase hydration measures, 
indicating further hydration (ie, euhydration or hyperhydration) compared to placebo 
controls. We also hypothesized naproxen would significantly decrease P[Na+] compared 
to placebo controls. 
METHODS 
Design 
We used a double-blind, randomized and counterbalanced, cross-over design. The 
independent variables were placebo or naproxen and hot or ambient environment. The 
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dependent variables were: plasma osmolality (Posm), urine osmolality (Uosm), urine 
specific gravity (Usg), percent change in body mass (%BM), P[Na+], plasma potassium 
concentration (P[K+]), fluid volume consumed (Fvol), urine volume (Uvol), heart rate 
(HR), and blood pressure (BP).  
Participants 
Eleven participants (5 male, 6 female) were recruited from the local community. 
Participants read and signed an Institutional Review Board approved informed consent 
form (Appendix A) prior to participation. Potential participants completed a health and 
injury history questionnaire (Appendix B) and were accepted if he/she was free of 
cardiovascular, respiratory, and metabolic disorders; musculoskeletal disorders preventing 
cycling exercise; fluid and electrolyte balance disorders; and gastrointestinal and 
swallowing disorders. Current prescription and non-prescription medication use was also 
asked. Females were asked supplemental questions on menstrual cycle and birth control. 
Potential participants then completed a graded cycling V̇O2max test (Appendix E.2) to 
determine qualification as moderately trained (male V̇O2max between 35-40 mL/kg; female 
V̇O2max between 32-40 mL/kg).9  
Experimental Conditions 
Participants completed 4 experimental conditions: 1) placebo and ambient 
(Control); 2) placebo and heat (Heat); 3) naproxen and ambient (Npx); and 4) naproxen 
and heat (NpxHeat). A minimum of 7 days separated each trial. A 24 hr dose (3 capsules) 
of placebo (cellulose) or naproxen (220 mg naproxen sodium/dose) was given to 
participants with instructions to take 1 capsule at 16 hrs, 8 hrs, and 0 hrs prior to data 
collection. Participants were given specific instructions to follow 24 hrs prior to data 
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collection, including directions for taking each capsule according to the manufacturer’s (ie, 
naproxen sodium) directions. Participants then completed a 90 min cycling bout in either 
a hot (mean temperature = 35.7 + 1.3°C, 53.2 + 3.2 % relative humidity [RH]) or ambient 
(mean temperature = 22.7 + 1.8°C, 52.4 + 5.5% RH) environment. After exercise, 
participants rested 3 hrs in an ambient environment (23°C, 56% RH). 
Instruments and Protocols 
Anthropometric Measures. Weight and body fat percentage was measured using 
a bioelectrical impedance analysis scale (Tanita SC-331S Body Composition Monitor, 
Tanita Co., Tokyo, Japan). Height was self-reported. 
Health and Injury History Questionnaire (Appendix B). The Health and Injury 
History Questionnaire uses the Canadian Society for Exercise Physiology, which 
developed the PAR-Q to identify individuals who should be seen by a medical doctor 
before becoming more physically active and both the American Medical Society for Sports 
Medicine and the American Orthopedic Society for Sports Medicine. These two 
organizations released pre-participation physical exam forms used to identify individuals 
at risk for injuries. Supplemental questions were added to identify individuals with 
potential medical illness or injury (eg, gastrointestinal disorders, exertional heat illness 
history, metabolic disorders, and daily medication use) that would exclude them from study 
participation.  
 Cycle Exercise Protocol. Participants completed a 90 min cycling protocol on a 
stationary bike (Monark Ergomedic 828E, Monark Exercise AB, Vansbro, Sweden). Prior 
to a 3 min warm up, participants were provided their target HR, equivalent to 70% 
V̇O2max,10 to maintain during 80 min of steady state cycling. Participants were instructed to 
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reach the HR by the end of the 3 min warm up. At the end of 80 min, participants performed 
10 min at maximum effort, with each participant given verbal encouragement by research 
assistants. The protocol concluded with a 5 min cool down. 
Hydration and Electrolyte Measures. Participants were required to be euhydrated 
prior to beginning data collection. Immediate hydration status was assessed using Usg. 
Further hydration analysis was conducted using Posm, Uosm, and %BM. Euhydration was 
defined as Posm < 290 mOsmols, Uosm < 700 mOsmols, Usg < 1.020, and %BM < 1%.11 
We collected blood from an antecubital vein into 6ml lithium heparin vacutainer 
tubes at pre-, post-, and 3 hrs post-exercise. Tubes were inverted several times to mix and 
immediately placed on ice. Samples were centrifuged at 3000 rpm for 15 min. Plasma was 
pipetted into microtubes and stored at -20°C until analysis. We measured osmolality using 
freeze point depression (Multi-sample Osmometer model 2020, Advanced Instruments, 
Norwood, MA). To determine changes in P[Na+] and P[K+] we utilized ion-selective 
electrodes (EasyLyte® Na/K electrolyte analyzer model REF 2277, Medica, Bedford, MA). 
Normal P[Na+] was defined as > 135 mmol/L4 and normal P[K+] < 5 mmol/L.12   
Urine was obtained pre-, post-, and 3 hrs post-exercise. A clean catch method was 
used in which the participant was instructed to urinate a small amount before placing the 
specimen cup in midstream to collect a minimum of 1 ounce of urine. We used a handheld 
clinical refractometer (model REF 312, Atago Company Ltd., Tokyo, Japan) to measure 
Usg. Urine aliquots were stored in microtubes at -20°C until analysis for osmolality using 
freeze point depression. 
Pre-, post-, and 3 hrs post-exercise BM was measured using a body composition 
analyzer (Tanita SC-331S Body Composition Monitor, Tanita Co., Tokyo, Japan). 
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Participants dressed in shorts and a t-shirt and voided urine before stepping on the scale. 
Immediately post-exercise participants were asked to towel off sweat before weighing. 
Participants were then allowed to change clothes and instructed to return with their “wet” 
clothes to be weighed. Differences in “wet” versus “dry” clothes’ weight (measured at 
another time) were used to adjust BM for sweat loss.  
Urine Volume. All urine produced after pre-BM and hydration measures was 
collected into Uvol containers and urine cups (for Usg and Uosm measures). Total Uvol 
produced over the trial was measured using a graduated cylinder. 
Fluid Volume. To maintain hydration during exercise, participants were instructed 
to drink 3.5 ml/kg of water every 15 minutes. Participants were allowed to consume more 
than the required Fvol if they desired. At the end of exercise, researchers measured total 
Fvol consumed. During the 3 hr rest period, participants consumed water ad libitum and 
researches measured Fvol consumed during rest. 
Cardiovascular. To ensure participants remained at safe limits during exercise, 
HR was continuously monitored using Polar HR monitors (Polar Electro Inc., Lake 
Success, NY). To determine effects from naproxen, pre-, post-, and 3 hr post-exercise HR 
and BP were assessed. 
Diet and Activity Logs. To control for pre-data collection dietary and physical 
activity effects, participants were asked to track diet and physical activity for 3 days prior 
and 1 day after data collection using an online nutrition software FoodProdigyTM (ESHA 
Research, Salem, OR). Participants were asked to mimic diet and physical activity habits 
the 24 hrs prior to each trial.  
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Experimental Procedures (Figure 3.1) 
Information Session. After consenting participants were determined free of 
disqualifying medical conditions and to be moderately trained, a research assistant 
randomly assigned an experimental condition order. Participants and primary investigators 
were blind to whether participants were completing a naproxen or placebo trial. 
Participants were familiarized with the online diet and activity log and the V̇O2max test was 
used to familiarize participants to the stationary cycle. Participants were instructed to not 
take any analgesic or anti-inflammatory medications during the course of the study.  
Pre-Data Collection. Seventy-two hrs prior to data collection, participants were 
sent an email with instructions for completing the diet and physical activity log. 
Participants were instructed to refrain from intense, vigorous exercise for 48 hrs.13 Twenty-
four hours prior, participants were provided written and verbal instructions for taking 2 
capsules (placebo or naproxen), to consume a small meal prior to reporting to the 
laboratory, encouraged to consume fluids to promote euhydration, refrain from all physical 
activity, and attempt to sleep a “normal” amount.  
Data Collection Session. Upon arrival to the laboratory, participants were verbally 
asked if they took their 2 pills before taking the 3rd pill. Participants were provided a HR 
strap and baseline HR and BP were assessed. Participants provided a urine sample and 
baseline Usg was measured to ensure euhydrated prior to BM and blood measures.  
Immediately following the cycling protocol participants weighed, provided a urine 
sample and had post- blood collected. Participants then rested in a semi-reclined/seated 
position where they were allowed to consume water ad libitum and given a snack. Snacks 
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were based on BM and the same for each trial. At the conclusion of the 3 hr rest period, 
blood, urine, weight, BP, and HR were measured.  
Statistical Analysis 
IBM SPSS Statistics (version XXII; IBM Corporation, Armonk, NY) was used for 
all analyses. Descriptive statistics (mean and standard deviations) for all dependent 
variables were calculated. A one-way ANOVA was used to determine differences in 
demographics between genders (eg, age, height, weight). A 3 (time) x 4 (condition) 
repeated measures ANOVA determined differences for plasma, urine, %BM, HR, and BP. 
Greenhouse-Geisser corrections were used for P[Na+], BP, and HR because these variables 
violated sphericity. Post hoc analysis was conducted for significant main effects using 
Bonferroni corrections. We used a one-way ANOVA to determine differences between 
conditions and gender for Fvol consumed during exercise, total Fvol, and Uvol. To control 
for body mass, Fvol was corrected to ml/kg and a one-way ANOVA determined differences 
between conditions and gender. We used paired sample t-tests to determine differences in 
sweat rate and Fvol during exercise. Using G*Power (version 3.1.9.2, Heinrich Heine 
University, Dusseldorf, Germany),14 post hoc power calculation with means and variances 
for Usg and Uosm indicated a statistical power > 0.9. Significance level was set at P < 0.05 
for all analyses. 
RESULTS 
 We began the study with 16 participants; 2 participants dropped due to the study 
intensity and 3 dropped due to the time commitment. Our final sample size = 11. There 
was no significant difference between genders for age (mean = 27.8 + 5.7 yrs), weight (79.1 
+ 17.9 kg), V̇O2max (41.4 + 5.7 mL/kg), sweat rate (0.9 + 0.3 L), baseline resting HR (52.6 
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+ 6.6 bpm) and baseline resting BP (116/80 mmHg). Due to lost samples, the sample size 
for Posm, P[Na+], and P[K+] ranged between conditions (Control = 5, Npx = 3-4, Heat = 
4, and NpxHeat = 3-4). Diet logs indicated no significant differences between calorie, fat, 
carbohydrate, sodium, and protein intake between conditions. On average, male daily 
sodium intake was significantly greater than females (2.7 + 0.3 g vs. 2.0 + 0.2 g, P = 0.038; 
Appendix F, Table F.2). Physical activity level 24 hrs prior to data collection was not 
significantly different between conditions and remained low to sedentary. 
Cardiovascular 
There was a significant main effect for HR over time (mean pre = 66.8 + 14.3 bpm, 
post = 177.4 + 16.2 bpm, and 3 hr post = 65.5 + 11.8 bpm, P < 0.001). There was no 
significant HR difference between conditions or genders. Similarly, a significant main 
effect occurred for BP over time (mean pre = 118/73 mmHg, post = 137/72 mmHg and 3 
hrs = 116/77 mmHg, P < 0.008). There were no significant differences between conditions. 
We found a significant main effect for systolic BP between genders (P = 0.005). Post-hoc 
analysis showed males were significantly higher at pre-, post- and 3 hrs post-exercise (P < 
0.016). Regarding experimental conditions (Appendix F, Figure F.6), male systolic BP was 
significantly higher than females post-exercise in Npx (150.8 vs 124.4 mmHg, P = 0.017) 
and NpxHeat (144.2 vs 124.0 mmHg, P = 0.043). At 3 hrs post-exercise, males were 
significantly higher within Heat (121.5 vs 111.6 mmHg, P = 0.028). 
Hydration 
Hydration, Fvol, and Uvol for each experimental condition are presented in Table 
3.1. All participants began trials euhydrated. Overall, Posm, Uosm, and Usg significantly 
decreased pre- to 3 hrs post-exercise, indicating participants became more hydrated 
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throughout trials. All conditions maintained an average BM loss < 1%. No significant 
differences were found in hydration measures between conditions at any time point. 
Though not significantly different, mean Uvol was lower in naproxen trials versus placebos 
and during heat trials versus ambient (Table 3.1). There was no significant difference in 
Uvol between genders (Appendix F, Table F.1).  
Neither Fvol during exercise or total was significantly different between conditions. 
As expected, participants tended to consume more fluid during exercise in hot conditions 
versus ambient (Table 3.1). Mean Fvol during exercise and overall was higher in both 
naproxen trials compared to placebos. This trend continued when corrected for body mass. 
Participants’ mean Fvol during exercise (1.5 + 0.7 L) was significantly greater than their 
sweat rate (0.9 + 0.3 L, P < 0.013). Males consumed significantly greater Fvol during 
exercise and total than females (Appendix F, Table F.1). During NpxHeat males consumed 
significantly more during exercise than females (2.0 + 0.6 vs. 1.3 + 0.5 L, P = 0.046). When 
corrected for BM, Fvol in males overall and during NpxHeat was not significantly different 
than females. During the Npx condition overall Fvol approached significance (males = 1.9 
+ 1.0 L and females = 0.9 + 0.5 L, P = 0.055) and trended to be different during exercise 
with BM corrections (males = 20.7 + 8.8 ml/kg and females = 12.1 + 5.0, P = 0.087). 
Electrolytes 
Table 3.2 shows plasma electrolytes by experimental condition. Mean aggregate 
P[Na+] was < 135 mmol/L at pre-, post-, and 3 hrs post-exercise. We found no statistically 
significant differences in P[Na+] between conditions at any time. Mean P[Na+] was highest 
during NpxHeat. There was a significant main effect for P[K+] changes over time (P = 
0.02), increasing, expectedly, pre- to post-exercise and decreasing after 3 hrs. There were 
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no significant differences between trials; however, both naproxen groups averaged higher 
than placebos post-exercise. Due to the low sample size, we were unable to determine any 
differences between genders. 
DISCUSSION 
We sought to determine whether naproxen adversely affected hydration and 
electrolyte measures during moderate-intense endurance cycling in either hot or ambient 
conditions. We based our hypotheses on previous research7 associating NSAIDs with 
promoting fluid retention through decreased Uvol and renal vasoconstriction, which dilutes 
electrolytes and increases blood pressure. Our results did not support our hypotheses, 
finding naproxen did not significantly decrease P[Na+], Posm, urine hydration measures or 
increase cardiovascular strain compared to placebos. We also found responses did not 
differ between either hot or ambient environmental conditions. 
Fluid and Electrolyte Balance 
Naproxen is highly effective at inhibiting renal PGs, resulting in decreased renal 
blood flow.3 Naproxen also suppresses the renin-angiotensin-aldosterone system, which is 
responsible for maintaining BP, plasma volume, and electrolyte balance.7 Specific renal 
consequences include decreased glomerular filtration rate, increased vasopressin (anti-
diuretic hormone), increased sodium retention, and decreased Uvol. Independently or 
concurrently, these effects cause water retention and vasoconstriction.7 In extreme cases, 
cell necrosis, interstitial nephritis, and renal failure may develop.3 Though these conditions 
can become severe, milder consequences include electrolyte imbalance, edema, and 
hypertension.4,7  
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Decreasing Uvol and increasing water retention is what makes NSAIDs a suspected 
contributor to hyponatremia. Despite this, few studies have examined this relationship, 
with most being observational studies with conflicting results.5,6,15,16 Ultra-distance 
triathletes using NSAIDs had significantly lower post-race P[Na+] compared to non-
NSAID users (mean = 140.2 mmol/L and 141.1 mmol/L, respectively, P < 0.02).5 The 6 
participants who experienced hyponatremia all reported using NSAIDs.5 In 15 marathon 
runners hospitalized with severe hyponatremia, 28.6% used NSAIDs.15 However, other 
observational studies found no relationship to hyponatremia.6,16,17 One inherent issue with 
existing literature is not knowing what type and how much of an NSAID someone took. 
All NSAIDs inhibit PGs, but their COX selectively and chemical make-up, along with an 
individual’s unique response, means each NSAID exerts effects differently.  
Another contributing factor for developing hyponatremia is an individual 
consuming water (hypotonic fluid) in excess of fluid lost through sweat and respiration.4 
If combined with other factors that dilute P[Na+], the individual can be at greater risk for 
hyponatremia. Current recommendations advise matching individual sweat losses rather 
than drinking in excess or following generalized protocols. Calculating sweat loss is 
relatively simple ([pre-activity body weight – post-activity body weight + fluid volume 
consumed – urine volume]/exercise time).18 Either lack of knowledge, ability, or resources 
may prohibit the average person from calculating his/her sweat rate. Instead, the person 
may guestimate or trial and error fluid intake during endurance activity. We chose to 
provide a standardized water protocol (3.5 ml/kg), rather than match sweat rates, and 
participants were allowed to consume more if desired. In part, using a standardized intake 
mimicked what an individual who does not know their personal water needs may do. We 
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found consuming water volumes exceeding sweat loss during 90 min cycling did not 
significantly deplete P[Na+] and there was no effect from NSAIDs. This is likely due to the 
short exercise duration. Though exertional hyponatremia has occurred in football,19-21 it is 
typically associated with long-duration endurance exercise (> 3 hrs).4,22 Our exercise 
session likely did not allow enough time to significantly deplete P[Na+]. During the 3 hr 
rest, when participants were allowed to drink water ad libitum they maintained euhydration 
and plasma electrolyte balance. 
 One interesting note is our mean P[Na+] was < 135 mmol/L in all conditions and 
time points except pre- and 3 hr post-exercise NpxHeat. Plasma sodium < 135 mmol/L 
without signs or symptoms is considered biochemical or asymptomatic hyponatremia.22 
Many individuals do not experience symptoms until P[Na+] decreases below 130 mmol/L 
and severe hyponatremia typically occurs below 120 mmol/L.11 Our participants 
maintained normal diets, consuming an average 2401.1 + 759.2 mg of sodium daily. The 
low P[Na+] can be explained by participants being instructed and attempting to arrive to 
the laboratory hydrated and by maintaining hydration during our exercise protocol. Pre-
exercise Usg, Uosm, and Posm indicated our participants were slightly hyperhydrated and 
became extremely hyperhydrated23 by 3 hrs post-exercise.  
Also interesting was that NpxHeat averaged more fluid consumed and had the 
lowest Uvol. Due to our low plasma sample size and lack of significance, we have difficulty 
definitively explaining why this response occurred. The trend with naproxen to produce 
less urine while consuming more fluid suggests participants were retaining water. Since 
we did not see significant decreases in P[Na+], Posm, or Usg pre- to post-exercise, we 
presume a portion of water remained in the stomach. Intense exercise slows gastric 
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emptying, which prevents fluid from being absorbed and/or used to maintain physiological 
processes.24  
In theory, increased Fvol and decreased Uvol should lead to BM gains. We found 
no significant difference in BM, which, again, may be attributed to exercise duration. 
However, both the Npx and NpxHeat averaged pre- to post-exercise BM losses, while both 
Control and Heat gained slightly or did not change (Table 3.1). Once exercise ceased (post- 
to 3 hrs post-exercise) this trend flipped, with Control and Heat indicating more weight 
loss than Npx and NpxHeat. Once exercise ceased, the possibility exists that GI and renal 
function returned to normal, promoting gastric emptying and water excretion as necessary 
to maintain fluid-electrolyte balance. Support for this explanation is seen with the slightly 
higher Uvol in Control and Heat. On the other hand, naproxen’s effects continuing 
throughout the rest period would explain the slight weight gain and lower average Posm at 
3 hrs post-exercise. This thought is an important note considering reported cases of 
hyponatremia developing hours after activity.19,21 Sustained water retention combined with 
continued hydration would place the person at even greater risk for diluting P[Na+]. 
Regarding potassium, our participants remained within normal P[K+] levels (< 5 
mmol/L).12  Potassium is tightly regulated by the kidneys, because elevated levels can 
cause cardiac arrhythmias and death.12 Even during exercise, when plasma levels can 
quickly spike due to working muscles releasing or failing to re-uptake potassium,12 the 
kidneys work efficiently to clear potassium. However, potassium will stay elevated if renal 
blood flow is decreased25 or through decreased energy metabolism12 and increased oxygen 
tension.26 NSAIDs can induce hyperkalemia,27 but there is little research regarding this 
association during exercise. The increase in our overall P[K+] means are similar to those 
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reported in existing literature.5,8,28 While not significantly different between conditions, the 
higher means with naproxen compared to placebos suggest there could be some effect from 
the NSAID. Among triathletes, NSAIDs resulted in significantly higher post-race P[K+] 
compared to those not using NSAIDs (4.51 + 0.46 mmol/L and 4.35 + 0.43 mmol/L, 
respectively, P = 0.002).5 In contrast, Dumke et al,5  found over the counter ibuprofen did 
not significantly affect P[K+] in ultra-distance runners. Since type of NSAIDs were not 
reported, it is not possible to make comparisons among specific NSAIDs. Research has 
established, compared to no NSAID exposure, odds for developing kyperkalemia with 
ibuprofen are lower (odds ratio = 0.94) compared to naproxen (odds ratio = 1.08).27 Using 
a higher naproxen dose for a longer duration may induce significant P[K+] changes during 
exercise. 
Cardiovascular 
 Our results indicate 3 220 mg naproxen doses over 24 hrs did not significantly 
affect pre-, post-, or 3 hr post-exercise HR or BP. Cardiovascular responses often occur 
concurrently with renal responses, since altering fluid-electrolyte balance can control 
plasma volume and BP. Disregarding renal effects, naproxen is less effective at directly 
altering the cardiovascular system because naproxen is more COX 2 selective.29 This 
naproxen effect is in comparison to aspirin, which is more selective toward COX 1.30 
Further, naproxen reversibly inhibits platelets while aspirin irreversibly inhibits platelet 
aggregation, making aspirin highly effective at reducing cardiovascular events (ie, stroke, 
heart attack).30 Lack of cardiovascular effects could be attributed to naproxen itself or to 
our methodology. By maintaining hydration we limited cardiovascular changes that would 
otherwise be seen with hypohydration. We also limited our participants to healthy, young, 
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moderately trained individuals. The same cardiovascular results may not be seen in 
different populations (eg, older, poor physical conditioning, cardiovascular or renal 
disease). 
Gender 
Previous literature identifies females are at higher risk for hyponatremia because of 
smaller body weights, excessive water intake, and longer race times compared to males.4 
Though these factors play a role, hormonal differences between genders is also an 
important consideration. Resting plasma vasopressin varies in females depending on 
menstrual phase. Vasopressin is significantly lower than males during the early follicular 
phase, but not during luteal.31 These variances may help explain why we found differences 
in Fvol between genders. Males consumed significantly more fluid than females both 
during exercise and overall. Interesting, males consumed significantly more fluid during 
exercise in the NpxHeat, and approached significance in Npx, compared to females. 
Gender differences did not occur during Control and Heat and we found no difference in 
females’ Fvol between conditions. Considering the change in vasopressin during menstrual 
phases, which we did not account for, the lack of significant findings among females could 
be partially explained by hormones.  
Related to Fvol, thirst is listed as a potential side effect for several NSAIDs. There 
is extremely limited research examining NSAIDs on thirst or Fvol during exercise. Among 
NSAID and non-NSAID users completing an 82 km mountain run (n = 44; 36 males, 8 
females), NSAID users (n = 16) consumed significantly more fluid than non-users (6.1 + 
1.5 L vs 5.1 + 2.2 L, P = 0.08).17 Our results support, at least in males, naproxen increases 
fluid intake. We used naproxen sodium, which is bioequivalent to naproxen except for rate 
 54 
 
of absorption. The salt of a given NSAID is commonly used because it allows the drug to 
dissolve faster and exert effects earlier. A 220 mg naproxen sodium dose contains 
approximately 20 mg of sodium. Not all salts exert the same effects and 20 mg is relatively 
low, but Wemple et al,32 found 46 mg/Lof sodium chloride added to a flavored beverage 
significantly increased fluid intake. Naproxen sodium may stimulate thirst. Another 
mechanism for thirst stimulation is NSAIDs increasing vasopressin.7 Vasopressin is 
typically upregulated during dehydration in order to restore plasma volume, and its increase 
is positively and linearly associated with thirst.31  
Extensively examining cardiovascular effects between genders is difficult because 
we cannot compare plasma measures and did not assess hormones. We identified no 
differences between or within genders for HR. Blood pressure is generally higher for men 
than females,33 which is attributed to physical differences, hormones, and vascular 
responsiveness.31 Male baseline BP was slightly higher than females, but not significantly. 
Naproxen significantly elevated post-exercise male systolic BP compared to females. This 
did not occur during Control and Heat. The increased Fvol with naproxen in males could 
partially explain the higher systolic BP. Seemingly, males would have a higher plasma 
volume, which would increase BP.  
Limitations and Future Research 
 One limitation to our study is not measuring aldosterone and vasopressin. 
Measuring these hormones would provide a better explanation on how naproxen influences 
fluid and electrolyte regulation. Measuring plasma naproxen levels would have been useful 
to determine the drug’s concentration at 3 hrs post-exercise. Naproxen has a long half-life 
compared to other NSAIDs. Therefore, we would expect naproxen to continue exerting 
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effects during the 3 hr rest, while other NSAIDs would not. This knowledge would be 
important when considering post-activity effects. Our 90 min cycling was likely too short 
to elicit significant P[Na+] changes, considering much of the hyponatremia research is in 
marathon and ultra-distance events. Due to lost samples, our sample size for plasma 
electrolytes and osmolality was low, preventing us from achieving statistical significance 
between conditions. Finally, we did not control for menstrual phase. 
 Future research in laboratory settings is warranted to determine the relationship 
between NSAID use and hydration-electrolyte balance during exercise. Because each 
NSAID is unique, studies should evaluate different types, dosages, and length of use. 
Research should evaluate longer endurance exercise bouts to elicit plasma electrolyte 
depletion. Shorter exercise bouts are relevant, as well, considering the potential for 
electrolyte depletion associated with other risk factors such as inadequate nutrition, 
excessive hypotonic fluid intake, and/or excessive sweat sodium loss. Using different 
hydration regimens (metered versus ad libitum) and fluid types (eg, carbohydrate-
electrolyte beverages) is also merited. Considering the trend for increased Fvol with 
naproxen, evaluating vasopressin and thirst would be interesting. Along these lines, 
examining the salt of different NSAID types would provide meaningful information. 
Finally, controlled studies evaluating markers of renal function and gender differences, 
including differences during menstrual phases is merited.  
Conclusion 
Acute naproxen intake did not adversely affect hydration, electrolyte, or 
cardiovascular measures during cycling in either hot or ambient conditions. An important 
note is the context of our findings, and that we identified some trends. Our participants 
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were hydrated, moderately endurance trained, free of many confounding risk factors, and 
the cycling protocol was moderate in duration (90 min). Second, NSAIDs vary in 
selectivity and chemical make-up. Our participants consumed the over the counter strength, 
recommended daily naproxen sodium dose.  
We encourage clinicians and other personnel to consider an individual’s personal 
risk factors when recommending naproxen. Finding higher post-exercise systolic BP with 
naproxen in males versus females warrants consideration for potential adverse events 
during exercise in males with pre-exiting hypertension. Further, we found naproxen 
promoted greater fluid intake in males during ambient and hot environments. Beginning 
exercise slightly hyperhydrated and consuming water in excess of sweat rate during a 90 
min exercise time began to show the trend for naproxen to induce water retention through 
decreased Uvol. Though our participants maintained electrolyte balance, their P[Na+] was 
lower than 135 mmol/L. Together, these results show the importance in considering 
individuals who may have risk factors for renal and/or cardiovascular imbalances during 
exercise. 
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Table 3.1. Hydration Measures, Fluid Volume, and Urine Volume for Experimental Conditions (M + SD) 
  Aggregate Placebo Npx Heat NpxHeat 
       
Posm 
(mOsm/L) 
Pre 286.6 + 6.4a 285.8 + 5.3 288.8 + 4.8 285.5 + 10.1 287.8 + 6.6 
Post 284.8 + 6.7 288.2 + 6.6 281.9 + 3.9 285.9 + 10.6 283.8 + 4.9 
3 hr post 282.4 + 5.9 286.4 + 3.3 277.4 + 6.6 283.6 + 6.9 281.1 + 4.9 
       
Uosm 
(mOsm/L)b 
Pre 399.5 + 172.1c 441.6 + 187.5 431.8 + 193.5 341.4 + 131.7 389.9 + 183.4 
Post 277.3 + 236.0 246.8 + 223.7 244.2 + 184.1 233.1 + 213.9 390.2 + 310.0 
3 hr post 176.2 + 132.9 192.4 + 107.8 185.6 + 130.4 201.3 + 173.0 122.7 + 113.3 
       
Usg 
Pre 1.012 + 0.005 1.013 + 0.005 1.014 + 0.006 1.011 + 0.004 1.012 + 0.004 
Post 1.011 + 0.008 1.010 + 0.007 1.010 + 0.008 1.010 + 0.008 1.013 + 0.009 
3 hr post 1.007 + 0.006d 1.007 + 0.005 1.007 + 0.006 1.007 + 0.006 1.007 + 0.007 
       
∆BM (%) 
Pre - Post -0.1 + 0.8 0.1 + 0.8 -0.3 + 1.1 0.0 + 0.6 -0.1 + 0.8 
Pre - 3 hr -0.4 + 0.9 -0.6 + 0.4 -0.1 + 0.6 -0.5 + 0.6 -0.5 + 0.9 
Post - 3 hr -0.3 + 0.7 -0.5 + 0.8  0.0 + 1.3 -0.4 + 0.5 -0.0 + 0.6 
       
Uvol (ml) 1012.9 + 519.1 1157.3 + 681.4 1075.3 + 572.3 982.6 + 508.6 836.6 + 214.2 
 
Fvol (L) Exercise 1.5 + 0.7 1.1 + 0.4 1.4 + 0.9 1.6 + 0.6 1.7 + 0.7 Total 2.1 + 1.1 1.7 + 0.6 2.1 + 1.5 2.2 + 1.0 2.5 + 1.3 
       
Fvol (ml/kg) Exercise 17.8 + 6.3 14.2 + 4.2 16.8 + 8.3 19.6 + 4.9 20.4 + 5.8 Total 25.9 + 10.0 21.5 + 6.6 25.5 + 13.4 27.3 + 8.1 29.5 + 10.6 
aSignificantly higher than 3hr post (P = 0.01, observed power = 0.08). bSignificant main effect across time for all conditions 
(P < 0.001). cSignificantly higher than post (P = 0.003) and 3 hr post (P < 0.001). dSignificantly lower than pre (P < 0.001) 
and post (P = 0.03). 
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Table 3.2. Plasma Electrolytes for Experimental Conditions (M + SD) 
  Aggregate Placebo Npx Heat NpxHeat 
       
PNa+ 
(mmol/L) 
Pre 134.3 + 4.6 133.5 + 5.7 133.2 + 4.5 133.5 + 3.2 135.0 + 2.9 
Post 133.5 + 3.2 133.3 + 2.9 131.5 + 4.8 132.2 + 5.6 134.8 + 3.9 
3 hr post 134.3 + 3.1 133.1 + 1.9 133.5 + 0.3 132.9 + 4.7 135.3 + 2.7 
       
PK+ 
(mmol/L)a 
Pre 3.9 + 0.4 3.9 + 0.6 4.1 + 0.4 3.9 + 0.2 3.6 + 0.1 
Post 4.2 + 0.4 4.2 + 0.7 4.4 + 0.3 3.9 + 0.1 4.2 + 0.2 
3 hr post 3.9 + 0.2 3.8 + 0.3 3.8 + 0.0 4.0 + 0.3 3.9 + 0.3 
       
aSignificant main effect across time (P = 0.02, observed power = 0.08). 
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Figure 3.1. Experimental Procedures Schematic.  
Blood measures include plasma osmolality, plasma sodium concentration, and plasma potassium concentration. Urine measures include 
urine osmolality and urine specific gravity.  
Abbreviations: BM = body mass; BP = blood pressure; HR = heart rate. 
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CHAPTER 4 
NAPROXEN EFFECTS ON GASTROINTESTINAL DISTRESS AND PERFORMANCE DURING 
CYCLING IN THE HEAT1
1Dawn M. Emerson, J. Mark Davis, Stephen CL Chen, Toni M. Torres-McGehee, J. 
Larry Durstine, Charles C. Emerson, Craig E. Pfeifer, Joseph D. Bivona, Justin V. 
Stone. To be submitted to Med Sci Sport Exerc. 
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ABSTRACT 
Purpose: Our primary objective was to determine effects of naproxen on gastrointestinal 
(GI) distress symptoms and performance in hydrated humans cycling in the heat. Methods: 
We utilized a double-blind, randomized and counterbalanced, cross-over design. 
Participants were 11 moderately endurance trained volunteers (6 male, 5 female; age = 27.8 
+ 6.5 yrs, weight = 79.1 + 17.9 kg, height = 177 + 9.5 cm, and V̇O2max = 41.4 + 5.7 ml/kg). 
Independent variables were placebo or naproxen (one 220 mg pill every 8 hrs for 24 hrs) 
and hot or ambient environment. Dependent variables were max heart rate (HR), rate of 
perceived exertion (RPE), distance, GI symptoms, and fecal occult blood. Measures were 
taken pre-, during, and post-90 min cycling. Four trials: 1) placebo and ambient (Control); 
2) placebo and heat (Heat); 3) naproxen and ambient (Npx); and 4) naproxen and heat 
(NpxHeat) were completed and separated by 7 days minimum. Results: No statistically 
significant differences in RPE, max HR, distance, fecal occult blood, or GI symptoms 
between conditions were found. Average max HR was higher during Npx (176.2 + 15 bpm) 
than Control (175.7 + 14.2 bpm) and NpxHeat (179.0 + 18.0 bmp) than Heat (177.8 + 18.2 
bpm). Mean distance covered was highest during Npx (3.3 + 0.8 miles) and lowest in 
NpxHeat (2.8 + 0.8 mile). Gastrointestinal symptoms occurred during exercise in 64% of 
trials. Of the reported GI symptoms during ambient trials, 10% were serious compared to 
7% in Heat and 1% in NpxHeat. Dizziness and headache during exercise were only 
reported during placebos. Conclusion: Acute naproxen intake did not significantly affect 
performance or GI distress during 90 min cycling. The potential interaction between 
naproxen and heat stress, as indicated by higher HR and lower distance traveled, warrants 
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further research.  Key Words: NSAIDs, gastrointestinal bleeding, heart rate, perceived 
exertion, cycling 
INTRODUCTION 
A high prevalence of prescription and over the counter non-steroidal anti-
inflammatory drug (NSAID) use among various age groups, sport types, and competition 
levels exists.(38,40,41) These drugs are often used prophylactically or as treatment 
following injury.(11,39,40) For example, individuals may take NSAIDs in order to 
“continue playing” or in attempt to mitigate pain and inflammation during activity. Because 
of their association with anti-inflammatory and analgesic effects, there is a perception 
NSAIDs can increase performance during physical activity.(40)  
Acetaminophen has been found to enhance performance by alleviating pain,(12,23) 
but research on NSAIDs is limited and results are inconclusive. Existing literature 
primarily focuses on aspirin, males, and short, intense exercise bouts in ambient 
environments.(6,8,15,18) For example, using aspirin (dose = 20 mg/kg of body weight) 1 
hr prior to exercise did not significantly affect power output, rate of perceived exertion 
(RPE), heart rate (HR), or alleviate muscle pain during a ramped maximum exertion 
cycling protocol.(6) Similarly, a lower aspirin dose (10 mg/kg) 1 hr prior to maximum 
lower extremity resistance exercises increased RPE and perceived leg pain compared to 
placebo.(18) Gilbert et al.(15) investigated an acute aspirin dose (975 mg 1 hr prior) and 
chronic (975 mg 3 times a day for 4 days) on max graded treadmill runs. Acute aspirin 
significantly increased RPE, while chronic significantly increased post-exercise lactate, 
RPE, hematocrit, and fatigue.(15) Lastly, ibuprofen (1.2 g) 1 hr prior to treadmill running 
to fatigue did not improve time to exhaustion or RPE and resulted in no significant change 
 65 
 
to blood lactate or HR.(8) From these results, NSAIDs appear to have little effect and, in 
some instances, may degrade performance. 
NSAIDs may also negatively affect performance through physiological 
mechanisms such as damage to the gastrointestinal (GI) tract,(22) cardiovascular system, 
and kidneys.(4) Severity for adverse NSAID effects varies depending on dosage, length of 
use, formula, and individual risk factors (eg, sensitivity to the drug, previous adverse 
events, and health status).(22) However, in general, NSAIDs are known to cause ulcers, 
perforations, and hemorrhaging along the GI tract.(14,22) Symptoms of GI distress (eg, 
nausea, cramping, diarrhea, pain, and bloating) can be subjective and highly variable 
between individuals. Further, GI distress can be caused by factors such as stress, fatigue, 
and diet.(16,25,28) NSAIDs also increase cardiovascular strain by inducing 
vasoconstriction and increasing hypertension in peripheral and renal blood vessels.(4) 
Independently or concurrently, these NSAID driven events could decrease performance.  
Our primary aim was to determine effects of an acute over the counter dose of 
naproxen on GI distress symptoms and performance measures during moderate-intense 
endurance exercise in a hot environment. A secondary aim was to investigate potential 
gender differences. We hypothesized naproxen would induce significantly more GI distress 
and decrease performance compared to placebo controls. We also hypothesized GI distress 
and performance decrements would not be different between males and females. 
METHODS 
Participants 
As part of a larger study, 11 participants (5 male, 6 female; age = 27.8 + 6.5 yrs, 
weight = 79.1 + 17.9 kg, and height = 177 + 9.5 cm) were recruited from the university and 
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local community. Participants read and signed an Institutional Review Board approved 
informed consent form (Appendix A) prior to participation. To be included in the study 
participants completed a health and injury history questionnaire (Appendix B). Participants 
were free from cardiovascular, respiratory, and metabolic disorders; musculoskeletal 
disorders preventing cycling exercise; fluid and electrolyte balance disorders; and GI and 
swallowing disorders. Questions also asked about current medication use. Females were 
asked additional questions on menstrual cycle. Participants completed a graded cycling 
V̇O2max test (Appendix E.2) to determine qualification as moderately trained (male V̇O2max 
between 35-40 mL/kg; female V̇O2max between 32-40 mL/kg).(27)  
Experimental Conditions 
Participants completed all 4 experimental conditions in a randomized, counter-
balanced order with 7 days minimum between each trial. The 4 experimental conditions 
were: 1) placebo and ambient (Control); 2) placebo and heat (Heat); 3) naproxen and 
ambient (Npx); and 4) naproxen and heat (NpxHeat). A 24 hr dose (3 capsules) of placebo 
(cellulose) or naproxen (220 mg naproxen sodium/capsule) was given to participants prior 
to exercise. Participants consumed 1 capsule at 16 hrs, 8 hrs, and 0 hrs prior to data 
collection. All participants were given specific take home instructions (Appendix C.4) to 
follow 24 hrs prior to data collection, including directions for taking each capsule 
according to the manufacturer’s directions. All experimental trials took place in an 
environmental chamber (hot = 35.7 + 1.3°C, 53.2 + 3.2% relative humidity) or laboratory 
(ambient = 22.7 + 1.8°C, 52.4 + 5.5% relative humidity). 
Instruments and Protocols 
 Cycle Exercise Protocol. Participants completed a 90 min cycling protocol on a 
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stationary bike (Monark Ergomedic 828E, Monark Exercise AB, Vansbro, Sweden). 
Participants began with a 3 min warm followed by 80 min at a steady HR equivalent to 
70% V̇O2max.(35) The final 10 min were performed at max effort and the protocol 
concluded with a 5 min cool down. 
Rate of Perceived Exertion. The Borg Scale measured participants’ RPE pre-, 
every 15 min during, and post-exercise. 
Cardiovascular. To ensure participants remained at safe limits and assist with 
maintaining the target HR during 80 min stead state cycling, HR was continuously 
monitored and recorded every 5 min using Polar HR monitors (Polar Electro Inc., Lake 
Success, NY). To determine effects on performance, we measured max HR at the end of 
the 10 min max effort. 
Gastrointestinal Symptom Index (Appendix D). Gastrointestinal distress was 
assessed using a previously designed symptom questionnaire.(31,32) The index is divided 
into 3 sections: 1) upper abdominal problems (heart burn, reflux, belching, bloating, 
stomach pain/cramping, nausea, vomiting); 2) lower abdominal problems (intestinal/lower 
abdominal pain/cramping, flatulence, urge to defecate, side aches/stitch, loose stool, 
diarrhea); and 3) systemic problems (dizziness, headache, muscle cramps, urge to 
urinate).(31) Symptoms are scored on a 10-point scale (0 = no problems at all and 9 = the 
worst it has ever been). A score of > 4 is considered “serious”.(32) Questionnaires were 
administered pre-, post-, and 3 hrs post-exercise. An additional questionnaire was 
administered at the time of the post-exercise fecal sample (~ day post).  
To determine GI symptoms during exercise, a scale was developed based on the GI 
symptom questionnaire. Participants were verbally asked every 15 min “Are you currently 
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experiencing GI symptoms?” If yes, he/she was asked to verbalize the symptom and rank 
the severity on a 10-point scale (0 = no problems at all and 9 = the worst it has ever been).  
Fecal Occult Blood. To determine GI bleeding, fecal occult blood (FOB) was 
measured using take home kits (Fisher HealthCareTM Sure-VueTM Fecal Occult Blood Slide 
Tests System, Thermo Fisher Scientific Inc., Waltham, MA). For each experimental trial, 
participants provide the first stool sample after initiating naproxen/placebo and the first 
stool sample following the exercise protocol.  
Hydration Measures. Participants were required to be euhydrated prior to 
beginning data collection. Hydration status was determined using urine specific gravity 
(Usg). Urine was obtained pre-, post-, and 3 hrs post-exercise. A handheld clinical 
refractometer (model REF 312, Atago Company Ltd., Tokyo, Japan) measured Usg. 
Euhdyration was defined as Usg < 1.020.(34) To maintain hydration during exercise, 
participants were provided 3.5 ml/kg of water to consume every 15 min. 
 Diet and Activity Logs. To control potential effects on GI distress and 
performance, participants were asked to track diet and physical activity for 3 days prior 
and 1 day after data collection using an online nutrition software FoodProdigyTM (ESHA 
Research, Salem, OR). Participants were asked to mimic dietary and physical activity 
habits during the 24 hrs prior to each data collection session. Additionally, participants 
were instructed to refrain from eating red meat during the 3 days prior and 1 day after due 
to the potential to skew FOB tests.    
Experimental Procedures  
Information Session. After consenting participants were determined free of 
disqualifying medical conditions and verified to be moderately trained, they were randomly 
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assigned to an experimental condition order by a research assistant. Participants and 
primary investigators were blind to whether participants were completing the naproxen or 
placebo groups. Participants were familiarized with the online diet and activity log and the 
V̇O2max test was used to familiarize individuals to the stationary cycle. Participants were 
instructed to not take any pain or inflammation medications during the course of the study.  
Pre-Data Collection. Participants were sent an email with instructions for 
completing the diet and physical activity log 72 hrs before data collection. Participants 
were instructed to refrain from intense, vigorous exercise for 48 hrs.(29) Twenty-four hrs 
prior, participants were provided written instructions for taking 2 capsules (placebo or 
naproxen) and directions for diet, hydration, and activity. Participants were instructed to 
consume a small meal at least 2 hrs prior to arriving to the laboratory to ensure food passed 
through the stomach. 
Data Collection Session. Upon arrival to the laboratory, participants were verbally 
asked if they took their 2 pills before taking the 3rd pill. Participants were instructed to 
provide a urine sample into a urine cup and void everything else into the toilet. Baseline 
Usg was measured to ensure participants were euhydrated.  
Participants were provided a HR monitor and the cycling protocol began with a 3 
min warm up on the bike. Participants maintained their target HR during the 80 min steady 
state exercise and consumed water to maintain hydration. Every 15 min a research assistant 
asked participants their RPE and GI symptoms. The last 10 mins of the cycling protocol 
was completed at max effort. Each participant was given verbal encouragement by research 
assistants for each trial. At the conclusion of the max effort, participants were asked RPE 
and GI symptoms, HR was recorded, and distance traveled during the 10 mins of max 
 70 
 
cycling was recorded. Following a 5 min cool down on the bike, participants completed a 
post-GI symptom index and provided a urine sample. Participants then rested 3 hrs in a 
semi-reclined/seated position in an ambient environment (23°C, 56% RH). Water was 
consumed ad libitum and each participant was given a non-sucrose snack. At the 
conclusion of the rest period, urine, BP, HR, and GI symptoms were measured.  
Statistical Analysis 
IBM SPSS Statistics (version XXII; IBM Corporation, Armonk, NY) was used for 
all analyses. Descriptive statistics (mean and standard deviations) for all dependent 
variables were calculated. Demographical (eg, age, height, weight) and dietary (eg, calories 
and protein) differences were assessed using a one-way ANOVA. We used a one-way 
ANOVA to determine differences between conditions for distance, max HR, and FOB. 
Eight (time) x 4 (condition) repeated measures ANOVAs determined RPE differences for 
all data and between and within genders. Because RPE violated sphericity, Greenhouse-
Geisser corrections were used. Post hoc analysis was conducted for significant main effects 
with Bonferroni corrections. Using G*Power (version 3.1.9.2, Heinrich Heine University, 
Dusseldorf, Germany),(10) post hoc power calculations with means and variances for HR 
and distance indicated a statistical power > 0.9. Significance level was set at P < 0.05 for 
all analyses.  
Due to non-parametric data, we used Wilcoxon signed rank tests to identify 
differences in GI symptoms pre-, post- and 3hr post-exercise within and between 
conditions. Wilcoxon signed rank were also used to determine differences within gender. 
To reduce multiplicity, questions were sectioned into upper, lower, and systemic 
symptoms. Responses were averaged and analyzed. Because of the number of tests and 
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chances for inflation, P values are considered “interesting” rather than significant.(31,32) 
We determined frequency of symptoms scored > 4 (considered “serious”) within each 
condition. Kruskal-Wallis analysis determined differences between genders. To control for 
other factors that may influence GI symptoms, Spearman’s rho correlations were run for 
max core temperature (data presented in Chapter 2), fluid volume consumed during 
exercise (data presented in Chapter 3), max HR, max RPE, and distance. 
RESULTS 
 Table 4.1 contains participant demographics. There was no significant differences 
between age, weight, and V̇O2max for gender. Participants began experimental trials 
euhydrated (mean Usg = 1.012 + 0.005) and maintained euhydration throughout exercise 
(1.011 + 0.008) and recovery (1.007 + 0.006). Diet log results indicated no significant 
differences between conditions for calorie, fat, protein, carbohydrate, or sodium intake. 
Also, no significant differences in exercise (calories burned) 24 hrs prior to data collection 
existed, with all participants maintaining sedentary to low activity. No significant 
differences existed within genders between experimental conditions. We found, overall, 
males consumed significantly more calories, protein, and sodium than females (Appendix 
F, Table F.2). Subsequent analysis identified the only significant difference between 
genders within conditions occurred with protein for NpxHeat (male = 65.4 + 2.7 g and 
female = 44.7 + 3.2 g, P = 0.004).  
Performance 
Table 4.2 shows max HR, RPE, and distance traveled during 10 min max effort for 
each condition. There was an overall significant main effect (P < 0.001) for RPE over time, 
but no significant differences between conditions. Within gender, RPE did not significantly 
differ between conditions (Appendix F, Table F.3). The only difference between gender 
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and conditions occurred in NpxHeat with pre-exercise males significantly lower (7 + 1) 
than females (9 + 2, P = 0.03). Significant differences occurred between overall males and 
female RPEs. Females were significantly higher at 0 and 15 min cycling (10 + 2 vs. 8 + 2 
and 11 + 2 vs. 9 + 3, respectively, P < 0.03). On the other hand, males were significantly 
higher at 90 min (19 + 2 vs. 18 + 2, P < 0.03).   
Distance was not significantly different between conditions. On average, distance 
traveled was lower during heat trials compared to ambient (Table 4.2). Interestingly, mean 
distance was slightly higher for Npx compared to Control. This effect was not found in the 
hot environment, with NpxHeat having the lowest distance covered. There were no 
statistically significant difference between males and females for distance within or 
between conditions (Appendix F, Table F.4). Overall, we found males trended toward 
greater distance than females (3.2 + 0.7 miles vs 2.8 + 0.9 miles, P = 0.085). Similar to 
overall condition results, both males and females in ambient conditions averaged greater 
distance compared to heat. Furthermore, the Npx condition resulted in the highest average 
distance for both genders (Appendix F, Table F.4).  
As expected, mean max HR was higher during heat trials compared to ambient, but 
was not significantly different (Table 4.2). Heart rate was highest during NpxHeat and 
lowest in the Control trial. There were no statistically significant difference within or 
between genders (Appendix F, Table F.4). Females’ mean max HR was highest in NpxHeat 
(180.2 + 17.2 bpm) and was higher than males for both heat trials. Male max HR was 
highest during the Npx condition (179.5 + 15.1 bpm).  
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GI Symptoms and FOB 
Mean and max scores for each upper, lower, and systemic GI symptom were totaled 
for each time point (pre- to day-post) and are presented in Table 4.3. Both Heat and 
NpxHeat had higher averages and max scores compared to ambient conditions. Urge to 
urinate was the most frequent symptom reported. Reflux/heartburn, vomiting, abdominal 
pain, and diarrhea were only reported during heat trials.  
Appendix F, Table F.5 shows aggregate upper, lower, and systemic GI scores for 
each time point with Wilcoxon results. Heat resulted in higher mean upper GI symptom 
scores post-exercise (0.3 + 0.3). Higher mean and serious systemic post-exercise scores 
occurred in Control (0.9 + 0.9, 6% serious), Npx (0.6 + 0.6, 6% serious), and Heat (0.7 + 
0.9, 3% serious) compared to NpxHeat (0.3 + 0.4, 0% serious). Control continued to 
experience more frequent and serious lower and systemic symptoms at 3 hrs post-exercise 
and was greater than any other condition. Day-post results showed Heat experienced higher 
mean and serious scores for upper (1.3 + 2.5, 18% serious), lower (1.9 + 12.4, 6% serious) 
and systemic (1.3 + 2.2, 5% serious). Only NpxHeat resulted in more serious lower GI 
symptoms day post (12%).  
There were no significant differences for GI symptoms between conditions within 
genders. The only significant differences between genders occurred at 3 hrs within the Heat 
condition, χ2(1) = 4.4, P = 0.036, with a mean rank 4.5 for males and 7.8 for females. There 
were no positive FOB tests pre-exercise. One positive FOB test indicated GI bleeding post-
exercise in the Npx condition. However, this test was likely a false positive, since it 
occurred in a menstruating participant. 
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During Exercise 
Overall, GI symptoms occurred during exercise in 64% of trials. Only 1 participant 
experienced no GI symptoms during any trial. Eight-two percent of participants reported 
at least 1 symptom during Control, 73% during Npx, 45% during Heat, and 55% during 
NpxHeat. Mean and max GI symptom scores during exercise are presented in Table 4.4. 
Urge to urinate and nausea was most frequent for all conditions and highest during ambient 
trials. Greatest percentage of serious scores (10%) occurred for systemic symptoms, 
specifically urge to urinate, during Control and Npx (Appendix F, Table F.6). NpxHeat had 
the least systemic symptoms reported (0.0 + 0.8, 1% serious). Dizziness and headaches 
were reported only during placebo conditions. Though lower GI symptoms were frequently 
reported during exercise for all conditions, none were classified as serious. Upper GI 
symptoms were commonly reported with Heat (0.6 + 1.0, 3% serious), NpxHeat (0.3 + 0.9 
and 2%), Control (0.3 + 0.6, 1%), and Npx (0.4 + 0.7, 1%). Nausea and vomiting were the 
only reported serious upper GI symptoms. There were no significant differences for GI 
symptoms during exercise either within or between genders. 
Correlations 
We identified no significant correlations for GI symptoms to fluid volume, core 
temperature, max RPE, or max HR. We found a significant positive correlation between 
max RPE and HR for Control (ρ = 0.8, P = 0.002), Npx (ρ = 0.8, P = 0.006), and Heat (ρ 
= 0.6, P = 0.43), but not for NpxHeat. A significant positive correlation was found for max 
core temperature and HR only during Control (ρ = 0.7, P = 0.025). Distance traveled was 
significantly correlated to max RPE during Npx (ρ = 0.6, P = 0.044) and to core 
temperature during NpxHeat (ρ = 0.7, P = 0.028). During Heat, we found a significant 
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positive correlation between lower and upper GI symptoms (ρ = 0.9, P = 0.001) and lower 
and systemic GI symptoms (ρ = 0.7, P = 0.03). 
We identified several significant correlations within genders. Distance and max HR 
in females were strongly correlated during the Control (ρ = 1.0, P < 0.001), but this did not 
occur in the males. Likewise, distance was strongly correlated to max HR (ρ = 1.0, P < 
0.001) and RPE (ρ = 1.0, P < 0.001) during Npx, but this was not seen in males. During 
Npx, we found male RPE was negatively correlated with upper GI symptoms (ρ = -1.0, P 
< 0.001). In the Heat, female, but not male, RPE was strongly correlated to distance (ρ = 
1.0, P < 0.001) and fluid volume (ρ = 1.0, P = 0.005). Finally, within NpxHeat, female 
distance was significantly correlated to upper GI symptoms (ρ = 0.9, P = 0.041) and HR (ρ 
= 1.0, P = 0.005). On the other hand, in males, core temperature was strong correlated to 
distance (ρ = 0.8, P = 0.036) and systemic GI symptoms (ρ = 0.9, P = 0.029). 
DISCUSSION 
Extensive evidence shows NSAIDs negatively affect the GI and cardiovascular 
systems,(13,17,20,22) yet there remains a high prevalence of NSAIDs use before and 
during exercise.(11,38-40) Often, NSAIDs are taken to prevent or alleviate pain and 
inflammation and, seemingly, these effects would increase performance. Ours results show 
a 24 hr dose of naproxen does not improve performance, as measured by RPE, distance, 
and max HR. We also found compared to placebos, naproxen did not significantly increase 
GI symptoms pre-, during, or post-exercise and these responses were not different between 
males and females.    
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Performance 
Like previous studies using aspirin(6,15,18) and ibuprofen,(8) naproxen did not 
improve performance. However, contrary to our hypothesis, we did not find naproxen 
significantly decreased performance variables. A potential explanation for the lack of 
statistical significance is using a low dose. Variation in dosage is partly due to differences 
in cyclooxygenase (COX) selectivity and half-life. Compared to aspirin and ibuprofen, 
naproxen is more selective toward inhibiting COX 2, which is produced by tissues locally 
in response to damage(21) and is a key mediator of pain and inflammation.(1) Through 
higher selectivity, naproxen is considered a more effective anti-inflammatory and analgesic 
than other NSAIDs.(2) Naproxen also has a longer half-life, 10-20 hrs, meaning individuals 
can take less doses than aspirin (2-3 hr half-life) and ibuprofen (2-4 hr half-life).(5) With 
these considerations, higher aspirin and ibuprofen doses are recommended to elicit anti-
inflammatory and analgesic effects, and therefore higher doses are seen in 
literature.(6,8,15,18) Increasing the naproxen dose (ie, prescription strength) and extending 
time used (ie, more than 24 hrs) could elicit different, more significant responses. This 
thought is supported when examining acute versus chronic aspirin use, with acute eliciting 
significantly increased RPE, while chronic significantly affected RPE, lactate, hematocrit, 
and fatigue.(15)  
Our participants were euhydrated throughout exercise; therefore, increased HR was 
not dehydration induced, but rather associated with experimental conditions. When 
examining heat trials, NpxHeat averaged less miles with a higher HR and RPE compared 
to Heat. This same increase in cardiovascular strain was seen when we examined gender 
differences. Males averaged the same mileage in heat trials, but they experienced higher 
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max HR with naproxen. Females covered the least amount of distance and experienced 
their highest HR during NpxHeat. Keeping in mind NSAID effects on the cardiovascular 
system (vasoconstriction and increased BP) and the cardiovascular systems’ response to 
intense exercise under thermal stress (increased HR to maintain cardiac output),(24) our 
results suggest combining naproxen and heat could increase cardiovascular strain and max 
RPE, resulting in less distance. 
Slightly different results were found among the ambient conditions. Naproxen 
resulted in the greatest distance covered with no change in RPE and a slightly higher HR. 
Both males and females averaged their greatest distance during the Npx trial compared to 
Control. Males experienced their highest max HR and RPE during Npx, suggesting they 
were cycling at a higher workload than during Control. While females averaged more 
mileage during Npx, their max HR was lower than any other trial. The slight differences 
between heat and ambient suggests environment may impact the effects of naproxen on 
performance. To our knowledge, examining NSAIDs on performance in the heat has not 
been conducted. Da Silva et al.(8) used ambient conditions (18-21°C) and since other 
laboratory studies do not provide environment information,(6,15,18) we assume these were 
also conducted in ambient conditions.  
Our high correlation between max HR and max RPE in all conditions, except for 
NpxHeat, suggests our participants were able to accurately assess their RPE and were 
exhibiting max effort at 90 min. During minutes 30 to 80 of steady state, RPE did not differ 
between genders. This is consistent with genders working at a relative % V̇O2max during 
treadmill running and cycling,(33) but contrasts Cook et al,(7) who found females reported 
lower RPE than males during cycling at given percentages of peak power output. Once 
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cycling reached peak power output, males reported significantly higher RPE than females 
(19.6 + 0.9 and 18.7 + 1.4, respectively, P < 0.008).(7) The significantly higher aggregate 
values for our male participants compared to females reflects at max effort males report 
higher RPE, but when working at a relative percentage of V̇O2max males and females 
respond similarly. Moreover, this was not influenced by taking naproxen or by the 
environment. 
Gastrointestinal Distress 
 Intense physical exercise and heat stress can induce GI symptoms and is heavily 
influenced by factors such as previous and current medical history, medication, nutrition, 
and exercise mode. Typically, endurance exercise elicits more GI symptoms than 
anaerobic, and running generally induces greater symptoms than cycling.(29,30) The 
etiology for GI distress is not well understood, but is suggested to be attributed to 
mechanical vibrations,(9) GI ischemia-reperfusion,(3,37) and inflammatory 
responses.(3,19) Prevalence for GI symptoms during exercise in our study is similar to 
ultra-distance runners (60%).(36) Type of symptoms (ie, nausea, diarrhea, and vomiting) 
was also similar to runners.(36) However, considering the prevalence of GI bleeding during 
running,(25) we were surprised to find a lack of positive FOB, particularly with the 
NpxHeat. We likely attenuated the incidence for GI bleeding by using a less impactful 
exercise (cycling) and a shorter, moderate-intense exercise bout.  
 Contrary to our hypothesis, naproxen did not significantly increase GI distress 
compared to placebo. One of the most notable findings is naproxen preventing dizziness 
and headache during exercise, but not before or after exercise, in both heat and ambient 
trials. Compared to Control, Npx experienced more upper GI symptoms during exercise 
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but less systemic symptoms. Both Heat and NpxHeat experienced upper GI symptoms, but 
NpxHeat, once again, experienced less systemic. The high percentage of serious scores in 
the ambient conditions compared to heat are probably due to the exercise intensity during 
80 min cycling prior to max effort. Because participants cycled at a steady HR, during the 
heat trials HR naturally increased in response to thermal strain. This forced participants to 
cycle at a lower intensity to maintain target HR. Less intensity explains the lower 
percentage of serious scores and symptoms in the heat. Additionally, urge to urinate during 
heat trails was likely mitigated by increased fluid needs in the hot environment (ie, 
sweating). Interestingly, higher frequency and serious scores were reported day-post during 
Heat and NpxHeat trials compared to ambient. These data suggest lingering effects from 
exercise in a hot environment, which was, to some extent, alleviated by naproxen. We did 
not assess physiological measures day-post, but exercise and thermal stress induce 
inflammatory responses(35) that can last hours to days after.(26) Increased inflammation 
could explain higher GI symptoms day-post and is an important consideration for 
individuals exercising on consecutive days.  
Despite slight differences in cardiovascular and performance measures between 
genders, we found no differences in GI symptoms. Furthermore, GI symptoms in females 
were not different during menstruation. In our study, GI symptoms were not correlated 
with the amount of fluid ingested, core temperature, max HR, or max RPE. Instead, GI 
symptoms were most likely induced by exercise, environment, and/or naproxen. 
Performance variables seemed to be influenced more by each other, particularly between 
RPE and HR. Correlations among genders were slightly different than overall. The only 
significant correlations among males occurred during Npx and NpxHeat. During Npx, 
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more GI symptoms resulted in lower RPE in males, presumably limiting their ability or 
desire to cycle at max effort.  In NpxHeat, higher core temperatures were associated with 
longer mileage and more systemic GI symptoms. In females, longer distance during 
NpxHeat was related to higher GI symptoms and HR. These two findings suggest the GI 
symptoms during NpxHeat occurred as a result of working at max rather than GI symptoms 
inhibiting effort, as seen with the Npx in males. 
Limitations and Future Research 
 As with any subjective measure, we assume participants were honest when 
answering the GI symptom indexes. Similarly, we did not measure V̇O2max or power output 
during exercise, and therefore, must base our assumption that participants gave the same, 
max effort during each trial on HR and RPE. Frequency and severity for urge to urinate 
during and post-exercise was likely skewed by forcing participants to drink to maintain 
hydration, making it difficult to determine actual naproxen effects. This would be mitigated 
if participants drank the same fluid volume during each trial; however, participants were 
allowed to consume more fluid than provided. As previously mentioned, using a constant 
HR rather than V̇O2max resulted in a lower exercise intensity during heat trials. Our results 
are applicable for individuals who exercise at a given HR (eg, as a way to maintain pace), 
but this methodology mitigated finding significance during experimental conditions. 
Another potential limitation was using guaiac-based FOB to determine GI bleeding. By 
measuring heme-, FOB has high specificity for detecting blood from any portion of the GI 
tract (ie, stomach, small intestine, and colon). However, its sensitivity varies depending on 
brand. It is possible, due to low sensitivity, the FOB was not able to detect blood in our test 
samples, resulting in false negatives. An alternative testing option is using fecal 
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immunological test, which is not affected by diet and is highly sensitive to blood in stool. 
However, this test is less specific, only being able to detect bleeding from the colon. 
 There are several areas for future research to examine NSAID effects on 
performance and GI distress during exercise. Research should examine different dosages 
(eg, prescription strength) and length of use (eg, 3 days, 7 days, 14 days). It is pertinent to 
examine hypohydrated individuals, which would increase cardiovascular strain, GI 
distress, and perceived exertion in both ambient and hot conditions. Using a carbohydrate 
electrolyte beverage for hydration would introduce potential GI distress. Research is 
needed on different exercise modes, intensity, and length. Lastly, further research is 
warranted in both males and females to identify potential gender differences. 
Conclusion 
  Among hydrated, moderate-endurance trained males and females, a 24 hr over the 
counter dose of naproxen did not improve performance during a 90 min cycling bout in 
either ambient or hot conditions. Additionally, participants reported upper, lower, and 
systemic GI symptoms during exercise, but naproxen did not increase occurrence or 
severity. The trend for higher HR with lower distance, as well as correlations among males 
and females for GI symptoms and distance in NpxHeat, suggest combining naproxen and 
thermal stress could be detrimental to performance. Considering prevalent NSAID use 
among physically active persons and known effects on the cardiovascular and GI systems, 
further research on health and performance measures is warranted, particularly in hot 
environments.  
 
 82 
 
REFERENCES 
1. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially 
metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 
1999;274(17):11660-6. 
2. Capone ML, Tacconelli S, Sciulli MG, et al. Human pharmacology of naproxen 
sodium. J Pharmacol Exp Ther. 2007;322(2):453-60. 
3. Carden DL, Granger DN. Pathophysiology of ischemia-reperfusion injury. J Pathol. 
2000;190:255-66. 
4. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and 
selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795-804. 
5. Ciccone CD. Davis's Drug Guide for Rehabilitation Specialists. Philadelphia, PA: F. 
A. Davis; 2013. 
6. Cook DB, O'Connor PJ, Eubanks SA, Smith JC, Lee M. Naturally occurring muscle 
pain during exercise: assessment and experimental evidence. Med Sci Sport Exerc. 
1997;29(8):999-1012. 
7. Cook DB, O'Connor PJ, Oliver SE, Lee Y. Sex differences in naturally occuring leg 
muscle pain and exertion during maximal cycle ergometry. Intern J Neuroscience. 
1998;95:183-202. 
8. Da Silva E, Pinto RS, Cadore EL, Kruel LF. Nonsteroidal anti-inflammatory drug 
use and endurance during running in male long-distance runners. J Athl Train. 
2015;50(3):295-302. 
9. de Oliveira EP, Burini RC. The impact of physical exercise on the gastrointestinal 
tract. Curr Opin Clin Nutr Metab Care. 2009;12(5):533-8. 
10. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power 
analysis program for the social, behavioral, and biomedical sciences. Behav Res 
Methods. 2007;39(2):175-91. 
11. Feucht CL, Patel DR. Analgesics and anti-inflammatory medications in sports - use 
and abuse. Pediatr Clin N Am. 2010;57:751-74. 
12. Foster J, Taylor L, Chrismas BC, Watkins SL, Mauger AR. The influence of 
acetaminophen on repeated sprint cycling performance. Eur J Appl Physiol. 
2014;114(1):41-8.
 83 
 
13. Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-
inflammatory drugs and the risk of myocardial infarction in the general population. 
BMC Med. 2005;3:17-22. 
14. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-
inflammatory drugs. Arch Intern Med. 1992;152:625-32. 
15. Gilbert JA. Acute and chronic effect of apirin on selected endurance variables. Sports 
Med Train Rehab. 1995;6(4):299-307. 
16. Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. 3rd ed. 
St. Louis, MO: Saunders Elsevier; 2009. 
17. Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. 
Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of 
stroke. Arch Intern Med. 2008;168(11):1219-24. 
18. Hudson GM, Green JM, Bishop PA, Richardson MT. Effects of caffeine and aspirin 
on light resistance training performance, perceived exertion, and pain perception. J 
Strength Cond Res. 2008;22(6):1950-7. 
19. Jeukendrup AE, Vet-Joop K, Sturk A, et al. Relationship between gastro-intestinal 
complaints and endotoxaemia, cytokine release and the acute-phase reaction during 
and after a long-distance triathlon in highly trained men. Clin Sci. 2000;98:47-55. 
20. Lewis SC, Langman MJS, Laporte J-R, Matthews JNS, Rawlins MD, Wiholm B-E. 
Dose–response relationships between individual nonaspirin nonsteroidal anti-
inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a 
meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54:320-6. 
21. Li H, Edin ML, Gruzdev A, et al. Regulation of T helper cell subsets by 
cyclooxygenases and their metabolites. Prostaglandins Other Lipid Mediat. 
2013;104-105:74-83. 
22. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability 
among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 
Arthritis Rheum. 2010;62(6):1592-601. 
23. Mauger AR, Taylor L, Harding C, Wright B, Foster J, Castle PC. Acute 
acetaminophen (paracetamol) ingestion improves time to exhaustion during exercise 
in the heat. Exp Physiol. 2014;99(1):164-71. 
24. McArdle WD, Katch FI, Katch VL. Exercise Physiology: Energy, Nutrition, and 
Human Performance. Fifth ed. Baltimore, MD: Lippincott Williams & Wilkins; 
2001. 
25. Moses FM. The effect of exercise on the gastrointestinal tract. Sports Med. 
1990;9(3):159-72. 
 84 
 
26. Pedersen BK, Rohde T, Ostrowski K. Recovery of the immune system after exercise. 
Acta Physiol Scand. 1998;162:325-32. 
27. Pescatello LS, ed ACSM's Guidelines for Exercise Testing and Prescription. 9th ed. 
Baltimore, MD: Lippincott Williams & Wilkins; 2014. Arena R, ed. Exercise 
Testing. 
28. Peters HPF, Bos M, Seebregts L, et al. Gastrointestinal symptoms in long-distance 
runners, cyclists, and triathletes: prevalence, medication, and etiology. Am J 
Gastroenterol. 1999;94(6):1570-81. 
29. Peters HPF, Wiersma WC, Akkermans LM, et al. Gastrointestinal mucosal integrity 
after prolonged exercise with fluid supplementation. Med Sci Sport Exerc. 
2000;32(1):134-42. 
30. Peters HPF, Wiersma WC, Koerselman J, et al. The effect of a sports drink on 
gastroesophageal reflux during a run-bike-run test. Int J Sports Med. 1999;20:65-70. 
31. Pfeiffer B, Cotterill A, Grathwohl D, Stellingwerff T, Jeukendrup AE. The effect of 
carbohydrate gels on gastrointestinal tolerance during a 16-km run. Int J Sport Nutr 
Exerc Metab. 2009;19:485-503. 
32. Pfeiffer B, Stellingwerff T, Hodgson AB, et al. Nutritional intake and gastrointestinal 
problems during competitive endurance events. Med Sci Sport Exerc. 
2012;44(2):344-51. 
33. Robertson RJ, Moyna NM, Sward KL, Millich NB, Goss FL, Thompson PD. Gender 
comparison of RPE at absolute and relative physiological criteria. Med Sci Sport 
Exerc. 2000;32(12):2120-9. 
34. Sawka MN, Burke LM, Eichner ER, Maughan RJ, Montain SJ, Stachenfeld NS. 
American College of Sports Medicine position stand. Exercise and fluid replacement. 
Med Sci Sport Exerc. 2007;39(2):377-90. 
35. Starkie RL, Hargreaves M, Rolland J, Febbraio MA. Heat stress, cytokines, and the 
immune response to exercise. Brain Behav Immun. 2005;19(5):404-12. 
36. Stuempfle KJ, Hoffman MD, Hew-Butler T. Association of gastrointestinal distress 
in ultramarathoners with race diet. Int J Sport Nutr Exerc Metab. 2013;23:103-9. 
37. ter Steege RW, Kolkman JJ. Review article: the pathophysiology and management 
of gastrointestinal symptoms during physical exercise, and the role of splanchnic 
blood flow. Aliment Pharmacol Ther. 2012;35(5):516-28. 
38. Tscholl P, Alonso JM, Dolle G, Junge A, Dvorak J. The use of drugs and nutritional 
supplements in top-level track and field athletes. Am J Sports Med. 2010;38(1):133-
40. 
 85 
 
39. Warden SJ. Prophylactic use of NSAIDs by athletes: a risk/benefit assessment. Phys 
Sportsmed. 2010;1(38):1-7. 
40. Warner DC, Schnepf G, Barrett MS, Dian D, Swigonski NL. Prevalence, attitudes, 
and behaviors related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) 
in student athletes. J Adolescent Health. 2002;30:150-3. 
41. Wharam PC, Speedy DB, Noakes TD, Thompson JM, Reid SA, Holtzhausen LM. 
NSAID use increases the risk of developing hyponatremia during an Ironman 
triathlon. Med Sci Sport Exerc. 2006;38(4):618-22. 
 86 
 
Table 4.1. Participant Demographics (M + SD) 
 Aggregate 
(N = 11) 
Male 
(N = 6) 
Female 
(N = 5) 
Age (yrs) 27.8 + 5.7 28.7 + 5.3 26.8 + 6.5 
Weight (kg) 79.1 + 17.9 88.4 + 14.0 67.9 + 16.5 
Height (cm) 177.0 + 9.5 183.2 + 5.3a 169.5 + 7.8 
Body fat (%) 15.2 + 8.3 10.7 + 4.0a 20.6 + 9.1 
V̇O2max 
(mL/kg) 41.4 + 5.7 43.6 + 5.3 38.7 + 5.3 
aSignificant difference between genders (P < 0.04). 
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Table 4.2. Performance Measures during Cycling for Experimental Condition 
(M + SD) 
 
Control Npx Heat NpxHeat 
Distance (miles) 3.2 + 0.8 3.3 + 0.8 2.9 + 0.8 2.8 + 0.8 
Max HR (bpm) 175.7 + 14.2 176.2 + 15.0 177.8 + 18.2 179.0 + 18.0 
RPE     
Pre 8 + 2 9 + 3 9 + 3 8 + 2 
80 min 13 + 2 13 + 3 12 + 2 12 + 2 
Post 19 + 2 19 + 2 18 + 2 19 + 2 
     
No significant differences between trials.  
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Table 4.3. Mean and Maximum Gastrointestinal Symptom Scores for Experimental Conditions 
Symptoms Control  Npx  Heat  NpxHeat 
Max M + SD  Max M + SD  Max M + SD  Max M + SD 
Upper            
Reflux/Heartburn - -  - -  6 0.1 + 0.9  - - 
Belching 1 0.1 + 0.4  - -  6 0.2 + 0.9  4 0.1 + 0.6 
Bloating 5 04 + 1.2  2 0.2 + 0.4  6 0.5 + 1.3  2 0.2 + 0.8 
Stomach pain 2 0.3 + 0.6  2 0.2 + 0.5  6 0.4 + 1.3  2 0.3 + 1.1 
Vomiting - -  - -  2 0.2 + 1.1  2 0.2 + 1.1 
Nausea 3 0.2 + 0.5  1 0.0 + 0.2  6 0.5 + 1.4  3 0.3 + 1.2 
Lower            
Intestinal cramps 2 0.3 + 0.7  1 0.0 + 0.2  8 0.5 + 1.6  2 0.2 + 1.2 
Flatulence 3 0.3 + 0.8  2 0.1 + 0.5  4 0.3 + 0.9  5 0.3 + 1.0 
Urge to defecate 5 0.4 + 1.0  4 0.2 + 0.7  6 0.5 + 1.5  7 0.3 + 1.4 
Abdominal pain - -  - -  2 0.1 + 0.5  - - 
Loose stool/Diarrhea - -  - -  4 0.4 + 1.5  7 0.4 + 1.7 
Systemic            
Dizziness 3 0.1 + 0.5   2 0.1 + 0.3  3 0.2 + 0.7  3 0.2 + 0.6 
Headache 5 0.6 + 1.0  2 0.1 + 0.4  5 0.3 + 0.9  3 0.2 + 0.6 
Muscle cramps 3 0.1 + 0.4  1 0.0 + 0.2  6 0.1 + 0.9  - - 
Urge to urinate 8 0.8 + 1.9  7 0.9 + 1.7  8 0.9 + 1.7  5 0.5 + 1.2 
            
Based on aggregate scores for all symptoms reported at pre-, post-, 3 hrs post-, and day post-exercise. 
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Table 4.4. Mean and Maximum Gastrointestinal Symptom Scores for Experimental Conditions during Exercise 
Symptoms Control  Npx  Heat  NpxHeat 
Max M + SD  Max M + SD  Max M + SD  Max M + SD 
Upper            
Reflux/Heartburn - -  2 0.0 + 0.2  - -  - - 
Belching - -  - -  - -  - - 
Bloating - -  3 0.1 + 0.3  4 0.1 + 0.5  2 0.0 + 0.2 
Stomach pain - -  2 0.1 + 0.4  4 0.1 + 0.6  - - 
Vomiting - -  - -  5 0.1 + 0.5  7 0.1 + 0.7 
Nausea 8 0.2 + 0.9  8 0.1 + 0.8  7 0.1 + 0.9  7 0.1 + 0.7 
Lower            
Intestinal cramps 3 0.3 + 0.9  - -  4 0.1 + 0.6  3 0.1 + 0.4 
Flatulence 1 0.0 + 0.1  - -  - -  - - 
Urge to defecate - -  4 0.1 + 0.4  4 0.0 + 0.4  4 0.1 + 0.6 
Abdominal pain - -  - -  - -  - - 
Loose stool/Diarrhea - -  - -  - -  - - 
Systemic            
Dizziness 4 0.1 + 0.5  - -  5 0.1 + 0.5  - - 
Headache 4 0.2 + 0.9  - -  4 0.0 + 0.4  - - 
Muscle cramps - -  - -  - -  - - 
Urge to urinate 8 0.8 + 1.9  8 0.9 + 1.9  7 0.4 + 1.5  5 0.1 + 0.7 
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CHAPTER 5 
PROPOSAL
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INTRODUCTION 
During intense exercise, especially in hot, humid environments, a number of body 
systems must work concurrently to cool the core, maintain muscle function, and maintain 
vital cardiovascular function. The cardiovascular system’s response to exercise and thermal 
stress depends on the intensity of each, but in general responds by increasing peripheral 
blood flow and shunting blood away from the gut toward working muscles. Peripheral 
vasodilation allows the release of metabolic heat produced during exercise, and shunting 
blood to working muscles allows the individual to maintain the given activity. As exercise 
and thermal load increase, the system must prioritize whether to maintain blood pressure 
(BP), skin blood flow, or muscle function.1 The cardiovascular system can temporarily 
maintain BP, and overall cardiac output, by increasing heart rate (HR). However, 
maximum exertion and thermal overload, especially if combined with dehydration, can 
exceed this ability.1 Upon cardiovascular compromise, and with the gastrointestinal (GI) 
tract in a state of ischemia from decreased blood flow, core temperature (Tc) will increase 
and systemic inflammatory response (SIR) occurs.2,3  
Prevalence of previous illness and GI distress during exercise and thermal stress 
suggests the GI tract and immune system impact the development of exertional heat illness 
(EHI), especially exertional heat stroke (EHS). Symptoms of EHS (vomiting, dehydration, 
multi-system organ failure, etc.)4 are similar to SIR5 and may be driven by GI distress. 
Gastrointestinal barrier dysfunction leads to the entry of bacterial lipopolysaccharide (LPS) 
into the circulation (known as endotoxemia), release of inflammatory cytokines, and a 
number of other factors that compromise the immune system. Consequently, SIR and 
thermal stress intolerance occurs, which dramatically increases the risk for EHS and death. 
 92 
STATEMENT OF THE PROBLEM 
Extensive scientific literature exits examining potential risk factors,6,7 ways to 
prevent,8,9 and ways to treat EHS.10,11 Unfortunately, preventable deaths from EHS still 
occur.12 One potential contributing factor to EHS development may be non-steroidal anti-
inflammatory drugs (NSAIDs). Research has shown NSAIDs increase GI permeability 
during exercise in thermoneutral environments,13-15 cause GI distress16,17 and induce 
inflammatory responses.18 Despite knowing GI distress and inflammation are associated 
with EHS and NSAIDs, limited research has evaluated NSAIDs’ effects on Tc during 
exercise under thermal stress.  
SPECIFIC AIMS AND HYPOTHESIS 
Overall Hypothesis. Naproxen (NSAID) will increase GI permeability and inflammation 
during exercise in the heat, and will be associated with increased GI distress and 
thermoregulatory strain (Figure 5.1). This overall hypothesis is tested under three specific 
aims.  
Specific Aim 1. Determine the effects of naproxen on the GI tract and inflammation during 
exercise in the heat. 
Hypothesis 1.1. GI tract permeability is greater in participants taking naproxen 
compared to placebo controls during exercise in the heat.  
Hypothesis 1.2. GI distress, indicated by GI symptoms (eg, nausea, cramping) and 
occult fecal blood, is greater in participants taking naproxen compared to placebo 
controls during exercise in the heat.  
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Hypothesis 1.3. Plasma concentration of inflammatory cytokines (TNF-α and IL-
6) is increased in participants taking naproxen compared to placebo controls during 
exercise in the heat. 
Specific Aim 2. Determine effects of naproxen on thermoregulation and performance 
during exercise in heat.  
Hypothesis 2.1. Participants taking naproxen will experience a faster rise in Tc 
during exercise in the heat compared to placebo controls. 
Hypothesis 2.2. Cardiovascular strain (HR, BP, fluid imbalance) is greater in 
participants taking naproxen compared to placebo controls during exercise in the 
heat.  
Hypothesis 3.2. Distance covered during exercise in the heat is lower in 
participants taking naproxen compared to placebo controls. 
Specific Aim 3. Determine the relationship between naproxen and the GI tract and 
inflammation on thermoregulation during exercise in the heat. 
Hypothesis 3.1. Participants taking naproxen will have an increased Tc due to 
increased GI permeability and inflammatory cytokines. 
LITERATURE REVIEW 
GASTROINTESTINAL TRACT 
Anatomy & Physiology of Gastrointestinal Tract 
The GI tract is a long, continuous, muscular tube made up of the mouth, pharynx, 
esophagus, stomach, small intestine, and large intestine. Three parts make up the small 
intestine: duodenum, jejunum, and ileum. The large intestine is made up of 8 parts: 
transverse colon, descending colon, ascending colon, cecum, sigmoid colon, rectum, 
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appendix, and anal canal. The GI tract is lined by an epithelial barrier made up of 4 layers, 
from deep to superficial: mucosa, submucosa, muscularis externa, and serosa.19 
Stomach 
 The stomach is a storage area and site of chemical breakdown of food products. 
When the stomach is empty, mucosa and submucosa layers fold inward to form rugae,19 
allowing the stomach to expand as food is ingested. The stomach is divided into four major 
regions - cardia, fundus, body, and pylorus. Closest to the heart, the cardia region contains 
the gastroesophageal sphincter, which controls food entering the stomach or prevents 
stomach contents from entering the esophagus.19 The fundus is the dome shaped region, 
extending slightly superior and lateral to the cardia, resting against the diaphragm. The 
largest region, the body, curves into the pylorus. At the distal portion of the pylorus is the 
pyloric sphincter, which controls stomach contents entering the small intestine.19 Although 
made up of the same epithelial and muscular layers, the 4 stomach regions vary slightly in 
their function during digestion.20 As food moves in to the cardia region, there is only 
rippling of tissue layers. However, the muscularis layer of the body and plyorus regions 
are much thicker and therefore more powerful. Subsequently, food products in these 
regions are aggressively mixed with the gastric juice to produce chyme.19,20 Converting 
solid food products to chyme, a creamy paste,19 allows for absorption of nutrients and 
elimination of byproducts through the GI tract. 
Gastric emptying, the time from food entering stomach to entering small intestine, 
typically takes 4 hours.19 However, this time is heavily influenced by type of food, amount 
of fluid, and individual health factors. Gastric emptying is faster with greater amounts of 
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fluid or carbohydrates. On the other hand, gastric emptying time slows down with more 
solid or fatty meals.19  
The stomach contains a number of defense features against bacteria and other 
pathogens. A large collection of lymph nodes are responsible for fighting pathogens within 
the peritoneal cavity and intraperitoneal organs.19 Gastric acid is the stomach’s key 
defense. With a pH around 2, gastric acid is designed to control the amount of bacteria 
present in the stomach and digest proteins.19  
Small Intestine 
Three unique structure modifications of small intestine epithelium allows for 
increased absorption. Together, the mucosa and submucosa layers are permanently folded 
into circular folds, or plicae circulares. These folds slow the movement of digestive product 
to allow for full absorption. On the outside of the mucosa cells are villi, fingerlike 
projections made of epithelial cells. Villi absorb nutrients into the blood stream through 
their dense capillary bed. Microvilli are located on the plasma membrane of mucosa cells 
and contain enzymes that complete digestion of carbohydrates and proteins.19  
Like the stomach, the small intestine contains a number of protective factors.  
Between villi are crypts of Lieberkühn. Within crypts are Paneth cells that release 
lysozyme, an antibacterial enzyme that protects the small intestine from bacteria.19 Another 
protection against bacteria comes from Peyer’s patches located in submucosa and 
immunocytes.19,21 The small intestine contains intestinal juice. However, unlike gastric 
juice, intestinal juice has a relatively neutral pH, is primarily made up of water and mucus, 
and does not contain many digestive enzymes. The primary function of intestinal juice is 
to protect the epithelial lining from pathogens.19  
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Large Intestine 
 Notable differences occur in the large intestine layers. Because most nutrient 
absorption takes place in the small intestine, the simple columnar epithelium contains no 
folds, villi, or digestive enzyme secretions. Large intestine characteristics include a thick 
mucosa layer, large number of goblet cells, and a large number of deep crypts. Mucosa is 
especially important to protect the wall against passing feces and acids/gases from 
bacteria.19  
 Most bacteria that enter the large intestine have been killed by highly acidic gastric 
juice or small intestine lysozymes. However, a number of bacteria enter the large intestine 
and colonize; this is known as the bacterial flora. Bacteria are naturally occurring, playing 
several imperative roles in maintaining human health. For instance, the bacteria flora 
assists in mucosal homeostasis, repair, and glucose transporter induction; induced capillary 
formation; innate immunity induction;22 and is useful in synthesizing some important 
vitamins (B complex and K). Large intestine bacteria are responsible for fermenting 
indigestible carbohydrates. A major consequence to this fermentation is the release of acids 
and gases such a carbon dioxide, hydrogen, nitrogen, and methane. Some of these gases 
are odorless, but dimethyl sulfide is extremely odorous. On average, the large intestine 
produces about 500ml of gas a day and this number increases with high carbohydrate rich 
foods (eg, beans).19 
Blood Flow  
 Gastrointestinal blood supply comes from hepatic, splenic, and left gastric branches 
of the celiac trunk. Under normal resting conditions, the GI tract receives approximately 
20-25% of cardiac output, increasing with meal consumption and decreasing with intense 
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exercise.19,23 In addition to food and exercise, other factors such as age, temperature 
(environment or body), training status, and disease affect GI tract blood flow.23 In general, 
blood flow is regulated by the autonomic nervous system’s parasympathetic and 
sympathetic divisions.19  
Parasympathetic Nervous Division 
Parasympathetic nerve fibers originate from the cranial and sacral spine.19 The 
vagus nerve accounts for approximately 80-90% of cranial parasympathetic fibers, 
innervating the heart, lungs, and majority of visceral organs, including the GI tract (liver, 
gallbladder, stomach, pancreas, small intestine, and proximal large intestine).1,19 At rest 
and during digestion, the parasympathetic nervous division slows HR and respiration and 
dilates blood vessels to the GI tract to allow relaxation and stimulate food digestion.1 At 
onset of exercise, and during low to moderate intensity exercise, parasympathetic nerves 
are inhibited to allow HR to increase. When an individual approaches maximum intensity 
exercise, parasympathetic nerves are further inhibited and sympathetic nerves are directly 
stimulated.1   
Sympathetic Nervous Division 
Much more complex, the sympathetic nervous division is commonly referred to as 
the “fight or flight” response. Sympathetic fibers originate in the thoracic and lumbar spine 
and innervate the heart, lungs, all visceral organs, all arteries and veins, and skin.19 The 
sympathetic division stimulates release of norepinephrine and epinephrine to increase HR, 
BP, and respiration,1 and vasoconstrict cutaneous and visceral blood vessels to shunt blood 
to working muscles and limit nonessential functions (eg, digestion).19 During extreme 
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intense exercise, visceral blood flow may decrease up to 80%,24 placing these organs at 
risk for ischemic injury.  
Other Regulators of Blood Flow 
 The greatest control of blood flow during exercise comes from central command, 
where the cerebral cortex controls anticipatory responses to exercise as well as responses 
during activity through the medulla and sympathetic-parasympathetic nerves. Baroreceptor 
and mechanoreceptors, located in blood vessels, respond to changes in mechanical 
pressure. Muscle chemoreceptors respond to changes in oxygen, carbon dioxide, hydrogen 
levels, and other metabolites from muscle activity. Other responses include 
vasoconstriction of blood vessels in inactive muscles and GI blood vessels and vasodilation 
in active muscles. Central command responses are faster than sympathetic responses 
(sympathetic stimulation typically does not take place until moderate to intense exercise) 
and are involved with emotional responses to exercise or stress.1   
Other hormonal regulators of blood flow include angiotensin II, aldosterone, 
vasopressin, and atrial natriuretic peptide. Often working collectively, these hormones 
exert their effects by either acting on the heart, blood vessels, or kidneys. The renin-
angiotensin-aldosterone mechanism occurs in response to sympathetic nerve activity. 
During hypovolemia or hypotension, renin, an enzyme released by juxtaglomerular cells, 
promotes production of angiotensin I. Angiotensin-converting enzyme converts 
angiotensin I to angiotensin II, causing vasoconstriction and subsequent increase in BP. 
Also stimulated is aldosterone secretion from the adrenal cortex. Aldosterone stimulates 
reabsorption of sodium in the kidneys, subsequently pulling water with it and increasing 
both blood volume and pressure.1 Vasopressin is a hormone released by the posterior 
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pituitary in response to hypovolemia, hypotension, or increased plasma osmolality (ie, high 
plasma sodium concentration). In order to reestablish vascular homeostasis, vasopressin 
acts on the kidneys to promote water reabsorption. Thus, it is alternatively known as anti-
diuretic hormone.1,25 Lastly, atrial natriuretic hormone responds to atrial stretching, often 
from increased BP. Acting as a protective response and “fine tuning” BP, atrial natriuretic 
hormone inhibits vasopressin, aldosterone, renin, and sodium reabsorption in the 
kidneys.1,25  
Gastrointestinal Barrier 
 Overall purpose of the GI barrier is to prevent foreign substances such as food 
product, acids, and toxins from passing from the intestine into the blood stream.26 Barrier 
maintenance is imperative, and its function is tightly controlled. The GI barrier is 
comprised of 3 factors: physical, physiological, and immunological. Physical factors 
include the 4 epithelial tissue membranes layers. Membrane tissue integrity is primarily 
maintained by the apical junctional complex.19,27 Together, physiological factors (ie, 
mucus secretions and bicarbonate) and immunological factors (ie, macrophages) protect 
the tissues and entire GI tract from toxins and acid.19,28  
Tissue Membranes 
Mucosa is the innermost layer of moist epithelial membrane that lines the lumen. 
Major mucosa functions include secretion of mucus, digestive enzymes, and hormones 
(making the mucosa an endocrine organ); absorption of digested end-products into the 
blood stream; and protection against infectious disease.19 Stomach mucosa is exposed to 
extremely harsh gastric juice.19 The acidity of gastric acid is imperative in defense against 
excessive bacteria formation.18 However, exposure to gastric acid can cause severe 
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epithelial or organ tissue damage.21 Therefore, mucosa cells, which are rich in bicarbonate, 
are imperative to protect and neutralize pH at the epithelial cell surface. Any damaged cells 
are quickly shed and replaced by undifferential stem cells residing in gastric pits. The entire 
epithelium surface is completely replaced every 3-6 days.19,21  
The mucosa has 3 sublayers: lining epithelium, lamina propria, and muscularis 
mucosae.19 Lining epithelium is heavy in mucus secreting cells and biocarbonate alkaline 
secretions that create the protective GI barrier and allow food to pass through easier.19,21 
Lamina propria, made up of loose areolar tissue, allows capillaries to reach the epithelial 
layer and lymph nodes to fight against bacteria and pathogens.19 Muscularis mucosae is a 
layer of smooth muscle cells that allow local movement of the mucosa.19 
The second tissue membrane layer, the submucosa, is made up of elastic connective 
tissue that allows the stomach to expand and regain its normal shape after a large meal. 
This layer contains blood vessels, lymphatic vessels, lymph nodes, and nerve fibers.19 
Muscularis externa, the third tissue layer, is responsible for segmentation and peristalsis. 
The smooth muscle contractions and relaxations propel contents through the tract and is 
collectively known as GI motility. The circular layer creates sphincters throughout the tract 
to prevent backflow and control food passing from one section to the next.19 The fourth, 
outermost layer is the serosa, which is made up of areolar connective tissue covered by a 
single layer of squamous epithelial cells.19    
Apical Junctional Complex 
In healthy GI barriers, epithelial cell integrity is maintained by the apical junctional 
complex, made up of tight junction, adherens junction, and desmosome.27 Tight junctions 
are multi-protein complexes formed by distinct contacts between two adjacent plasma 
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membranes.29 Tight junctions contain transmembrane proteins, called claudins, and 
peripheral proteins, called zonula occludens. Tight junctions are supported by adherens 
junctions and desmosomes. Adherens junctions provide strong support to membranes to 
allow cell-cell communication.27 Both tight and adherens junctions are connected to a 
perijunctional actomyosin ring,29,30 which controls junction position. When actomyosin is 
relaxed tension is reduced on the junctions, decreasing tight junction permeability. On the 
other hand, when actomyosin is contracted, junctions are moved, and tight junction 
permeability increases.30 Movement of tight junctions is driven by myosin light chain 
kinase, which phosphorylates myosin light chain in the perijunctional actomyosin ring.31,32    
Tight junctions vary along the entire GI tract, differing in their tightening ability 
depending on the segment function. For example, duodenum tight junctions have greater 
ability to tighten than those in the ilieum.33 This is important because the duodenum is 
exposed to more acid chyme leaving the stomach than the ilieum. Compared to the small 
intestine, the colon has greater ability to tighten.33 This is likely because most nutrient 
absorption has already occurred and cells need to be protected from the large bacterial 
colony. 
 Gastrointestinal Distress 
 Gastrointestinal distress can present as any number of symptoms, including 
abdominal pain, cramping, bleeding, dyspepsia, constipation, diarrhea, nausea, emesis, 
reflux, or urge to urinate or defecate.34,35 Unfortunately, etiology of these symptoms is often 
complex and sometimes not well understood due to a number of confounding factors within 
and between subject populations. Gastrointestinal distress can occur from systemic 
conditions or from GI damage/irritation. Systemic driven GI distress may originate from 
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triggers such as stress, emotions, fever, fatigue, or other diseases.34,35 Direct damage or 
irritation can be caused by GI disease, trauma, or even diet.36 
Etiology of GI Distress Symptoms 
Abdominal Pain 
 Abdominal pain may originate from referred, mechanical, inflammatory, or 
ischemia-reperfusion sources. Conditions such as muscular injuries, muscle guarding, or 
spinal pathologies may cause referred abdominal pain.34 Mechanical abdominal pain may 
occur from stretching of an organ wall, jarring or vibrations, increased abdominal pressure, 
body position, or contraction of abdominal wall and diaphragm.35,37,38 Inflammatory pain 
originates from release of inflammatory mediators.39  
 One of the primary causes of abdominal pain is GI ischemia. Appropriate blood 
flow is not only important in providing oxygen and nutrients to tissues,19 but in buffering 
acid exposure and healing damaged tissue.40 Ischemic pain occurs when blood flow to an 
area is decreased to the point where tissues are not supplied with appropriate oxygen and 
nutrients.34 Vascular endothelial cells are particularly vulnerable to ischemia, presenting 
with altered membrane potential, decreased fluidity, impaired cytoskeleton, decreased 
energy stores, or releasing inflammatory mediators.41 Reperfusion following ischemia has 
also been identified as a source of pain and inflammation, causing swelling, disruption of 
the basal membrane, leukocyte adherence, and production of reactive oxygen species 
(ROS).41,42  
Gastritis and Peptic Ulcers  
 General stomach wall inflammation is referred to as gastritis. Gastritis includes a 
number of conditions that typically only affect the mucosal layer and is classified as acute 
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or chronic. Acute gastritis includes mucosal lining erosion. Causes are sometimes unclear 
but often associated with medication, alcohol, or stress. Chronic gastritis is less common 
and includes causes such as diabetes, autoimmune diseases, or infection by helicobacter 
pylori bacteria.19,21,34 Signs and symptoms of gastritis vary, some individuals are 
asymptomatic, but most common symptoms include abdominal pain or discomfort, nausea, 
vomiting, heartburn, or occult blood loss.34  
 An ulcer occurs when erosion reaches the submucosa layer. Duodenal ulcers are 
more common than gastric ulcers, and, like gastritis, are most commonly caused by 
bacteria. Gastric ulcers are most commonly caused by NSAIDs. Other causes include 
alcohol, coffee, smoking, trauma (eg, burns), and increased age.19,34 Psychological stress 
is also a contributing factor, especially in individuals with recurrent ulcers.34 Both gastric 
and duodenal ulcers present similarly, with severe pain, burning, cramping or aching, 
distention, and nausea. Pain typically fluctuates with gastric secretions and food intake. In 
duodenal ulcers, pain typically occurs 1-3 hours after eating. On the other hand, eating may 
either relieve or exacerbate gastric ulcers.34 This is because presence of food allows gastric 
acid to target something other than the stomach lining; however, food could be the irritant 
causing damage. If left untreated, ulcers could lead to perforation of the stomach or 
intestinal wall, peritonitis, and/or severe hemorrhaging.34  
Nausea and Emesis  
 Nausea is stimulated from the autonomic nervous system when stomach nerve 
endings are irritated. Causes of nausea can range from strong emotions to toxins such as 
drugs or alcohol that irritate the GI tract.34 Emesis can occur from a number of triggers, 
including bacterial irritation, alcohol, and certain drugs. The medulla receives an impulse 
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from irritated sites that triggers abdominal wall and diaphragm contraction. Intra-
abdominal pressure increases, then the cardiac sphincter closes, soft palate rises to close 
off the nasal passage, and contents from the stomach, and potentially duodenum, are forced 
upward.19 
Dyspepsia and Gastrointestinal Reflux 
 Dyspepsia is general abdominal discomfort, sometimes referred to as indigestion. 
Dyspepsia is often caused by gastroesophageal reflux. When stomach contents move 
backward into the esophagus the acidity causes a burning sensation, usually located behind 
the sternum (heartburn). Some causes of gastroesophageal reflux include alterations in 
esophageal peristaltic activity; increased gastroesophageal sphincter relaxation; 
consumption of alcohol, spicy or highly seasoned foods; medications; stress or 
nervousness; and large movement (eg, bending and lifting) after a large meal.34,43,44  
Diarrhea and Constipation  
 Diarrhea and constipation occur when food product passes too quickly or too slowly 
through the large intestine.19 If stool passes quickly water is not absorbed and stool 
becomes “loose”. When stool sits too long in the large intestine too much water is absorbed 
and stool becomes hard. Specific causes of diarrhea and constipation vary, but include 
disease, diet, medications, and strenuous exercise. Constipation can also cause mechanical 
abdominal pain.34  
GI Bleeding   
 Depending on the cause, GI bleeding can be identified by either brown colored 
emesis, hematemesis, melena (black, tarry stool), or hematochezia (maroon colored 
stool).34 Severe GI bleeding during exercise is rare, but may be associated with peptic 
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ulcers, trauma, systemic illness, or chronic alcohol or NSAID use.34 Most often GI bleeding 
presents as occult blood in feces and occurs from stomach damage.35 Symptoms such as 
nausea, vomiting, diarrhea, and abdominal pain may be secondary to GI bleeding.34 
Measurement Techniques 
Gastrointestinal Distress Questionnaires 
Qualitative surveys are inherently limited due to subjectivity, but are clinically 
useful tools to determine how someone feels. Gastrointestinal symptoms are commonly 
assessed prior to and after physical activity in order to determine change in GI symptoms 
that may be attributed to exercise or experimental conditions.36,45,46 Administering 
questionnaires during physical activity may be done,46-49 although this is more practical 
during laboratory studies.  
There are number of other challenges to existing GI symptom research. A common 
limitation is survey variability across studies. Some questionnaires provide specific 
questions to distinguish upper and lower abdominal symptoms, number of occurrences and 
severity,36,43 but others are less descriptive. Not identifying GI symptoms at rest (baseline) 
and not controlling for diet, medications, or supplement use is another common limitation. 
Lastly, timing of survey administration also varies, with post-activity time ranging from 
immediately45 to 2 hrs post.36  
Endoscopy 
 Endoscopy is the gold standard to objectively quantify GI damage.50 Sometimes 
combined with biopsies, endoscopy allows medical providers or researchers to examine 
the GI lining, identify specific damage, and measure severity. Endoscopy is frequently 
used, but invasive and requires intensive equipment.  
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Occult Fecal Blood Measures  
 Another objective measure of GI damage is occult fecal blood. There are two major 
types of fecal tests – guaiac-based fecal occult blood test (g-FOBTs) and fecal 
immunological test (FIT). Each has unique advantages and disadvantages. Regardless of 
test type, kits can be self-administered and are recommended for early detection of serious 
GI diseases.51 
 The g-FOBT uses guaiac to test for heme in stool. Differences exist among test 
brands, some with lower sensitivity for occult blood than others.50 Advantages to g-FOBT 
are its specificity and ability to detect blood loss from any portion of the GI tract.51 A major 
disadvantage of g-FOBT is interference with certain plants and red meat. Red meat 
contains heme, which may alter tests results. Individuals using g-FOBT are instructed to 
not eat certain foods for at least 72 hrs prior to conducting the test.52 
The FIT was introduced as a more selective alternative to g-FOBT. Designed to use 
anti-bodies to selectively detect globin, FIT identifies colon blood loss. By detecting globin 
rather than heme, there is no dietary interference or potential drug interactions. The major 
disadvantage to FIT is inability to identify small intestine or stomach bleeding.51  
 Since fecal occult tests are commonly used for early detection of cancer, specificity 
and sensitivity compared to colonoscopy is of particularly high interest. The FIT has been 
shown to have significantly higher sensitivity compared to g-FOBT in detecting cancer,50 
with 65-90% sensitivity with one-time testing.51 On the other hand, g-FOBT has 
significantly higher specificity.50 Considering advantages and research outcomes, FIT is 
the recommended method for detecting occult fecal blood.51  
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Gastrointestinal Permeability 
The apical junction complex, specifically tight junctions, closely regulates GI 
permeability. There are 2 primary permeability pathways: paracellular and transcellular. 
Paracellular permeability allows passive diffusion of large molecules, like proteins and 
bacteria, between adjacent cell membranes. Transcellular permeability allows active or 
passive diffusion of small molecules, such as ions, through specific cell membrane 
channels.27,53  
The GI tract has a usual amount of permeability for small molecules (< 150 Da) 
through non-mediated diffusion.53 Gastrointestinal permeability is considered leaky 
because it naturally allows a certain amount of fluid and ion exchange across the surface.27 
On average, 8-9 L of fluid pass through the GI tract daily. Of that, only 100-200 ml is not 
absorbed and excreted through urine and feces. In the event of increased permeability, 
decreased fluid reabsorption can present clinically as diarrhea.54 A number of other 
molecules can improperly pass through the GI barrier. The immune system can typically 
neutralize escaped molecules unless there is a state of severe stress or disease. For example, 
if LPS molecules in an immunocompromised individual are allowed to pass from the GI 
tract to the bloodstream, local and systemic inflammation can ensue and further increase 
permeability. If uncontrolled, serious conditions like endotoxemia, septic shock, EHS, or 
death can occur.26,29  
Tight Junctions 
Tight junctions are the rate-limiting step in regulating paracellular permeability.29 
Tight junctions are dynamic, continuously undergoing remodeling and restructuring as 
they interact with outside stimuli. Inflammatory mediators, hormones, and pathogens 
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increase permeability at tight junctions through two mechanisms: 1) actin-myosin ring 
dysfunction through cytoskeleton disruption, and 2) direct damage to tight junction 
proteins.54 Specific mechanisms include stimulated myosin light chain kinase transcription, 
endocytosis or transmembrane protein cleavage, altered protein kinases and second 
messengers, and increased claudin expression.27 
Research on chronic inflammatory bowel diseases and cell cultures have associated 
tight junction dysfunction to elevated inflammatory cytokines and inflammatory 
enzymes.55-57 Pro-inflammatory cytokines alter intestinal permeability by increasing tight 
junction protein transcription, protein degredation, and modulating kinases and 
cytoskeleton.27 Others have been shown increased permeability by stimulating enzymes 
that cleave phospholipid membranes57 and epithelial-neutrophil interactions.58  
Endotoxin 
 As previously mentioned, there is an extensive bacteria flora throughout the GI 
tract. The outer cell membrane wall of gram-negative bacteria is predominately made up 
of LPS. Unlike gram-positive bacteria, the complex membrane is designed to protect 
against outside substances, making them more resistant to immune responses and antibiotic 
medications.59 Three components make up LPS, an O-polysaccharide chain (O-antigen), a 
core oligosaccharide sequence, and a lipid A region. The lipid A portion contains 
hydrophobic fatty acid chains and is toxic in humans. Therefore, LPS is often referred to 
as endotoxin60 and entry into the circulation as endotoxemia. 
Under healthy conditions the GI barrier prevents LPS from entering the circulatory 
system. A certain amount of LPS in blood is normal (< 0.10 ng/ml),61 coming from dead 
bacteria and LPS shedding.62 The liver and immune system work together to clear LPS.63 
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As blood filters through the liver Kupffer cells and hepatocytes neutralize LPS through 
endocytosis.64 A major immunological response comes from neutrophils releasing 
bactericidal/permeability-increasing proteins. They have a high affinity for endotoxin65 and 
neutralize activity by decreasing membrane integrity, altering electrochemical gradients, 
inducing apoptosis, and inhibiting cytokine release.66,67 
Measurement of GI Permeability 
 Compared to animal models, there are few techniques for measuring GI 
permeability in humans. Measures of plasma LPS provide a general indicator of GI 
permeability,28 but have inherent limitations during analysis and cannot provide specific 
information regarding extent and location of GI permeability. Probes such as 
sugars/carbohydrates, chromium-labelled ethylenediaminetetra-acetate (Cr-EDTA), and 
polyethylene glycol (PEG) are commonly used to determine altered permeability 
location.28,68  
Sugar/Carbohydrate Probes 
A common permeability technique utilizes urine measures of non-digestible, non-
metabolized probes in an orally ingested solution.28 Solutions typically include 3 sugars: 
sucrose, lactulose, and rhamnose;28 however, others such as mannitol, sucralose, and 
xylose have been used.26,69 Sucrose (molecular weight = 342 Da) is not digestible in the 
stomach, and under normal healthy conditions will pass into the small and large intestine 
where it can be absorbed.69 When stomach permeability increases it allows sucrose to leak 
out. Therefore, presence of sucrose in the urine indicates increased stomach permeability. 
Similarly, lactulose is not digestible in the small intestine. Due to its large molecular weight 
(342 Da) lactulose only passes through paracellular routes (ie, tight junctions) and its 
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presence in urine indicates increased small intestine permeability.28 To control for non-
barrier (GI permeability) related urinary excretion, such as GI transit time, fluid 
distribution, and renal clearance, rhamnose (molecular weight = 164 Da) is taken with 
lactulose.26,28 Together, rhamnose and lactulose should be affected similarly by any non-
barrier related factors. The difference between rhamnose and lactulose is attributed to 
absorption route, where rhamnose detects “small pore” (para- and/or transcellular) 
permeability and lactulose detects “large pore” (transcellular) permeability.26,28,68 Intestinal 
permeability is presented as a percentage, or ratio, of lactulose to rhamnose in urine.26,28 
Drawbacks vary depending on type of sugar used. Lactulose and other sugars are 
present in some foods, which may be excreted in urine. Sugar probes are susceptible to 
metabolism and degradation from bacteria, which would underestimate permeability.68 
However, research has shown no significant difference in intravenous delivered lactulose 
recovery (92.7 + 1.2%) compared to Cr-EDTA (97.4 + 0.5%), which cannot be metabolized 
and is not degraded by bacteria.68 This suggests lactulose is an appropriate measure for GI 
permeability. Overall risk of consuming the solution is low, but some reported side effects 
have included minor GI disturbances.53 Low-risk in combination with efficiency makes 
sugar probes the standard and preferred GI permeability technique.  
Chromium-labelled Ethylenediaminetetra-acetate (Cr-EDTA) 
A less commonly utilized technique, Cr-EDTA uses a γ-ray emitting isotope in an 
orally ingested solution. Percentage excreted in urine indicates more small intestine 
permeability. Advantages to Cr-EDTA is resistance to bacterial degradation.68 The major 
negative effect of Cr-EDTA is the small exposure to radiation, albeit minimal compared to 
an abdominal x-ray (0.12 mSv versus 1.4 mSv).69  
 111 
Polyethylene Glycol (PEG) 
A mixture of polymers, PEG comes in a variety of molecular weights (400-
4,000Da)28 that are orally ingested and measured for urinary concentration to determine 
permeability. Specificity of PEG is high due to using polymers of varying masses to mimic 
the mass of small molecules (eg, rhamnose), medium molecules (eg, lactuose and Cr-
EDTA), and large molecules (eg, LPS). Despite high specificity, use of PEG has declined 
due to variability and inconsistency in GI measures. Using intravenous injected probes and 
comparing to Cr-EDTA, percent recovery of PEG-400 polymers was only 40.7 + 1.8%.68 
Losses are attributed to PEG’s lipid solubility, allowing it to more easily pass through 
tissues and, in the case of intravenously injected probes, pass into the GI tract.70,71 Large 
losses of PEG polymers lead to underestimated permeability, making it less sensitive in 
detecting small permeability changes.68   
Plasma Lipopolysaccharide  
  Plasma LPS concentration provides a general idea of GI barrier dysfunction and is 
frequently used in human research to measure endotoxemia.61,72-74 Limulus amebocyte 
lysate assays are the preferred technique. They are highly sensitive and measure biological 
endotoxin activity.75 Unfortunately, there are several disadvantages when using this 
measure. First, plasma LPS levels do not identify the specific area of GI barrier dysfunction 
(ie, gastroduodenal, small intestine, or colon). Second, because LPS is located in the 
external environment, there is a risk for assay contamination during collection, handling, 
and storage. Third, and not well understood, LPS can be bound or cleared by a number of 
biological components (ie, platelets, bile salts, high-density lipoproteins, and LPS-binding 
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protein). Inactivation is maximum when temperatures range 37-45°C, and could lower LPS 
levels below the assay’s detection ability.75 
INFLAMMATORY RESPONSES 
Whether caused by trauma or a pathogen the body will launch an immune response 
to neutralize the problem. Resultant signs and symptoms such as fever, pain, lethargy, 
swelling, and redness are often considered negative. In actuality, inflammatory responses 
are vital to prevent and counter threats. Unfortunately, inflammation can be negative if not 
controlled (eg, autoimmune diseases and secondary hypoxic injury). Therefore, many 
components of the inflammatory response have both pro- and anti-inflammatory roles 
depending on stimuli and these responses are closely regulated in attempt to maintain 
homeostasis. 
The two types of immunity are acquired and innate. Acquired immunity includes 
specific responses that have adapted due to previous exposure. These responses include 
humoral and cell-mediated events (antibody secretion and proliferation of antigen-specific 
T and B cells). Innate immunity includes all immune response that have no immunologic 
memory to previous pathogens.34 Innate responses include phagocytes (neutrophils, 
monocytes, macrophages, mast cells, and tissue dendrite cells) and basophils, eosinophils, 
and lymphocytes.19,34 Often working congruently with innate and required responses, other 
components vital during inflammation include cytokines, heat shock proteins (HSPs), 
ROS, and prostanoids.  
Inflammatory Components 
Lymphocytes  
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Lymphocytes play a major role in inflammatory mediation and work in close 
conjunction with antigen-presenting cells (APCs), such as phagocytes. After a phagocyte 
digests a pathogen, antigenic material is presented on the surface so it can be recognized 
more easily as a pathogen. Phagocytes then present the cell to lymphocytes, specifically 
T4 lymphocytes (cells). T cells provide cell-mediated immunity and make up between 65-
85% of bloodborne lymphocytes.19 There are multiple subdivisions of T cells, two that are 
responsible for destroying pathogenic cells are T4 cells (helper T cells) and T8 cells 
(cytotoxic T cells).19  
Once a T cell is presented and/or bound to an antigen it must be stimulated to 
continue with cell destruction or abort. This is referred to as costimulation. While there are 
numerous types of signals, the major signal for continued destruction comes from 
cytokines. Making up 75% of all T cells,34 T4 cells are vital to the immune response even 
though they do not directly destroy a pathogenic cell. They “help” by providing 
costimulation signals for destruction, activating macrophages, assisting natural killer cells 
(NKCs), and stimulating proliferation of other T and/or B cells. Proliferation temporarily 
increases activated T and B cells to respond to the current pathogen attack. It also 
contributes to acquired immunity by forming memory T and B cells that remain in the body 
until the same antigen is presented again.19,34 T4 cells are further classified as either Th1 
or Th2, where Th1 cells mediate aggressive cytotoxic, phagocytic inflammatory responses 
and Th2 cells mediate less-tissue destructive, cell mediated responses.76  
 Cytotoxic T cells directly attack and destroy a cell. These cells bind to a presented 
antigen and, depending on the type of T8 cell, release a cytotoxic chemical into the target 
cell’s plasma membrane. The T8 cell then detaches from the target cell and continues 
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throughout the body looking for other pathogenic cells. Cytotoxic chemicals typically 
accompany perforin, a cytolitic protein that forms transmembrane pores in target cells.19 
Once a pore is formed, chemicals like granzymes, a family of serine proteases, or TNFs 
enter and trigger apoptosis by cell lysis and/or DNA fragmentation.77,19  
Regulatory T (Treg) cells are a subset of T cells that are less understood. Known to 
be immunosuppressive, these cells are designed to slow down or stop immune responses 
by releasing anti-inflammatory cytokines,19 inhibiting T cell activation and cytokine 
release, inhibiting APCs,78 and upregulating Treg cell production.79 Research has shown 
Treg cells also contain cytotoxic properties, utilizing perforin80 and granzymes to control 
T cells, NKCs, and other cytotoxic cells.79 While Treg cells are considered important in 
preventing autoimmune reactions,19 excessive Treg production is implicated in tumor and 
disease progression.81  
Another type of lymphocyte, NKCs are important in initial immune response and 
are less specific than adaptive immune lymphocytes. As a result, NKCs are able to target 
many different viruses, bacteria, and tumor cells with or without an APC.19,34 Their primary 
function is to destroy foreign or damaged cells; this is predominately done by targeting cell 
membranes and releasing perforin to create cell lysis.82 In addition to direct cell destruction, 
NKCs promote cell death by influencing T and B cell response and producing a variety of 
cytokines and growth factors.83  
Cytokines 
 Cytokines are chemical mediators, connecting the immune system to other body 
systems. Cytokines regulate responses like cell proliferation, apoptosis, chemotaxis,19,34,59 
fever, leukocytosis, acute protein synthesis, muscle catabolism, and the hypothalamic-
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pituitary-adrenal axis.84 There are several types of cytokines; interleukins (ILs) and TNFs 
are two families.  
Interleukin (IL) 
 There are more than 30 different ILs found in humans, identified numerically and 
often with additional sub-classifications. Originally identified as chemical mediators 
produced by leukocytes (“-leukin”), in actuality T4 cells, NKCs, macrophages, endothelial 
cells, monocytes, and other cell types express ILs. Interleukins act as either pro- or anti-
inflammatory mediators by modulating growth, differentiation, and activation.85,86 
The pro-inflammatory cytokine IL-1 is primarily released by macrophages and 
stimulated by other cytokines (IL-4 and IL-6) and endotoxin.86 One major function of IL-
1 is to co-stimulate T cells to release IL-2, a growth factor that activates NKCs and 
enhances proliferation of B cells, T cells, and macrophages.19,86 Other IL-1 functions are 
fever induction by increasing the hypothalamus’ set-point temperature,19,34 stimulating PG 
production,34 hypotension during septic shock, and inducing sleep and lethargy.86 
A prominent pro-inflammatory mediator during early immune responses,85 IL-6 is 
primarily induced by monocytes and other cytokines (IL-1 and TNFs).87 IL-6 is 
multifunctional, enhancing T cell proliferation and activity, B cell differentiation and 
antibody production, macrophage differentiation, and positive acute-phase protein 
synthesis.86,87 IL-6 also acts as a thrombopoietin, promoting platelet production,87 and, 
along with IL-1, is responsible for fever and IL-2 expression.86  
An anti-inflammatory mediator, IL-10 is primarily expressed by monocytes, T 
cells, and B cells.88 IL-10 is effective at inhibiting APCs89 and T4 cell, phagocyte, and 
NKC mediated expression of IL-1β, IL-6, and TNF-α.85,86 The IL-10 family includes IL-
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22, which is prominent in anti-apoptosis and cell repair in inflammatory skin, liver, and GI 
diseases.90 IL-22 is suggested to protect GI barrier integrity by promoting cell proliferation 
and increasing expression of anti-microbial molecules and mucins.90  
Tumor Necrosis Factor (TNF) 
The most prominent TNF member is the pro-inflammatory cytokine TNF-α, also 
referred to as cachectin. These cytokines are derived from neutrophils, phagocytes, T cells, 
endothelial cells, and mast cells.55,86 TNF-β is primarily produced from lymphocytes86 and 
has historically been referred to as lymphotoxin. TNFs have direct cytotoxic effects and 
promote destruction of target cells, particularly tumor cells, by activating T cells and 
phagocytes.19,86  
Research has identified a clear relationship between TNF-α and severe cachexia in 
chronic infections and cancer.86 Along with IL-1, TNF-α contributes to hemorrhagic 
necrosis,87 vascular endothelial cell lysis,91 and stimulates IL-6 expression.87 TNF-α is 
highly induced by endotoxin,92 causing increased tight junction permeability by 
stimulating myosin light chain kinase27 and increasing vascular permeability. As a result, 
TNF-α is a key mediator in septic shock.92 
Heat Shock Protein (HSP) 
 Heat shock proteins are molecular chaperones that assist in proper folding during 
protein synthesis.60 There are many different HSP families numbered according to their 
molecular weight.19 Majority of HSPs are constitutive60 and found abundant throughout 
the body.93 A few HSPs are inducible, protecting cells exposed to stressors such as 
hyperthermia, hypothermia, inflammation, trauma, energy depletion, hypoxia, or 
toxins.19,94,95,96  
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Understanding exact HSP mechanisms is complicated, particularly since they have 
many functions and protect different cell areas. One suggested induction mechanism is in 
response to stress signals from abnormally folded and denatured proteins.97 Other research 
suggests HSPs are induced by increased reliance on anaerobic metabolism following 
mitochondria damage98 or altered cytoskeleton structure resulting in inhibited 
mitochondria function.99 Still yet, another mechanism is in response to inhibited RNA 
processing following cell nuclei thermal stress.100 Regardless of the exact mechanism, HSP 
induction is associated with an increased demand for protein synthesis.  
Primary functions of HSPs are to prevent denaturation and/or allow damaged cells 
to undergo apoptosis rather than necrosis by maintaining mitochondrial function.101 
Apoptosis is a controlled event and requires ATP. If mitochondria are damaged and cells 
undergo necrosis, leaked cell contents may perpetuate or trigger inflammatory 
responses.101 More recent research suggests HSPs have a variety of pro- and anti-
inflammatory functions during immune responses. HSPs may facilitate APCs,102 improve 
tolerance to103,104 and inhibit expression of TNF-α and IL-1,105,106 and promote NKC 
activity.96 
Another protective function of HSPs is development of thermotolerance. Increased 
expression and accumulation of HSPs following thermal stress allows cells to survive 
subsequent stress by protecting against protein denaturation. Thermotolerance is 
temporary, lasting 3-5 days, and dependent on initial temperature and duration of 
exposure.107 Considered one of the most highly inducible,108 HSP70 is preferentially 
induced during thermal stress and protects against ROS and cytokine driven 
apoptosis.94,101,109,110  
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Reactive Oxygen Species (ROS) 
 Reactive oxygen species are free radicals (eg, superoxide, hydrogen peroxide, and 
hydroxyl) released as byproducts of cell and body processes (eg, aerobic metabolism).101 
These free radicals are extremely reactive to cells60 and easily pull electrons from 
molecules.59 Several mechanisms increase ROS production. During hypoxia the imbalance 
between inputting electrons for fuel oxidation and transferring electrons to molecular 
oxygen results in ROS formation.60 Other mechanisms for ROS release are ischemia-
reperfusion injury,42 phagocytosis,101 and arachidonic acid metabolism.111 
Balance between positive and negative ROS effects is complex and depends on 
other inflammatory responses. A primary function of ROS is regulation of stress 
proteins.101 Acting like second-messengers, they trigger activation of other pathways and 
factors.112 Some ROSs are cytoprotective, upregulating HSPs by causing a cell to express 
a stress response or inducing some protein denaturation.101,112 Other ROSs provide defense 
against pathogens and toxins.101  
Despite their protective anti-inflammatory effects, ROS also promotes pro-
inflammatory responses by creating oxidative stress and cell damage. A primary target for 
ROS damage is lipid membranes. For example, ROSs stimulate phospholipase A2,111 
which breaks down phospholipid membranes by hydrolyzing fatty acids. ROSs have also 
been shown to increase cytokine gene expression.111 Excessive ROS accumulation can 
result in cytotoxic effects to enzymes, amino acids, DNA, and mitochondria.60,112  
Cyclooxygenase (COX) 
Trauma and other inflammatory stimuli activate phospholipase A2,60 which 
releases arachidonic acid, a crucial fatty acid incorporated in the phospholipid membrane 
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structure. Arachidonic acid is the precursor for production of 3 eicosanoids: prostaglandin 
(PG), thromboxane (TX), and leukotriene.60 Leukotriene production is catalyzed by 
lipooxyngease, which is not inhibited by NSAIDs113 and therefore will not be further 
discussed in this literature review. To produce TXs and PGs (collectively known as 
prostanoids), arachidonic acid must be converted to the prostaglandin endoperoxides PGG2 
and PGH2.114 These conversions are catalyzed by PGH synthases, more commonly 
referred to as cyclooxygenase (COX).115  
There are two well established COX derivatives in humans, COX-1 and COX-2. 
Both derivatives are responsible for converting arachidonic acid to TXs and PGs,116 but 
vary in their functions. Inherently located in most tissues, COX-1 is responsible for 
production of prostanoids that regulate gastric mucus secretions, platelet aggregation, and 
renal blood flow.25,116 Present in small amounts naturally, COX-2 is induced locally by 
inflammatory mediators (eg, cytokines and endotoxin)115,76 and mediates inflammation, 
pain, and fever.25,60,116  
Prostanoids 
All prostanoids are derived from prostanoic acid, and most commonly by 
arachidonic acid. Prostaglandins possess a 5-member carbon ring, with different types 
designated by letters A-K in accordance with the nature and position of substituents.117 In 
humans, the most common biologically active PGs are dienoic (designated by a subscript 
2).118 These PGs include PGE2, PGD2, PGF2,60 PGI2 (prostacyclin), and PGA2 and PGJ2 
(cyclopentenones).115  
In general, PGs are essential to maintaining GI mucosal barrier integrity, vascular 
tone, and renal function. They also are responsible for pain, inflammation, and implicated 
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in certain chronic diseases. Hormonal stimuli, such as angiotensin II,119 vasopressin,120 or 
bradykinin,121 is typically necessary for most PG synthesis, but some PGs can be induced 
by cell-cell interactions.117 In order to exert their effects, PGs must be actively transported 
across membranes. However, because they are readily deactivated, they exert only local 
effects.117 Non-cyclopentenone PGs act through binding to specific transmembrane G 
protein receptors. For example, PGE2 receptors are designated E prostanoid receptor (EP) 
1-4. Once bound and depending on the desired action, effects may include up or down 
regulation of second messengers cyclic adenosine monophosphate (cAMP) or calcium, 
altered membrane potential, or activation of specific protein kinases.117,122  
Identifiable by an oxygen bridge between carbon 6 and 9,117 PGI is important in 
maintaining cardiovascular function.122 Endothelial and vascular smooth muscles cells 
constitutively express PGI.117 Prostacylin is a potent vasodilator and inhibitor of platelet 
aggregation, leukocyte adhesion, and vascular proliferation.114,123 Its efficacy led to 
development of PGI as a pharmacological treatment in a number of cardiovascular and 
renal diseases.114 
Derived from PGE and PGD respectively, PGA and PGJ contain a unique 
cyclopentenone ring structure. Cyclopentenone PGs contain an α,β–unsaturated carbonyl 
group that can react with glutathione (GSH) or other target cell proteins.117 Glutathione is 
an anti-oxidant that protects cells against ROS and other toxins. Cyclopentenone PGs are 
highly active; by reacting with GSH, they elicit a number of physiological effects other 
PGs cannot. For example, PGA and PGJ have been shown to induce HSP74 by inhibiting 
cell proliferation.124 They can also induce apoptosis in tumor cells125 and inhibit DNA and 
RNA viruses.126  
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Instead of a 5 carbon ring, TXs have a heterocyclic ring.117 Thromboxanes with 
unstable bicyclic oxygenated rings are designated TXA, and those with stable oxane rings 
TXB.117 Like PGs, subscript numerals distinguish the number of double bonds117 and they 
exert their effects through G protein receptors.122 All prostanoids have relatively short half-
lives. However, TXs are extremely unstable, with 20-30 sec half-lives.117,122 In comparison, 
under normal blood pH and temperature the half-life for PGI is 2-3 min.127 Though TXs 
elicit inflammatory effects, TXA2 is predominately produced from COX-1 in platelets. 
Along with PGIs, TXs play a major, albeit opposing, role in vascular function.117  
Functions of Prostanoids 
Gastric Mucosal Protection 
Throughout the GI tract COX-1 is expressed constitutively and produces 
cytoprotective PGE2 and PGI2. Damage or irritation to gastric mucosa epithelial lining up-
regulates COX-2 expression,128 and subsequently PGE2 and PGI2 as a defensive, anti-
inflammatory response.18 Research on the exact protective mechanisms has predominately 
focused on animal and cell cultures. Additionally, like PGI analogues developed for 
cardiovascular disease treatment, the effectiveness of PGE in protecting the GI mucosa has 
led to use of PGE analogues in studies. Existing research concludes a multifaceted 
protection by maintaining blood flow, inhibiting cell apoptosis, reducing acid secretion, 
promoting mucus and bicarbonate secretion, inhibiting ROSs, inhibiting GI hypermotility, 
and maintaining tight junctions.  
Increased Epithelial Blood Flow 
Vasodilation by PGE2 and PGI2 increases blood flow, which prevents cell necrosis 
by increasing platelets and promoting angiogenesis and cell proliferation. In addition, 
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preserving adequate GI blood flow maintains relatively neutral pH even during times of 
high acid secretion.18 Importance of blood flow is evident in GI diseases or conditions 
where blood flow is impaired. In patients with portal hypertension there is a higher risk of 
developing GI ulcers and bleeding. This risk is associated with decreased PG,18 which was 
shown in rodents with reduced portal blood flow from stomach cirrhosis. Cirrhotic rodents 
exposed to a mucosal irritant had a significantly blunted blood flow compared to controls 
(2 + 8% vs 51 + 5%, P < .001). However, PGE administration significantly increased blood 
flow in cirrhotic rodents compared to controls (83 + 12% vs. 22 + 8%, P < .01).129  
Apoptosis Inhibition 
Ability for PGs to prevent mucosal cell apoptosis has been shown in vitro. Isolated 
guinea pig gastric mucosal cells placed under maturation-dependent stress were used to 
mimic high turnover rate seen in vivo with acid exposure and damage. When compared to 
control cells, PGE2 inhibited spontaneous cell apoptosis and significantly increased cell 
viability (P < .01).130 Apoptosis inhibition occurred even after DNA fragmentation 
occurred by protecting mitochondria in a rapid, yet transient and dose dependent manner.130 
Similarly, when cells were stressed by 4% ethanol, PGE2 significantly increased cell 
viability (P < .01) compared to control cells.131  
Inhibited Gastric Acid Secretion 
Although somewhat controversial, PGI2 and PGE2 inhibit gastric acid secretion. 
Healthy males orally administered PGE2 showed significantly reduced gastric acid 
secretion by approximately 40% compared to control (P < .05).132 These results are 
supported by studies linking acid secretion and gastric ulcer development. A 12 week 
pharmacological study compared no treatment, a proton-pump inhibitor (known acid 
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suppresser), and a PGE1 analogue on GI ulcer development in 458 patients with previous 
gastric ulcer history. After 12 weeks of NSAID use, 93% of patients using PGE were ulcer 
free compared to only 51% of control and 81% of proton-pump inhibitor participant. Of 
those who developed ulcers, time to occurrence was significantly prolonged with PGE (P 
< .001) compared to no treatment and was not significantly different than the proton-pump 
inhibitor.133  
One suggested mechanism of gastric acid inhibition is increased mucosal blood 
flow, but others believe PGs elicit non-blood flow mediated inhibition. Intravenous PGE2 
and PGI2 in dogs significantly inhibited acid secretion (P < .05). PGI2 resulted in increased 
mucus blood flow while PGE2 decreased blood flow.134 Even stronger support for PGE 
acid secretion inhibition comes from in vitro studies where blood flow is not a factor.135 
This suggests PGE2 and PGI2 reduce acid secretion by directly inhibit mucus secretory 
cells. These mechanisms are not clearly understood, but include altered intracellular 
cAMP135,136 and changes in cell membrane bound phospholipids that alter hydrogen, 
potassium, and ATPase activity.137   
Other studies have been unable to demonstrate significant reduction in acid 
secretion.138,139 Lack of agreement may be attributed to different measurement techniques 
or methods such as dose or duration of use. Type of PG used also explains conflicting 
results. Unlike endogenous PGE2, intravenous or orally administered PGs analogues are 
not rapidly metabolized and can exert longer lasting effects. This idea is supported by a 
study in healthy males comparing PGE2 to different doses of PGE2 analogues. No 
significant reduction in gastric acid secretion occurred with natural PGE2, but both 
 124 
analogues resulted in significant decreases directly proportionate to dosage and lasting 3 
hours after administration.140  
Increased Bicarbonate and Mucus Secretions 
Both in vivo and in vitro studies have demonstrated upregulating PGE2 production 
increases bicarbonate and mucus secretions to protect the GI barrier. Canines administered 
intravenous PGE2 resulted in significantly increased bicarbonate production compared to 
control (mean = 64.5 μmol/hr vs 34.0 μmol/hr, P < .05).141 These results are similar to 
studies on mucus secretion in amphibian cells,142 rabbit gastric epithelial cells,143 and 
rodents.144 In 6 healthy humans administered varying doses of a PG analogue, mucus 
secretion also significantly increased (P < .01) in direct proportion to administered 
doses.138  
Despite being abundant in gastric epithelium, research has been unable to identify 
endogenous PGI2 as a stimulator of bicarbonate secretion. One suggested reason for this is 
the location of epithelial producing PGI2 cells. Unlike PGE2 cells, which are on the surface 
near bicarbonate secreting cells, PGI2 cells are located deeper. Considering location and a 
short half-life, PGI2 may not have enough time to elicit effects on bicarbonate cells, and 
assumingly mucus cells, before being degraded.145 
Decreased GI Motility, Neutrophil Chemotaxis, and ROS 
Many protective mucosa effects are interrelated. This is particularly apparent when 
discussing GI hypermotility, neutrophil chemotaxis and ROSs inhibition. Hypermotility 
results in a number of GI disturbances and is associated with increased risk for lesions 
along mucosal folds.146,147 Repeated and excessive GI contraction and relaxation also leads 
to microcirculatory disturbances, with consequences similar to ischemic-reperfusion 
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injury.146 Lastly, hypermotility stimulates neutrophil chemotaxis and neutrophil adherence 
to vascular endothelium.148 When neutrophils increase at sites of inflammation they 
interact and adhere to plasma membranes of endothelial cells and release ROS.149 If 
neutrophils accumulate in microvasculature, blood vessel occlusion can potentiate 
ischemic conditions.150  
Exogenous PGs are potent inhibitors of hypermotility, neutrophils and ROS.146,151 
Studies have demonstrated these effects using rodents with indomethacin induced GI 
mucosa lesions. Compared to control, PGE2 significantly inhibited lesion occurrence by 
83.6% (P < .05), and this was partly attributed to significant decreases in neutrophil 
chemotaxis and GI motility (83% and 81.3% respectively, P < .05).152 In a similar study, 
results showed pre-treatment with PGE2 significantly inhibited lesion formation (90.6%, 
P < .05) and GI motility.151 Using isolated neutrophils, release of ROS was significantly 
inhibited by PGE2 (P < .05) and, like many other protective effects, was dose dependent. 
This study also found PGD2, but not PGI2, was a significant and more potent inhibitor of 
ROS release (P < .05).153 Ischemia and reperfusion are potent producers of ROS154 and 
decreases GSH availability,149 which counters ROS.  
Decreased GI Permeability 
Decreased blood flow and ROS exposure can open tight junctions by damaging cell 
membranes and promoting necrosis. As a result, GI permeability increases and a cascade 
of events occurs, including cytokine release, endotoxin leakage, and monocyte activation.28 
Ability for PGs to protect GI mucosal integrity inherently assists in maintaining GI 
permeability. However, rather than preventing increased permeability PGs appear to 
maintain permeability after damage ensues. Some studies suggest PGs stimulate growth 
 126 
factors that promote epithelial cell repair.155 Others state permeability is maintained by 
contracting small intestine villi. Following 15 min of PGE2 exposure, villi height and crypt 
depth significantly decreased as result of villi smooth muscle contraction (P < .05). 
However, negligible effects occurred after 45 min of exposure.156 More recent studies 
allude to PG restoring barrier function through closing down tight junctions. An in vitro 
study used porcine ileum to examine GI permeability following induced epithelial damage. 
Both PGE2 and PGI2 contributed to barrier recovery by collapsing tight jucntions and 
tightening lateral membranes of crypt and villi to contiguous cells and basal membranes.157 
Another interesting and important finding from this study is the comparison of endogenous 
and exogenous PG. Exogenous PGs significantly decreased permeability earlier compared 
to endogenous (60 min versus 120 min, P < .01). However, by 180 min following injury 
there was no significant difference,157 suggesting both methods are effective at restoring 
GI barrier function. In a similar study design, PGI2 and PGE2 acted synergistically to close 
tight junctions by increasing intracellular cAMP and calcium signals at the cytoskeleton.158 
Vascular Tone and Renal Function 
Prostanoids play little role in vascular maintenance in normal healthy individuals. 
On the other hand, they are critical in maintaining homeostasis during altered 
cardiovascular states (eg, hypotension and heart failure) or altered fluid regulation (eg, 
renal disease, hypovolemia, and sodium imbalance). Prostanoids predominately 
responsible for vascular maintenance include PGI2, TXA2, and PGE2.  
Balance between COX-2 driven PGI2 and PGE2 production plays a significant role 
in cardiovascular diseases. Ischemia-reperfusion injury during a cardiac event increases 
PGI2 and PGE2 expression,159 which act in a protective manner to promote vasodilation 
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and inhibit platelet aggregation and vascular proliferation.117 Up-regulation of COX-2 
following endothelial cell damage stimulates PGI2 in attempt to inhibit artherogenesis. In 
contrast, PGE2 stimulates atherogenesis due to its strong pro-inflammatory effects.160 The 
strongest opposition to PGI2 is TXA2, which is predominately driven by COX-1 and 
promotes platelet aggregation, vasoconstriction, and vascular proliferation.117  
The complex relationship between PGE2 and PGI2 on kidney function can be 
summarized by three interrelated actions: 1) increased renal blood flow and natriuresis, 2) 
vasopressin inhibition, and 3) renin-angiotensin-aldosterone system stimulation. Produced 
by medullary interstitial cells, papillary collecting tubules, and glomeruli,161,162 renal PGs 
respond to hypertension, hypertonicity, and ischemia by stimulating vasodilation and 
increasing renal blood flow.118,163 Increased PGE2 production has also been shown to 
decrease renal tubular pressure by inhibiting sodium reabsorption through altered cation 
transport.164 Prostaglandins, particularly PGE2, inhibit vasopressin by altering cAMP 
activity165 and through negative feedback.120 Thirdly, both PGE2 and PGI2 can stimulate 
renin and angiotensin II release to cause vasoconstriction and increase BP.118  
Inflammation and Pain 
Pain sensation begins with peripheral nociceptors in damaged tissue transmitting 
external stimuli (eg, extreme heat, toxins, or mechanical stress) into electrical energy to be 
carried along afferent nerves to the spinal cord. Damaged tissues also release 
neurotransmitters, particularly substance P or glutamate. Concurrently, IL-1β, TNF-α, 
PGE2, PGI2, bradykinin, and numerous other chemical mediators can be released and 
potentiate inflammatory pain.39  
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Increased COX-2 expression during injury stimulates PG production,117 
preferentially producing PGE2 and PGI2.116,166 These two PGs are responsible for fever, 
swelling, redness, and pain – the cardinal signs of inflammation.117,122 Prostaglandins do 
not directly cause pain but contribute to local and disperse inflammatory pain by increasing 
afferent nerve ending sensitivity to bradykinin, stimulating calcium and sodium channels, 
and inhibiting potassium channels. In the spinal cord, PGs stimulate glutamate and 
substance P release and activate dorsal horn neurons.39 Coupling mediators (ie, PGs with 
bradykinin or bradykinin with substance P) results in an additive effect on vasodilation, 
increased vascular permeability, and pain.167,168  
Prostanoids regulate inflammation and pain processes in a number of other ways. 
Both PGE2 and PGI2 inhibit T cell signaling and differentiation, shifting differentiation 
from Th1 to Th2.76,122 Anti-inflammatory PGE2 functions include decreased lymphocyte 
proliferation117 and bradykinin stimulation, which is known to protect neurons and inhibit 
cytokine release.169 In addition to its potent changes in vascular tone, TXA2 stimulates 
lymphocyte activation and proliferation.117 Lastly, cyclopentenone PGs can induce 
apoptosis by increasing HSP 70 transcription170 and suppress gene expression of 
macrophage induced TNF-α, COX-2, and PGE2.171 Each prostanoid plays a unique role in 
the body, but in general their response to disease or injury is a vital attempt to maintain 
homeostasis. While inhibiting prostanoids may decrease some of the perceived negative 
effects (eg, fever, pain, inflammation), inhibition also diminishes any positive, protective 
effects. 
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Exercise Induced GI Distress and Inflammation 
Intense physical exercise induces a number of GI and acute inflammatory 
responses. Some underlying factors that potentiate these responses during exercise are 
nutrition, medical history, medication, hormones, dehydration, and Tc. Etiologies for GI 
dysfunction and inflammation are complex, and largely influenced by type, duration, and 
intensity of exercise.  
Type of Exercise 
GI Distress 
Specific GI symptoms vary across studies, but long distance endurance exercise is 
typically associated with more GI distress than anaerobic, short distance events. Among 30 
Ironman triathletes (29 males, 1 female, mean age = 33.0 + 6.0 yrs) completing a GI 
symptom questionnaire post-event, 93% reported experiencing some type of distress and 2 
participants were unable to complete the race due to severe GI distress. Most common 
complaints were flatulence (38%, n = 11), belching (35%, n = 10), general stomach 
problems (31%, n = 9), and bloating (24%, n = 7).74 In a sample of 125 runners (68 males, 
57 females, mean age = 37 + 9 yrs) completing the Marine Corps Marathon, there was a 
significant increase from hemoccult-negative stool pre-race to hemoccult-positive stool 
post-race (n = 29, P < .001).46 Other reported symptoms included abdominal cramps (n = 
21), diarrhea (n = 8), and vomiting (n = 1) during or post-race.46 Similar results were found 
in 15 ultra-distance runners. Sixty percent (n = 9) reported GI distress, predominately 
nausea (89%), abdominal cramps (44%), diarrhea (44%), and vomiting (22%).49  
Several studies have compared GI symptom occurrence, duration, and intensity 
between running and cycling, finding running causes more symptoms than cycling. During 
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a 180min cycle and running protocol in moderate temperature, 95% of participants (n = 
21/22) reported GI symptoms during exercise. Running resulted in significantly more 
symptoms than cycling (P < .05), specifically belching, heartburn, cramping, and side 
aches.172 A similar run-cycle-run protocol in 7 well trained male athletes resulted in 
significantly more reflux episodes during running than cycling.43 Gastrointestinal motility 
was significantly higher with cycling compared to rest (6.1 versus 4.7, P = .025) and 
carbohydrate beverage transit time progressively increased across rest, cycling, and 
running (138min, 193min, 240min, respectively, P = .03).173 
Inflammation 
Inflammatory responses during exercise include increased circulating pro-
inflammatory cytokines (IL-1β, IL-6, and TNF-α), PGE2, HSP70, and increased neutrophil 
and lymphocyte (T4 cell, T8 cell, and NKC) chemotaxis.174-176 Plasma IL-6 levels rise 
relatively quickly during intense exercise, peaking immediately after. In contrast, TNF-α 
responses are slower and peak hours post-exercise.174 In 9 sedentary males completing 45 
minutes of downhill running IL-1β, PGE2, and neutrophil chemotaxis significantly 
increased after exercise.177,178 No increase in IL-6 and TNF-α was found,177 which may be 
attributed to a short duration and lower exercise intensity. In 16 male marathon runners 
(mean age = 30.5 + 1.9 yrs, V̇O2max = 43.6 + 2.1 ml/kg/min) IL-6 significantly increased 
baseline to post-race (1.5 + 0.7 pg/ml to 94.4 + 12.6 pg/ml, P < .0001). Pre- to post-race 
IL-1β (0.61 + 0.24 pg/ml to 0.92 + 0.26 pg/ml, P < .005) and TNF-α (0.96 + 0.09 pg/ml to 
2.43 + 0.37 pg/ml, P < .0001) also significantly increased.176 Nine male Ironman triathletes 
competing in moderate temperatures (mean = 23.3 + 1.9°C) had significantly increased 
plasma HSP70 and IL-6 post-race (P < .001).175 
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Potential Etiologies 
Research is inconclusive regarding exact etiology of exercise induced GI and 
inflammatory responses. In part this is due to varying methodologies among controlled 
laboratory studies and the limitations of field studies. Potential etiologies include damage 
caused by mechanical vibrations, ischemia-reperfusion injury, and increased GI 
permeability with LPS translocation, but a combination of these factors is likely.  
 Gastrointestinal dysfunction during physical activity may be caused by mechanical 
vibrations and increased abdominal pressure.179 There is limited research in this area and 
the existing literature has several limitations. Using accelerometers on 6 well trained 
participants (3 males, 3 females) during separate cycling and running bouts resulted in 
significantly greater output during running (mean counts/min = 859.5+ 130.1 versus 425.8 
+ 149.5, P < .0001).38  Differences within activity affect vibrations as well. Running shoe 
components and surface type can increase or decrease vibrations transferred to the GI. 
Cycling position, such as standing, sitting, and leaning can also affect vibrations.38  
A profound shunting of blood during intense exercise results in local and systemic 
inflammatory responses. Ischemia occurs when splanchnic blood flow decreases more than 
50%23 and is often considered the primary cause of GI damage. Epithelial cells are 
particularly vulnerable. In hypoxic states they produce ROS and cytokines, attract 
neutrophils, and experience altered basal membrane attachment.41 Responses to GI 
ischemia-reperfusion impairs tight junctions, ultimately increasing permeability and LPS 
translocation.180 
Intense exercise during field and controlled laboratory studies increases GI 
peremability.61,181,182 Percent recovery of lactulose/rhamnose was significantly higher 
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during a 60 min run at 80% V̇O2max than lower intensities and rest (P < .05).182 With 
hydration controlled in a thermoneutral environment, 10 participants (9 males, 1 female) 
completed a rest, cycling, and running protocol. Small intestine permeability was 
significantly higher during running (mean lactulose/rhamnose ratio = 0.04 + 0.02; P < .01) 
compared to cycling (0.03 + 0.02) and rest (0.02 + 0.02).173  
Similar results are indicated with plasma LPS measures. During cycling to 
exhaustion in 10 males plasma LPS significantly increased pre- to post-exercise (0.14 to 
0.24 Eu/ml, P < .01).72 Higher incidence of vomiting, diarrhea, and nausea were reported 
in marathon runners with elevated LPS measures (0.33 + 0.04 ng/ml) compared to those 
with low LPS (0.08 + 0.01 ng/ml, P < .001).61 In attempt to identify if GI distress is 
associated with ischemia driven endotoxemia and inflammatory cytokines, blood measures 
were taken 24 hours pre-Ironman, immediately post-race, and 1, 2, and 15-20 hrs post-race. 
A significant increase from pre- to 1 hour post was found for mean LPS and IL-6 
concentration (0 pg/ml to 4 pg/ml, and 0 pg/ml to 40 pg/ml, respectively, P < .05). No GI 
symptoms were correlated with LPS concentration. However, some symptoms were 
significantly, albeit weakly, correlated to IL-6 (vomiting r2 = 0.268 and diarrhea r2 = 0.504, 
P < .05).74  
Heat Stress Induced GI Distress and Inflammation 
The greatest GI response to non-exertional thermal stress is impaired barrier 
function and subsequent LPS translocation. In 12 primates subjected to passive 
hyperthermia (41 + 0.3°C, 100% relative humidity), blood LPS measures significantly 
increased from 0.06 + 0.01ng/ml to 0.32 + 0.03ng/ml (P  < .01).183 In non-EHS patients 
(mean Tc = 42.1 + 0.2°C), significant decreases pre- to post-cooling were found for mean 
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plasma TNF-α (247.4 + 41.2 pg/ml to 133 + 27.9 pg/ml, P < .05) and LPS (12.26 + 1.86 
ng/ml to 6.12 + 1.18 ng/ml, P < .05).84 Raising Caco-2 human intestinal epithelial cell 
temperature from 37°C to 41°C cultures resulted in a  strong, linear, inverse relationship (r 
= 0.96) between temperature and transepithelial resistance,184 a measure of tight junction 
integrity. These results, along with HSP research suggest thermal stress induced 
permeability changes occur at tight junctions. Following 2hrs of heat exposure (Caco-2 cell 
temperature = 41°C) HSP70 expression peaked 4-8hrs post and tight junction protein 
expression decreased. When HSP was inhibited paracellular permeability was significantly 
greater (P < .001) than no HSP inhibition.184  
A number of other inflammatory mediators are released during passive 
hyperthermia. In particular, elevated IL-6 (220 + 44 pg/ml) was identified in 18 non-EHS 
patients with a mean Tc = 41.04 + 0.2°C.185 Another study showed pre-cooling IL-6 
concentration and severity of passive heat stroke was significantly correlated (r = 0.516, P 
< .03).186 In patients experiencing non-EHS, TNF-α significantly decreased pre- to post-
cooling (247.4 + 41.2 pg/ml to 133 + 27.9 pg/ml, P < .05) and remained above control 
values 31.4 + 8.4 pg/ml. Working synergistically, TNF-α and IL-6 may exacerbate 
hyperthermia.187 If combined with exercise, GI and inflammatory responses during thermal 
stress may lead to serious, potentially lethal conditions of endoxtemia, SIR, or EHS.      
EXERTIONAL HEAT STROKE 
Individuals may experience a number of symptoms when heat dissipation 
mechanisms are compromised during intense exercise in extreme thermal environments. 
Initially, minor symptoms such as dizziness, lightheadedness, or fainting may occur, which 
are typical of heat syncope. Heat syncope occurs due to decreased brain blood flow as a 
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result of peripheral vasodilation, postural blood pooling, diminished venous return, cardiac 
output reduction, and/or cardiac ischemia.9,188 A more serious EHI, heat exhaustion can 
occur as the cardiovascular fails and plasma volume decreases. Heat exhaustion symptoms 
include dizziness and lightheadedness, as well as fatigue, headache, normal-to-elevated Tc 
(< 40°C), nausea, vomiting, intestinal cramps, tachycardia, and/or hyperventilation. 
Complete thermoregulatory and cardiovascular system failure results in EHS.4 Excessive 
metabolic heat production dangerously increases Tc, and combined with decreased brain 
blood flow, the central nervous system is impaired and organ damage ensues.   
Uniqueness and Individuality of Exertional Heat Stroke Cases 
 Exertional heat stroke is identified by 2 key characteristics: 1) a Tc > 40°C and 2) 
alterations in central nervous system function.9 It is important to note that 40°C is not a 
“golden number”. It remains unclear why some individuals can participate in intense 
activity with Tc above 40°C without any EHS symptoms and other individuals experience 
EHS below 40°C. Some variability can be explained by physical conditioning, 
acclimatization, body mass, hydration, equipment or clothing, and sleep deprivation. These 
factors are well understood in regard to physiological strain and disseminating metabolic 
heat. Untrained, unacclimatized individuals with larger body-surfaces have decreased 
thermal tolerance.189  Dehydration impairs cardiovascular function, increasing Tc and 
perceptual thermal strain measures.190 Equipment and clothing creates a microenvironment 
that limits heat dissipation189   
Previous illness and medication use are known risk factors for EHS, but less 
understood because controlled laboratory studies in human subjects are not available. 
Insight into the impact these factors play in EHS primarily comes from case and 
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observational studies. A retrospective assessment of 38 EHS deaths among American 
college and high school football players identified 1 player who experienced a GI virus the 
day before and 1 who had a history of taking ephedra.191 A 19yr old male participating in 
intense exercise in the heat experienced multiple heat-related incidences. The first episode 
was precipitated by gastroenteritis.192 Clinical observations of 36 male EHS patients found 
1 experienced a fever the week prior, 6 presented with GI distress within 3 days of the 
event, and 1 had EHS 3 days earlier. In addition to the 6 with previous GI distress, 16 
patients experienced GI distress during the EHS.193 In one of the most publicized EHS 
deaths in American football, the athlete experienced GI distress (“upset stomach” and 
vomiting) the day prior to and day of his death.194  
Etiology: Models of Exertional Heat Stroke 
The hypothalamus is considered the body’s thermostat. Individual baseline Tc may 
vary slightly, but the hypothalamus attempts to maintain Tc at about 37 + 1°C. Unlike a 
thermostat, the hypothalamus cannot turn off heat and can only initiate responses designed 
to mitigate rising Tc. Hypothalamic driven mechanisms for heat loss include stimulating 
evaporative heat loss and cutaneous blood vessel vasodilation.1 Inability for the 
hypothalamus and thermoregulatory responses to rid heat gain can dangerously increase 
Tc.   
Heat transfer occurs by movement from warmer to cooler objects/environments. 
Sun exposure creates radiation heat gain. Radiation heat loss occurs when the body is 
warmer than surrounding air.19 Conduction involves movement of heat energy with two 
objects in contact with one another. For example, warm skin in contact with cold water 
allows heat to dissipate from the body to the water. Similarly, convection is heat exchange 
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between moving air/fluids, and is impacted by movement speed. Using the previous 
conduction example, when no movement occurs the water in contact with the skin will 
become warm and the skin will cease to dissipate heat. Moving the water across the skin 
will allow for cooler water to pass by, promoting additional heat dissipation. Less heat is 
lost with slower movement. Evaporation occurs through respiration and sweating and is 
the major defense against heat gain.1  
Early Theory of Exertional Heat Stroke 
Exertional heat stroke is typically thought to occur due to metabolic heat gain from 
working muscles and inability to dissipate heat to the surrounding environment.1 During 
fever, infection, or passive hyperthermia elevated Tc increases metabolic rate. However, 
during intense physical exercise metabolic heat from chemical and mechanical actions 
raises Tc.19 In effort to promote heat loss the hypothalamus induces skin capillary 
vasodilation to deliver blood throughout the circulatory.195 This also increases the demand 
to dissipate heat through evaporation, conduction, and convection.4  
High environmental temperature and humidity are major limiting factors for 
effective heat loss. The greatest EHS risk occurs when wet bulb globe temperatures exceed 
28°C,189 but has been reported in cooler environments (6 – 9.5°C).196 Through convection 
and conduction, the body will gain heat when environmental temperature is higher than 
body temperature. This requires a high demand in evaporative heat loss, seen with elevated 
sweat rates proportionate to elevated temperatures. In the presence of high humidity 
evaporative sweat loss is limited.1 The combination of metabolic heat production during 
intense exercise and inability to dissipate heat exceeds the body’s thermoregulatory 
response. As a result, Tc increases and an individual is susceptible to experiencing an EHS.  
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Dual Model of Exertional Heat Stroke 
More recently, the prevalence of previous illness and GI distress in EHS cases has 
led some to speculate that the GI tract and immune system are key underlying mechanisms. 
These general similarities have led researchers to examine a closely intertwined dual model 
for developing EHS. Both models are largely influenced by GI and immune responses due 
to prolonged exposure to intense exercise or hyperthermia during exercise.5 
First Model of Exertional Heat Stroke: Hyperthermia during Exercise 
The first EHS model is due to exercise and thermal stress. An increase in heat 
storage causes GI distress and increased GI permeability.5 Exacerbated by GI ischemia and 
inflammatory cytokines, increased permeability allows LPS to escape into blood 
circulation.5,197 Exercise can continue as long as circulating LPS is cleaned up through 
previously mentioned immune and liver responses. However, once the liver is 
overwhelmed, endotoxemia occurs and additional pyrogenic cytokines are released.5 At 
higher temperatures, such as with intense exercise, both pro- and anti-inflammatory 
cytokines are released. A somewhat futile immune system results, with the body producing 
anti-inflammatory cytokines to counteract endotoxin and pyrogenic cytokines. 
Unfortuantely, the pro-inflammatory cytokines (IL-6 and TNF-α) are necessary to 
neutralize endotoxemia.187 Cytokines also promote necrosis, vasodilation, acidosis, 
decreased plasma volume, increased vascular permeability, and fever.185,193,198 The end 
result is SIR, multi-organ failure, and/or EHS.5 
Second Model of Exertional Heat Stroke: Prolonged Exposure to Intense Exercise 
The second model states regardless of environmental conditions, prolonged intense 
exercise is immunosuppressive. Down-regulation of Th1, up-regulation of Th2, and 
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decreased NKCs contribute to blunted immune responses. In the event a pathogen is 
introduced, a sub-clinical infection develops5 where the individual may or may not 
experience symptoms.192 At this point, the individual attempts another bout of intense 
exercise, potentially in a thermal or thermoneutral environment. The compromised immune 
system and increased cytokines limits the liver’s ability to neutralize circulating LPS. Like 
the first model, if uncontrolled, endotoxemia, SIR, or EHS may occur.5  
An example of this model may be observed in individuals participating in 
successive intense exercise bouts (eg, pre-season football practices). The individual’s 
immune system is disturbed after the first intense exercise bout. On the following day, the 
individual attempts another bout of intense physical activity. However, GI damage and a 
compromised immune system decreases his/her thermal and work capacity. Unable to 
mitigate LPS, and with elevated pyrogenic cytokines, endotoxemia develops, Tc rises, and 
the person experiences an EHS.   
It is possible to develop EHS without experiencing endotoxemia. Animal studies 
have shown blocking LPS protects against heat stroke until a Tc > 43.8°C.199,200 Extremely 
high temperatures denature proteins and cause cell necrosis.5 Since EHS does not always 
occur in hot environmental temperatures and some individuals can exercise at 40°C with 
no EHS symptoms, the dual model provides insight into underlying GI and inflammatory 
factors that contribute to EHS. Furthermore, risk factors (eg, previous illness, medication, 
sleep disturbances, and nutrition) that alter GI integrity and immune responses play roles 
in the dual model.  
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NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)  
 Non-steroidal anti-inflammatory drugs (NSAIDs) include a large variety of 
prescription and non-prescription medications including acetylsalicylic acid (aspirin), 
ibuprofen (eg, Advil, Motrin), indomethacin (eg, Indocin), naproxen (eg, Aleve, 
Naprosyn), and numerous others. Prevalence of NSAID use among the general public is 
high, spending billions on over-the-counter pain medication.201 Consumer reports and 
advertisers suggest ibuprofen and naproxen are safe, affordable, and effective pain 
medications,202 which is supported by 2013 revenue reports including both Advil 
(ibuprofen) and Aleve (naproxen sodium) in the top 10 over-the-counter brands.203  
Prevalence of medication use among elite athletes has been well documented due 
to World Anti-Doping Agency and International Olympic Committee drug policies. 
Medication, particularly NSAIDs, is a concern across all age groups, sport type, and 
competition level. Physically active persons use NSAIDs prophylactically or following 
onset of inflammation, pain, and/or fever.204-208 Despite an injury, athletes may choose to 
use NSAIDs in order to continue participation or because they perceive it will help their 
performance.208 Among 3,887 elite international track and field athletes completing a 7 day 
recall of medication use, 3,237 reported taking medications, with COX-1 inhibitors the 
most common (27.3%, n = 782).206 In a similar study, of 912 elite athletes across 34 sports 
completing 3 day recall doping control forms, 24.7% (n = 225) reported NSAID use.207 Of 
particular interest, 22% (n = 50) reported taking multiple NSAIDs at one time.207 
Combining NSAIDs is not advised, particularly due to potential adverse drug reactions209 
and increased risk of GI damage.210 
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Similar prevalence of NSAID use has been reported in recreational athletes. Of 333 
ultra-distance triathletes, 100 (30%) reported taking NSAIDs within the 24 hours prior to 
the race.211 Less research has been conducted among youth and team sport athletes. 
However, of the available studies, prevalence of use is similar or even higher than in adults. 
Of 604 high school football players reporting medication use over the past 3 months, 75% 
(n = 452) reported using NSAIDs related to their sport participation.208 Two hundred thirty-
two independently administered NSAIDs (i.e. no adult supervision) and only 51 perceived 
any disadvantages to taking NSAIDs.208 Although this was a limited population, studies 
among the general population suggest adolescents often self-administer NSAIDs212,213 and 
are unaware of potentially toxic side effects.214,215  
NSAIDs are perceived as performance enhancing because they mitigate pain and 
inflammation. Differences between medication type, dosage, and exercise mode in existing 
literature make it difficult to conclusively state whether NSAIDs do or do not enhance 
performance. However, aspirin does not alleviate exercise induced muscle pain,216 and may 
degrade endurance exercise performance by increasing lactate production and decreasing 
time to fatigue.217 Results are similar in upper and lower extremity resistance exercise, 
finding aspirin increased rate of perceived exertion (RPE) and perceived leg pain versus a 
placebo.218 Further supporting the lack of performance enhancing effects, compared to 
placebo, aspirin had little effect on respiratory variables (respiratory rate, oxygen 
consumption, carbon dioxide, etc.), HR,217 anaerobic threshold onset, and work load.219   
Mechanisms of Action 
All NSAIDs work to reduce inflammation and pain, but their mechanisms of action 
varies depending on chemical structure. Consequently, their effectiveness as anti-
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inflammatory and anti-pain medications, along with their side effects, also varies greatly. 
The plant based salicylic acid (acetylsalicylic acid is a derivative) has been used for 
thousands of years to reduce inflammation and pain, long before its mechanism of action 
was understood. It was not until the 1970s researchers identified aspirin and all other 
NSAIDs’ mechanism of action – inactivation of COX.220,221 By inhibiting COX, and 
therefore PG synthesis, NSAIDs decrease inflammatory responses and inflammatory 
induced pain. An NSAID’s mechanism of action can be further defined as either “non-
selective” or “selective”, where non-selective inhibit both COX-1 and COX-2 and selective 
target COX-2 only.222  
The most common way to determine a drug’s selectivity is to measure the half 
maximal inhibitory concentration (IC50). This value represents the drug concentration 
needed to inhibit a substance or function by 50%.223 A ratio of COX-1 to COX-2 inhibition 
is determined by dividing the IC50 value for COX-2 in to COX-1. It is important to note 
that drug selectivity is a continuous variable; there is no absolute cut-off value to classify 
selective versus non-selective.223,224 Utilizing IC50 ratios may allow for more standardized 
comparison and classification220 within a study in regards to effectiveness and side effects. 
A drug is generally considered to be more COX-2 selective if it has a lower IC50 ratio. 
Unfortunately, within and between studies there is variability in using whole blood or cell 
cultures, assays, incubation time, and substrate concentration.225,226 Direct comparison 
across studies is not recommended. Instead, ranking NSAID selectivity relative to IC50 
ratios (eg, most COX-1 selective to least) is commonly seen. While this allows for some 
generalization across studies, when reviewing rankings one would also see large variability 
in IC50 ratios for a given drug.  
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Non-Selective COX Inhibitors 
Majority of NSAIDs, particularly those available over-the-counter, are non-
selective COX inhibitors. Due to different chemical compositions, inhibition of COX-1 
and COX-2 is not equal and each NSAID has its own selectivity toward one COX variant 
or the other. A “non-selective” NSAID may be more COX-1 selective, while still inhibiting 
COX-2 to a certain percent. Choosing one NSAID over another is often dependent on 
desired therapeutic effect and patient response to a given drug.  
Acetylsalicylic Acid (Aspirin) 
Acetylsalicylic acid is the most widely used and researched NSAID, partly because 
it is oldest and inexpensive. Its COX inhibition is heavily time dependent, with rapid liver 
enzymatic activity resulting in a relatively short 2-3 hour half-life.227 Acetylsalicylic acid 
is indicated for mild to moderate pain, fever, and reducing risk of cardiac events.227,228 Its 
ability to irreversibly inhibit platelet driven TXA2 production by almost 95%229 with low-
doses (30 mg per day) make it highly effective at preventing blood clots and reducing risk 
of heart attacks and strokes.229,230 Due to greater selectively toward COX-1 than COX-
2,18,222 much higher doses (320 mg per day)231 are recommended to achieve anti-
inflammatory effects.229 Research using recommended over-the-counter doses has been 
unable to identify substantial anti-inflammatory effects. Following endotoxin injection, 
oral ingestion of 1000 mg resulted in no change in circulating TNF-α and IL-6 versus a 
placebo in resting patients.232  
Ibuprofen 
Ibuprofen is another commonly used NSAID and the first non-aspirin over-the-
counter NSAID.228 Similar to acetylsalicylic acid, ibuprofen is indicated for mild to 
 143 
moderate pain, fever, and inflammatory relief and has a relatively short half-life of 2-4 
hours.227 Ibuprofen is considered equipotent against both COX derivatives.233 Extensive 
research has been conducted on inflammatory effects during various exercise bouts234,235 
or following endotoxin injection.236-238 Results are conflicting, with some studies showing 
ibuprofen has significant235-238 or no effect on inflammatory markers.234,235  
Contradictions in exercise studies can be partially explained by interpersonal 
differences of participants (eg, history of medication use and illness, age, acclimatization, 
and conditioning) and varying methodology (eg, exercise duration, intensity, environment, 
and medication dosage). A one-time 400 mg dose prior to 1500 m run in unknown 
environmental conditions showed no significant difference in TNF-α, IL-6, or IL-1β pre-, 
immediately post-, or 24 hours post.234 On the other hand, 29 runners completing a 160km 
ultramarathon in moderate temperatures (10°C-25°C, 56% relative humidity) were given 
600 mg of ibuprofen the afternoon prior to the race and another 1,200mg on race day (one 
200 mg tablet every 4 hours). Compared to no medication, most inflammatory markers, 
including IL-6, significantly increased pre- to post-race; however, there was no significant 
change in TNF-α.235  
Results from endotoxin injection studies at rest are slightly more consistent. As 
expected, ibuprofen blunts Tc rise following endotoxin challenge, but has been shown to 
increase inflammatory markers. Compared to control, two 800mg ibuprofen doses pre-
endotoxin injection significantly increased IL-6 (27 + 12 ng/ml vs. 113 + 66 ng/ml, P = 
.05, respectively) and TNF-α (369 + 44 pg/ml vs 627 + 136 pg/ml, P = .003, 
respectively).237 Similar results were found after subjects were given three 800mg doses 
(1.5 hours pre-, at the time of, and 3hrs after endotoxin challenge).238 
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Indomethacin 
Indomethacin is typically used to control moderate pain in patients who do not 
respond to other, less toxic NSAIDs. Absorption is variable depending on administration 
route, and average half-life is 4-6 hours.227 Like other non-aspirin NSAIDs, it is less 
effective at reducing cardiovascular events.239 However, it is a potent inhibitor of COX-
1240 making it useful as an anti-inflammatory agent. In 10 recreational athletes, 
indomethacin significantly blunted post-exercise NKC suppression, IL-6 expression, and 
TNF-α expression (P < .05).241,242   
Naproxen 
Naproxen is a relatively newer drug with less selectivity toward COX-1 than aspirin 
or indomethacin.243,222 Naproxen is available in either free acid or sodium form.244 
Naproxen sodium is commonly seen as Aleve® or naprosyn. The two forms are 
bioequivalent on all levels except rate of absorption. Gastric juice rapidly dissolves 
naproxen sodium, resulting in high plasma concentrations within 1 hr compared to 2 hrs 
with naproxen. The earlier onset of symptom relief with naproxen sodium is beneficial for 
acute pain.244 Over-the-counter doses (200 mg or 400 mg) are effective for mild to 
moderate pain, fever, and inflammation. Compared to other NSAIDs, naproxen has a long 
half-life of 10 to 20 hours.227 While a patient may need to take aspirin or ibuprofen every 
4 hours to maintain therapeutic effects, patients using naproxen are instructed to take 1 
dose every 8 hours and to not exceed 600 mg per day.227  
In regards to therapeutic effects, 500 mg of naproxen sodium twice a day has been 
shown to inhibit platelet COX-1 activity close to 95%. However, platelet inhibition is 
reversible and inconsistencies between subjects make it a less than ideal choice as a cardio-
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protective medication.245,246 Naproxen significantly inhibits PGE2 and PGI2,247 making it 
useful in a variety of inflammatory and pain diseases.244  
Selective COX-2 Inhibitors 
Three popular selective COX-2 inhibitors, also known as coxibs, are rofecoxib 
(Vioxx), valdecoxib (Bextra), and celecoxib (Celebrex). Meloxicam (Mobic) was not 
originally designed to be a COX-2 inhibitor, but research has shown it to be very COX-2 
specific.248 With little inhibition of COX-1, these NSAIDs are more effective as anti-
inflammatories while reducing toxic GI side effects.222 
Adverse Effects of NSAIDs 
Gastrointestinal Effects 
Risk and prevalence of adverse GI effects from NSAIDs is well established among 
published cases, multicenter case-control studies, and randomized control trials.17,69,243,249-
251 Time from initial NSAID use to onset of GI distress varies from days to several years252 
and risk increases with higher doses, longer use, longer half-life, slow-release formulation, 
greater COX-1 selectivity, and previous adverse events.243 In general, NSAIDs, 
particularly non-selective, cause adverse effects by inhibiting COX-1 and, therefore, GI 
protective PG effects – increased mucus and bicarbonate secretions, increased blood flow, 
decreased acid secretion, TJ maintenance, etc. Selective COX-2 inhibitors were developed 
to create a NSAID that reduced GI effects by preserving COX-1. However, research has 
shown both COX derivatives play a role in GI protection253 and NSAIDs may directly 
induce GI distress through non-PG mechanisms.16  
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Gastrointestinal Damage 
Specific GI damage includes colitis and ulcerative colitis; peptic ulcers; small and 
large intestine perforation, hemorrhaging and abscesses; and small intestine strictures.252,254 
The relationship between the spectrum of COX inhibition and relative risk (RR) for GI 
damage has been illustrated in a meta-analysis comparing common NSAIDs and doses. 
Lowest risk was found for the more COX-2 selective celecoxib (RR = 1.42, 95% CI 0.85 
– 2.37) and ibuprofen (RR = 2.69, 95% CI 2.17 – 3.33). The highest risk was found in the 
greater COX-1 specific ketorolac (Toradol; RR = 14.54, 95% CI 5.87 – 36.04). 
Interestingly, compared to no use, NSAIDs inhibiting both COX derivatives by greater 
than 80% resulted in a higher GI damage risk; this included naproxen (RR = 5.63, 95% CI 
3.83 – 8.28) and indomethacin (RR = 5.40, 95% CI 4.16 – 7.00).243 In a comparison of GI 
toxicity among 8,076 rheumatoid arthritis patients, naproxen use elicited significantly more 
upper GI damage (ulcers, obstruction, perforation, and bleeding) versus rofecoxib (121 vs 
56 events, P < .001).249 Thirty-six healthy participants (24 males, 12 females, mean age = 
48 yrs) with no previous NSAID intolerance were used to compare 500 mg naproxen versus 
100 mg nimesulide (a selective COX-2 inhibitor) administered twice a day for two weeks. 
Naproxen significantly inhibited PGE2 and PGI2 (P < .001) and caused stomach damage 
(hemorrhage, lesions, and ulcers) in 24 participants compared to 2 in the nimesulide 
group.250  
There is a lack of research on lower GI damage and results are less consistent 
regarding selectivity. In 34,701 rheumatoid and osteoarthritis patients receiving either 
diclofenac (non-selective) or etoricoxib, bleeding, perforation, obstruction, diverticulitis, 
and ulcers were reported, but there was no significant difference between treatment 
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groups.255 One the other hand, relative risk for developing serious lower GI damage was 
significantly greater with naproxen use compared to rofecoxib (0.46, P = .032).256 A 43 
year old female patient with low back pain regularly taking diclofenac (Voltaren) and 
intermittently using ibuprofen and indomethacin reported to a hospital with hematochezia. 
Examination and biopsy revealed ulcers along the ascending colon, cecum, and ileum. Two 
months after cessation of NSAIDs a follow-up colonoscopy revealed normal mucosa.257  
A concurrent inflammatory response may exacerbate GI damage. Intestinal edema, 
lymphocyte and neutrophil accumulation257 and increased cytokines is associated with 
gastric lesions. Oral administration of indomethacin and aspirin in rats significantly 
increased TNF-α and gastric lesion scores compared to control (P < .001). Pre-treatment 
of a TNF-α inhibitor significantly decreased indomethacin induced gastric lesions (P < 
.05).258 
Gastrointestinal Permeability 
Several randomized, blinded control trials have shown different NSAIDs increase 
GI permeability within hours and after single doses. In 14 healthy participants, GI 
permeability, measured using Cr-EDTA, significantly and linearly increased with potency 
after 2 single doses of aspirin (2.3 + 0.3%, P < .05), ibuprofen (2.9 + 1.2%, P < .001), or 
indomethacin (4.7 + 1.3, P < .001) compared to baseline (1.9 + 0.5%).259 Nineteen healthy 
females were used to determine differences in permeability following naproxen, 
meloxicam, indomethacin, or celecoxib. Compared to no NSAID, only naproxen resulted 
in significantly higher gastroduodenal permeability (median sucrose excretion = 78.4 mg 
[51.4 – 105.4 95% CI] versus 107 mg [82.9 – 138.5 95% CI], P < .05). In regards to small 
intestine permeability, naproxen significantly increased the lactulose/mannitol ratio (0.032 
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versus 0.022 [baseline], P < .05) while celecoxib had no significant effect.251 In 8 
participants (6 males, 2 females; mean age = 22.5 + 2.5 yrs; mean V̇O2max = 61.8 + 5.7 
ml/kg/min) running 60 min in a thermoneutral environment, aspirin and ibuprofen 
significantly increased gastroduodenal permeability compared to placebo (% sucrose 
secretion = 0.37, 0.22, and 0.09, respectively, P < .05). Only aspirin significantly increased 
small intestine permeability versus placebo (lactulose/rhamnose ratio = 0.09 versus 0.065, 
P < .05).14 An attempt to determine aspirin dosage needed to induce GI permeability found 
3 doses of 325 mg significantly increased gastroduodenal permeability (P < .05).260 
Overall, research supports acute, over-the-counter NSAID doses alter GI permeability. 
Some question has been raised against the generally accepted theory that NSAIDs 
induce permeability changes due to PG inhibition. Using 7 participants to determine if 
increased GI permeability was driven by COX inhibition, co-administration of PGE2 and 
indomethacin did not result in significant differences in excreted Cr-EDTA compared to 
indomethacin alone (6.6 + 4.4% and 4.6 + 1.5%, respectively).259 Similar results were 
found among 40 healthy participants administered indomethacin, indomethacin and 
exogenous PGE2, or indomethacin and metronidazole (an antibiotic). Co-administration of 
PGE2 failed to prevent increased GI permeability. On the other hand, metronidazole 
significantly inhibited GI permeability compared to indomethacin alone (P < .05).261 
Inability of PG to emolliate NSAID induced GI damage does not rule this mechanism out, 
particularly considering the limitations to exogenous PG use and other studies finding PG 
co-administration reduces GI permeability.262 However, it does allude to non-PG mediated 
mechanisms.  
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The GI mucosa is hydrophobic, preventing potentially harmful molecules from 
passing through.263 Altering hydrophobicity can increase GI permeability. Compared to 
saline, aspirin significantly decreased mucosa hydrophobicity among wild-type and COX-
1 deficient mice (P < .05). This was associated with significantly higher gastric lesion 
scores (P < .05).16 Further support comes from a group of researchers showing aspirin, 
ibuprofen, and naproxen interact with phosphatidylcholines (a group of constituent 
phospholipids in cell membranes). This interaction disrupts TJs and creates unstable pores 
by altering hydrophobicity, fluidity, and cell structure on mucosa surface and at the lipid 
bilayer.264,265  
Other suggested mechanisms are less researched and focus around NSAIDs 
reducing ATP production. The ability for metronidazole to maintain GI permeability in the 
aforementioned study suggests an inflammatory mediated mechanism.261 By reducing 
ATP, presumably through glycolysis and tricarboxylic acid cycle inhibition, there is a 
disruption of the cytoskeleton and loss of TJ regulation, increase in ROS production, and 
protein degradation.15, Results on glucose supplementation maintaining permeability are 
conflicting. Co-administration of an indomethacin, glucose, and citrate formula blunted 
permeability changes compared to indomethacin.266 In contrast, no difference in 
permeability occurred with 1300 mg of aspirin and replenishing glucose through a 
carbohydrate beverage.15 
Cardiovascular Effects  
As discussed earlier, PGs play an important role in maintaining cardiovascular 
function, producing prostanoids to maintain BP and blood volume. Selective COX-2 
inhibitors have greater cardiac risks. Like GI effects, degree of selectivity plays a role on 
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occurrence of cardiac events, meaning even non-selective NSAIDs cause adverse cardiac 
effects.246,267 Aspirin is cardioprotective, preventing blood clots by irreversibly inhibiting 
TXA2, but aspirin is also linked to increased bleeding time.268 Both selective and non-
selective NSAIDs have been shown to increase myocardial infarction246 and stroke risk.267 
Lastly, inhibiting COX driven vasodilation decreases skin blood flow,269 which limits the 
body’s ability to dissipate heat during exercise or thermal strain. 
Renal Effects 
In addition to altering renal function through cardiovascular effects, NSAIDs 
directly impact kidney function by inhibiting renal PGs, which maintain renal blood flow. 
Serious side effects include papillary necrosis and interstitial nephritis.118 Less serious side 
effects are fluid-electrolyte imbalances such as hyponatremia (plasma sodium 
concentration (P[Na+]) < 135 mmol/L) and renal hypertension. If coupled with volume 
depletion, a potential risk during exercise,34 these effects can be exacerbated and lead to 
acute renal failure.270 By inhibiting PGs, NSAIDs suppress the renin-angiotensin-
aldosterone system, decrease glomerular filtration rate, increase vasopressin, and increase 
sodium retention. As a result, water is retained and vasoconstriction occurs, leading to 
edema and hypertension.271,272  
Decreased urine production with increased water retention from NSAID use is 
considered a contributing factor for hyponatremia. Thirty percent of ultradistance 
triathletes (n = 100/333) reported using NSAIDs and had significantly lower post-race 
plasma sodium compared to athletes not using NSAIDs (mean = 140.2 mmol/L versus 
141.1mmol/L, P < .02). The 6 participants who experienced hyponatremia during the race 
all took NSAIDs (χ2 = 14.24, P = .0002).211 Out of 60 hospitalized marathon runners, 15 
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experienced severe hyponatremia. Percent NSAID use was significantly higher compared 
to normonatremic runners (28.6% versus 4.6%, P = .010).273 Other observational studies 
have not identified a relationship between NSAIDs and hyponatremia.274,275 Controlled 
laboratory studies are lacking and observational studies have inherent limitations. 
Nevertheless, it is known NSAIDs adversely affect fluid-electrolyte balance. Additional 
cardiovascular and thermoregulatory strain limits ability to dissipate heat and increases 
EHI risk. 
NSAIDs: A Risk Factor for Exertional Heat Stroke? 
Due to their anti-pyretic effects, taking NSAIDs during exercise and/or thermal 
stress has been speculated to lower Tc, but current literature is limited and inconclusive. 
After taking 7,800 mg of sodium salicylate or a placebo, 12 trained males walked for 100 
min at 3.8 mph in a hot, dry environment (48.9°C dry bulb, 26.7°C wet bulb) and 16 in a 
hot, wet environment (33.3°C dry blub, 30.6°C wet bulb). No significant differences in Tc 
were recorded between placebo and sodium salicylate in either environmental condition. 
Though not significant, Tc with salicylate began to increase compared to placebo at 40 min 
(hot, dry) and 30 min (hot, wet), continuing until the exercise protocol ended.276 A possible 
explanation for lack of significance between Tc could be the exercise protocol intensity. 
Mean HR was not significantly different between control (152 bpm) and NSAID (159 bpm) 
and below the established cut-off of 180 bpm to cease walking.276 An earlier study 
administered acetylsalicylic acid in either 1 dose, 48 hours, or 7 days on 10 males (age 
range = 23 – 26 yrs). Participants completed a short 20 min walk at 3.5 mph and 8.6% 
grade in a temperate environment (22.2°C, 50-55% RH). Resting, exercise, or recovery Tc 
was not significantly different across experimental groups and did not rise above 38°C.277  
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Ten male participants taking 6 days of rofecoxib or placebo completed an exercise 
protocol at 75% V̇O2max in temperate conditions (28°C, 50% RH). No significant difference 
was found in Tc between experimental conditions during the first 45 minutes of exercise 
(running). Experimental participants exhibited significantly lower Tc during the last 45 
minutes of cycling (mean difference = 0.33 + 0.26°C, P < .05) and throughout a 60 min 
recovery (mean difference = 0.34 + 0.26°C, P < .01). Overall, TNF-α significantly 
increased pre- to post-exercise (2.96 + 2.07 to 4.17 + 3.25 pg/ml, P = .03), but no difference 
was found between groups. Change in skin blood flow from rest to cycling was 
significantly higher in the experimental group versus placebo (P = .01).278 Together, these 
results suggest rofecoxib blunts Tc rise by increasing skin blood flow. This is in contrast 
to a recent study using aspirin. In a randomized, double-blind, crossover study (n = 14, 7 
males, 7 females, mean age = 55 + 1 yr), the effects of 7 days of low dose (81mg) aspirin 
on Tc, skin blood flow, thermal sensation, and hydration measures were compared to 
placebo and PlavixR (a prescription anti-platelet medication). Participants rested 40 min in 
a thermal environment (30°C dry bulb, 22°C wet bulb, 40% RH) then biked 2 hours at 60% 
V̇O2peak. Following rest, Tc was significantly higher for aspirin compared to placebo (P < 
.05) and remained significantly higher throughout exercise (P < .001).269 Rate of 
temperature rise, thermal strain, HR, and plasma volume were not significantly different 
between experimental groups, but skin blood flow was significantly decreased with aspirin 
use (P < .05).269 Attenuating skin blood flow, thus limiting heat dissipation, is elevates Tc.  
SUMMARY AND CONCLUSION 
 Literature supports a significant role of the GI tract and immune system in 
development of EHS. Together or alone, intense exercise and thermal stress increase GI 
 153 
permeability, LPS translocation, and inflammatory responses. The result is increased Tc 
and EHS risk. Several risk factors may accelerate EHS development, but NSAIDs are 
currently not considered a risk factor.  
Adverse NSAID effects share a number of components with the dual EHS model – 
GI damage, increased GI permeability, and inflammatory responses. Therefore, it can be 
inferred that NSAIDs use could exacerbate EHS risk via these shared mechanisms. There 
is limited research on NSAIDs and Tc during exercise and thermal stress. Existing 
literature typically fails to measure inflammatory markers and GI damage, varies from low 
to high intensity exercise, and varies from temperate to hot environments. Furthermore, 
using ibuprofen or acetylsalicylate is practical, but neither drug is a potent COX inhibitor. 
Naproxen is a commonly used, potent over-the-counter medication, but because it is 
relatively newer there is less research on its effects.  
Physical conditioning, acclimatization, electrolyte and fluid balance, and other 
intrapersonal factors may impact Tc during activity. Considering existing literature, there 
is a clinically relevant question as to whether NSAIDs should also be considered a risk 
factor for EHS. Unfortunately, there is an overall lack of well-developed, controlled studies 
with intense exercise in thermal environments. Future research is needed to examine how 
NSAIDs may negatively impact thermoregulation through effects on the GI tract and 
immune system. 
METHODS 
The purpose of this study is to determine the effects of over-the counter naproxen 
on Tc, GI permeability, GI distress, and inflammatory markers in hydrated, cycling adults 
in a thermal environment.  
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Research Design 
We will utilize a double-blind, randomized, cross-over design to determine the 
effects of naproxen on the dependent variables Tc, TNF-α, IL-6, GI permeability, GI 
distress symptoms, occult fecal blood loss, P[Na+], HR, BP, and performance (distance 
covered during a 10min time trial). Independent variables are naproxen (220mg 
naproxen/dose), placebo (0mg naproxen/dose), thermal environment (35°C, 30% 
humidity),279 and thermoneutral environment (15°C, 30% humidity).279 All participants 
will attend an informational session and complete the STEEP test to estimate V̇O2max. 
Participants will be randomly assigned to 1 of 4 groups: 1) placebo and thermoneutral 
(Control); 2) placebo and heat stress (PHeat); 3) naproxen and thermoneutral (Npx); and 
4) naproxen and heat stress (NpxHeat) in a counterbalanced order with a minimum of 7 
days between each data collection session. Dependent measures will be taken pre-, during, 
and post- a 90 min cycling protocol. 
Participants 
A convenient sample of participants (n ≈ 20; age = 18-38 yrs) from the University 
of South Carolina and surrounding community will be used to participate in this study. To 
be included in the study participants must be moderately trained (male V̇O2max between 
35-40 mL/kg; female V̇O2max between 32-40 mL/kg),280 non-heat acclimatized, in good 
general health and will be accepted based upon the absence of cardiovascular, respiratory, 
and metabolic disorders; musculoskeletal disorders preventing cycling exercise; fluid or 
electrolyte balance disorders; and GI or swallowing disorders. Participants will be screened 
using a Health and Injury History Questionnaire and read and sign an Institutional Review 
Board approved Informed Consent Form prior to participation. 
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Experimental Conditions 
Control Condition 
Participants in the Control condition will report to the laboratory 24 hrs prior to 
data collection and will be given 3 placebo capsules (glucose) and a Take Home Instruction 
sheet. Participants will complete a 90 min cycle trial in a thermoneutral environment (15°C, 
30% humidity).279 
Placebo and Heat Stress (PHeat) Condition 
Participants in the PHeat condition will report to the laboratory 24 hrs prior to data 
collection and will be given 3 placebo capsules (glucose) and a Take Home Instruction 
sheet. Participant will complete a 90 min cycle trial in a thermal environment (35°C, 30% 
humidity).279 
Naproxen (Npx) Condition 
Participants in the Npx condition will report to the laboratory 24 hrs prior to data 
collection and will be given 3 naproxen capsules (220mg naproxen/dose) and a Take Home 
Instruction sheet. Participants will complete a 90 min cycle trial in a thermoneutral 
environment (15°C, 30% humidity).279 
Naproxen and Heat Stress (NpxHeat) 
Participants in the NpxHeat condition will report to the laboratory 24 hrs prior to 
data collection and will be given 3 naproxen capsules (220mg naproxen/dose) and a Take 
Home Instruction sheet. Participant will complete a 90 min cycle trial in a thermal 
environment (35°C, 30% humidity).279 
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Instruments and Protocols 
Health and Injury History Questionnaire 
The Health and Injury History Questionnaire references the Canadian Society for 
Exercise Physiology, which developed the PAR-Q to identify individuals who should be 
seen by a medical doctor before becoming more physically active,281 and both the 
American Medical Society for Sports Medicine and the American Orthopedic Society for 
Sports Medicine.282 These two organizations have released pre-participation physical exam 
forms used to identify individuals at risk for injuries. Supplemental questions have been 
added to identify individuals with potential medical illness or injury (eg, GI disorders, 
history of EHS, metabolic disorders, daily NSAID use) that would exclude them from study 
participation.  
Dosage for Experimental Conditions 
A 24 hr dosage (placebo or naproxen) will be administered per the manufacturer’s 
recommendations of 1 capsule every 8 hrs, with the final dosage being taken upon arrival 
to the laboratory. A total of 3 capsules is consumed per the experimental protocol. Each 
dosage will be taken with 1 8oz glass of water and not with food, as this may alter the 
effectiveness of the dose. Previous studies have utilized NSAIDs to examine the effects of 
a 24 hrs dose on GI permeability14,260 and our total 24 hr dosage (660 mg) is comparable 
to previous research.14,235,260,283 
Take Home Instruction Packets 
Upon arrival to the laboratory 24 hrs prior to data collection, participants will be 
given a Pre-Data Collection Take Home Packet containing: 3 capsules (placebo or 
naproxen) with directions for taking capsules, a fecal occult blood test kit with directions, 
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and a pre-data collection GI symptoms survey. After completing the data collection trial, 
participants will be given a Post-Data Collection Take Home Packet containing: directions 
for collecting the last fecal stool sample, a GI symptom survey to complete when collecting 
the last fecal sample, and directions on returning the kit and survey to the researchers. 
STEEP Test 
The STEEP Test, adapted from the Bruce Protocol for cyclist, will estimate 
V̇O2max.284 The test will begin at a low intensity and progressively increase the work load 
15% every 1 minute. A V̇O2max between 40-50 mL/kg in males and 32-40 mL/kg in females 
will be considered “trained” and qualify for participation in the study. Results from V̇O2max 
and HR will also be utilized to determine appropriate resistance for each participant to 
maintain a steady state of 70% V̇O2max279 during cycling exercise trial. 
Cycle Exercise Trial 
Participants will complete a 90 min cycle trial at a steady state of 70% V̇O2max279 
for 80 min. The final 10 min of the trial will be completed at maximum effort. Distance 
covered during the 10 min will be utilized to determine performance. Cycling was chosen 
as the form of exercise due to the lesser impact on the GI tract compared to running.5,38 
Any changes in the dependent variables is better explained from the effects of naproxen or 
environment and not as responses to running. The exercise trial will begin with a 3 min 
warm and be conducted in an environmental chamber. 
Inflammatory Cytokines 
An intravenous catheter will be placed in the cubital vein prior to exercise. The 
catheter is secured so that only one needle stick is required and blood is collected pre-, 
during, and immediately post-exercise. A total of 6 ml per blood draw will be collected 
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into an ethylenediaminetetraacetic acid (EDTA) vacutainer tube and inverted several times 
to mix. EDTA tubes are the preferred choice to prevent coagulation of the blood sample 
prior to analysis.285 TNF-α and IL-6 is assessed using enzyme linked immunosorbent assay 
(ELISA) using high sensitivity kits (BD Biosciences TNF-α and IL-6 ELISA kits, BD 
Biosciences, San Diego, CA). 
Gastrointestinal Permeability 
To determine GI permeability, participants will arrive to the laboratory, void their 
bladder and then ingest 150 ml of a solution containing 5 g sucrose, 5 g lactulose, and 2 g 
mannitol (Sigma-Aldrich Co. LLC, St. Louis, MO). Urinary excretion of sugars will be 
determined by urine sugar concentration, total urine volume, and dose of sugar ingested.286 
Urine samples will be prepared and analyzed for percent excretion of sucrose, lactulose, 
and mannitol using gas chromatography with mass spectrometry.287 Sucrose will be used 
to determine gastroduodenal permeability, while the ratio of lactulose/mannitol is used to 
determine small intestine permeability.14  
Fecal Occult Blood Test 
 To determine GI bleeding fecal occult blood is measured using take home kits 
(Fisher HealthCareTM Sure-VueTM Fecal Occult Blood Slide Tests System, Thermo Fisher 
Scientific Inc., Waltham, MA). Kits include triple slide monitors, collection tissues, 
applicators, test instructions, and a mailing envelope. For each experimental trial, 
participants will provide the first stool sample after initiating NSAID/placebo 
administration and the first stool sample following the exercise protocol. Participants are 
instructed to document time of stool sample collection.  
  
 159 
Hydration and Sodium Balance 
Participants will be required to be euhydrated prior to beginning data collection. 
Hydration status is assessed by Posm, urine specific gravity (Usg), and body mass (BM). 
Euhydration will be defined as a Posm < 290 mOsmols, Usg < 1.020, and/or %BM < 1% 
change from baseline BM.288 
Blood is obtained pre-, during, and immediately post-exercise. Blood samples are 
collected into a 6ml EDTA vacutainer tube, centrifuged at 3000 rpm for 15 min, plasma 
pipetted into microtubes, and stored at -20°C until analysis. Osmolality is measured using 
a freeze point depression (Multi-sample Osmometer model 2020, Advanced Instruments, 
Norwood, MA). Plasma osmolality is considered one of the most valid and reliable 
measures of acute hydration status changes289 and is used to ensure participants are in a 
hydrated state throughout each trial.  
Urine is obtained pre- and post-exercise to obtain immediate estimates of hydration 
status. Participants must be in a euhydrated state prior to completing the data collection 
trial. A clean catch method will be used in which the participant is instructed to urinate a 
small amount before placing the specimen cup in midstream to collect a minimum of 1 
ounce of urine. Usg is measured using a handheld clinical refractometer (model REF 312, 
Atago Company Ltd., Tokyo, Japan). Designed for clinical use, the clinical refractometer 
measures total concentration of liquid compared to water. The clinical refractometer is 
calibrated before and after each Usg measurement using two drops of distilled water on the 
prism, holding the instrument toward light, and adjusting the turning screw to correspond 
the light and dark boundary at 1.000. Following calibration, two drops of specimen are 
pipetted onto the dry prism, the refractometer is held to the light, and the Usg is recorded.290   
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A Tanita body composition analyzer (model TBF-300, Tanita Corporation, 
Arlington Heights, IL) is used to measure BM pre-, immediately post-exercise, and 3 hrs 
post-exercise. Participants are asked to void urine before stepping on scale, dress in shorts 
and t-shirt, and towel off any sweat. Baseline BM measures are taken at the information 
session, where participants will provide a urine sample to determine euhydration (Usg < 
1.020). 
To determine changes in P[Na+] we will utilize ion-selective electrodes (EasyLyte® 
Na/K electrolyte analyzer model REF 2277, Medica, Bedford, MA). Plasma will be 
obtained using an intravenous catheter placed in the cubital vein. Blood will be centrifuged, 
plasma pipetted into microtubes and stored at -20°C until analysis. All samples will be 
discarded after analysis. 
Core Body Temperature 
Tc is recorded continuously throughout the exercise trial using rectal temperature 
(model 4600, YSI Precision Temperature Group, Dayton, OH). Participants are not allowed 
to exceed a Tc > 40°C/104°F. Rectal temperature is accepted as a valid and reliable 
measure of Tc,291 frequently used as a criterion measure of Tc during exercise under 
thermal stress,292,293 and is used in studies examining GI permeability and aspirin.14,15 
Gastrointestinal Symptom Index 
Gastrointestinal distress will be assessed using a symptom questionnaire adopted 
from previous research.45,294 The index is divided into 3 sections: 1) upper abdominal 
problems (heart burn, reflux, belching, bloating, stomach pain/cramping, nausea, 
vomiting); 2) lower abdominal problems (intestinal/lower abdominal pain/cramping, 
flatulence, urge to defecate, side aches/stitch, loose stoole, diarrhea); and 3) systemic 
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problems (dizziness, headache, muscle cramps, urge to urinate).45 Symptoms are scored on 
a 10-point scale (0 = no problems at all and 9 = the worst it has ever been). A score of > 4 
is considered “serious”.294 Questionnaires will be administered pre-, immediately post-, and 
2 hrs post-exercise. To determine GI symptoms during exercise, participants are verbally 
asked about current GI symptoms and severity every 15 min. 
Rate of Perceived Exertion 
The Borg Scale is used to measure the participants’ rate of RPE pre-, every 15 min 
during, and immediately post-exercise.  
Cardiovascular 
To ensure participants remain at safe limits and determine any effects from NSAID 
use, HR is continuously monitored using Polar HR monitors (Polar Electro Inc., Lake 
Success, NY). In addition, BP is measured every 15 min to ensure participants maintain a 
normal BP response throughout the trial. 
Diet and Activity Logs 
 Participants will be required to track diet and activity for 3 days prior to and 1 day 
after data collection using an online nutrition software (ESHA Research, Salem, OR). 
Participants are asked to refrain from red meat for 3 days prior and 1 day after data 
collection to limit false positive fecal occult blood tests. Logs are also used to help 
participants maintain similar dietary and activity habits during the 24 hrs prior to data 
collection.  
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Experimental Procedures (Figure 5.2) 
Information Session 
Consenting participants will sign the informed consent form and complete the 
Health and Injury Questionnaire. If participant has no disqualifying conditions (i.e. 
metabolic, cardiovascular, respiratory, and/or musculoskeletal disorders; current pain 
medication or NSAID use, etc.) he/she will complete the STEEP test to measure V̇O2max. 
Participants are randomly assigned to 1 of 4 groups, with all 4 groups being completed in 
a randomized cross-over design. Both the participant and primary investigator are blind to 
whether the participant is completing the Npx or placebo group. Take Home Instructions 
are reviewed with the participant at the end of a session and prior to leaving the laboratory. 
Participants are not allowed to take any other medications for pain or inflammation during 
the course of the study. Participants are instructed to refrain from intense, vigorous exercise 
2 days (48 hrs) prior to data collection, no exercise 24 hrs prior to data collection, and will 
complete an online dietary and activity log from 72 hrs prior to and 24 hrs post data 
collection.172  
Data Collection Session 
Participants will report to the laboratory 24 hrs prior to data collection to obtain 3 
pills (Npx or placebo), fecal occult blood tests, and Take Home Instructions. Participants 
will consume the 3 pills over the 24 hr period, drinking 1 8oz glass of water with each dose 
and not with food. At least 2 hrs prior to arriving for data collection, participants should 
consume a small meal and are instructed to consume the same meal prior to each trial. All 
data collection sessions are conducted at the same time of day for each participant and 
separated by a minimum of 7 days.  
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Upon arrival to the laboratory, participants will consume the 3rd pill. A member of 
the research team will measure hydration status to determine if the participant is in a 
euhydrated state. Participants are provided a rectal thermometer probe and a private area 
to insert the probe and a baseline Tc will be taken. A venous catheter is inserted into the 
cubital vein and 2 6ml vials of blood will be collected for baseline measures. Participants 
will complete a 3 min warm up on the bike prior to starting the 90 min cycle protocol. 
Participants will consume 3.5ml/kg of water every 15 min to maintain hydration status. Tc 
and HR will be monitored continuously. RPE and BP will be measured every 15 min. Two 
6ml vials of blood will be taken pre-, 80 min, immediately post-cycle, and 3 hours post-
cycle. At the conclusion of the cycling protocol, participants will weigh, provide a urine 
sample, and complete the GI symptom index questionnaire. Participants will then rest for 
3 hrs in semi-reclined/seated position in a thermoneutral environment. Participants will 
consume 3.5ml/kg of water every 15 min to maintain hydration status. Blood, urine, 
weight, and GI symptom measures are taken at the conclusion of 3 hrs rest. The cycling 
protocol will cease if one of the following criteria is met: 1) participant completes the 90 
min cycle protocol; 2) participant’s Tc = 40°C; 3) participant experiences severe GI distress 
(eg, vomiting); or 4) participant requests to stop the trial. 
Statistical Analysis 
SPSS statistical software (version XIIV; SPSS Inc, Chicago, IL) is used for all 
analyses. Descriptive statistics (mean and standard deviations) for all dependent variables 
is calculated. Repeated measures ANOVA is used to determine the differences of all 
dependent variables during exercise between the 4 groups. Significance level is set at P < 
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.05 for all analyses. Power analysis, a priori, calculated a participant number of 20 to have 
a power of 0.90, which is comparable to previously published studies.295 
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Figure 5.1. Working Model for Overall Study. 
NSAIDs will exacerbate responses seen during exercise and no thermal 
stress, increasing Tc through immune, GI, and cardiovascular pathways.
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Figure 5.2. Experimental Procedures Schematic. 
Includes information session and data collection. Blood measures include plasma osmolality, plasma sodium concentration, and 
cytokines TNF-α and IL-6. Urine measures include sugar excretion and urine specific gravity. Abbreviations: BM = body mass; BP = 
blood pressure; HR = heart rate; GI = gastrointestinal; RPE = rate of perceived exertion; Tc = core temperature. 
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APPENDIX A. INFORMED CONSENT FORM 
Title of the Study: Non-steroidal Anti-inflammatory Drugs on Gastrointestinal 
Permeability during Thermal Stress in Exercising Humans 
 
Investigators: Dawn M. Emerson, MS, ATC; J. Mark Davis, PhD; Toni M. Torres-
McGehee, PhD, ATC; Stephen Chen, PhD 
 
The purpose of this study is to determine the effects of the non-steroidal anti-inflammatory 
drug (NSAID) Naproxen on core body temperature (Tc), gastrointestinal (GI) permeability, 
inflammatory markers, and fluid regulation during exercise in a thermal environment. The 
study is being conducted to fulfill partial requirements for a Doctorate degree in exercise 
science - applied physiology. You are being invited to participate in this study because you 
are between the ages of 18 and 38yrs, endurance trained, and are in good general health. 
The study will take place at the Exercise Science Laboratories at the University of South 
Carolina’s Arnold School of Public Health. If you agree to participate, you will be 
participating with approximately 20 other people.  
 
STUDY PARTICIPATION 
After signing the informed consent form, potential participants will complete a Health and 
Injury History Questionnaire. Any potential participant with a health or safety concern will 
be required to have his/her questionnaire reviewed by the physician overseeing this study 
to determine inclusion or exclusion into the study. 
 
Upon acceptance into the study, participants will complete a cycle test to measure 
VO2max. Participants will then be randomly assigned to complete four trials: control (C), 
placebo and heat stress (PHeat), Naproxen (Npx), and Naproxen and heat stress (NpxHeat). 
You will complete all four conditions in a random order with a minimum of 7 days in 
between each trial. You will be unaware of whether you are taking a placebo or Naproxen. 
During the course of this study, you will be asked to maintain normal levels of physical 
activity, normal state of hydration, and avoid changes in caffeine consumption and 
dehydration-inducing substances such as alcohol. The study will require you to perform a 
90 minute cycle time trial and allow Tc, GI permeability, inflammatory markers, and 
hydration measurements before, during, and after the cycle bout. You will be provided 
fluids to consume throughout the sessions in order to maintain your hydration. The time 
commitment for each trial will be approximately 6 hours each time. Total time to complete 
all trials will be 24 hours.  
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CONDITIONS 
Control  
You will be given 3 placebo (no medicine) capsules with Take Home Instructions 
instructing you when to take each capsule. Upon arriving to the lab you will provide 
hydration measures, ensure the temperature sensor is working, and have a flexible catheter 
inserted into a vein in your arm for blood measures. You will complete a 90-minute cycle 
protocol in a cool environment (15°C/59°F, 30% humidity). 
 
PHeat 
You will be given 3 placebo (no medicine) capsules with Take Home Instructions 
instructing you when to take each capsule. Upon arriving to the lab you will provide 
hydration measures, ensure the temperature sensor is working, and have a flexible catheter 
inserted into a vein in your arm for blood measures. You will complete a 90-minute cycle 
protocol in a hot, humid environment (35°C/95°F, 30% humidity). 
 
Npx 
You will be given 3 over-the-counter doses of Naproxen with Take Home Instructions 
instructing you when to take each capsule. Upon arriving to the lab you will provide 
hydration measures, ensure the temperature sensor is working, and have a flexible catheter 
inserted into a vein in your arm for blood measures. You will complete a 90-minute cycle 
protocol in a cool environment (15°C/59°F, 30% humidity). 
 
NpxHeat 
You will be given 3 over-the-counter doses of Naproxen with Take Home Instructions 
instructing you when to take each capsule. Upon arriving to the lab you will provide 
hydration measures, ensure the temperature sensor is working, and have a flexible catheter 
inserted into a vein in your arm for blood measures. You will complete a 90-minute cycle 
protocol in a hot, humid environment (35°C/95°F, 30% humidity). 
 
INSTRUMENTS AND PROTOCOLS 
STEEP Test 
Used to measure VO2max, this cycle test progressively increases in difficulty and 
respiratory variables are measured throughout. Participants with a VO2max between 50-
60 ml/kg/min for males and 48-58 ml/kg/min for females will be considered endurance 
trained and qualify to participate in the study.  
 
Naproxen 
Naproxen (commonly known as Aleve), is an over-the-counter available NSAID. You will 
receive a 24-hour dosage (3 pills, 220mg per pill) with instructions on what time to take 
the pills (1 pill every 8 hours). 
 
Placebo 
During the placebo trials, you will be provided 3 pills that contain no medicine and are 
made to resemble the Naproxen. You will take 1 pill, every 8 hours. 
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Temperature Measures 
Temperature will be continuously monitored using a flexible rectal thermometer. 
Thermometers are attached to a cable which inserts into a machine that records 
temperature. After inserting the thermometer you will not need to remove it until 
completion of the session. Minimal discomfort should be felt during exercise. 
 
Blood and Urine Measures 
To obtain the blood we will draw blood from a vein in your arm prior to the cycling 
exercise. A flexible catheter will be used so only one needle stick is required and you will 
complete the exercises. For each blood draw, we will take 1 tube (1.2 tsp). Approximately 
9 blood draws will be done during one data collection session for a total of 5 tbsp (1/6th of 
what you would donate to the American Red Cross).  
 
To obtain urine samples, participants will be provided a cup, and will be able to use a 
private restroom to collect the urine sample. You will be instructed to completely void your 
bladder into the cup during each urine collection. The cup will be labeled with your 
participant number. 
 
GI Permeability, GI Bleeding, and Inflammatory Markers 
Gastrointestinal permeability will be determined by the presence of ingestible sugar probes 
in urine samples. Upon arriving to the laboratory you will be given 150ml (about ¾C) of a 
sugar-water solution to consume. You will then provide urine samples throughout the 
session for a total of a 5 hour period.  
 
To determine GI bleeding we will measure blood using take-home kits. Prior to each 
session you will be provide a kit, including instructions, and asked to collect the first stool 
sample after taking the first pill (Naproxen or placebo). You will then be asked to take the 
first stool sample following the exercise session. You will then bring the kit to the 
laboratory. Only your participant number will be used on take-home kits. 
 
Inflammation will be determined by the presence of the inflammatory markers TNF-α and 
IL-6 in your blood sample.  
 
Hydration and Electrolyte Measures 
We will determine hydration status and electrolyte balance through urine and blood 
measures. Hydration measures will include Posm, urine osmolality (Uosm), urine specific 
gravity (USG) and percent change in body mass (%BM). Electrolytes will be measured 
from P[Na+] and potassium (P[K+]).  
 
Borg Scale for Rate of Perceived Exertion 
We will measure your rate of perceived exertion before, every 15 minutes during, and after 
exercise.   
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Heart Rate and Blood Pressure 
To ensure participants remain at safe limits and determine any effects from NSAID use, 
we will continuously measure heart rate. Blood pressure will be measured before, every 15 
minutes during, and after exercise. 
 
Gastrointestinal Symptom Index 
GI distress before and after exercise will be assessed using a symptom questionnaire. The 
index is divided into 3 sections: 1) upper abdominal problems, 2) lower abdominal 
problems, and 3) systemic problems.  
 
Cycle Time Trial 
A 90-minute cycle time trial will be used to determine the participant's performance. 
Participants will cycle at a steady 70% VO2max for 80 minutes. Any participant that cannot 
complete this will be disqualified from the study. The last 10 minutes of the cycle trial will 
be a maximum effort for distance.     
 
Diet and Activity Logs 
You will be asked to complete an online form to track your diet and activity for 3 days 
before and 1 day after each data collection session. You will be given a login and password 
for your personal account.  
 
SECURITY OF PERSONAL INFORMATION 
Participation will be confidential. To assure your confidentiality, all information pertaining 
to this study and participation will be stored in a secure and locked cabinet. Additionally, 
a code number will be assigned to each participant at the beginning of the project. This 
number will be used on project records rather than your name, and no one other than the 
researchers will be able to link your information with your name. Data from all participants 
will be analyzed together. All blood and urine samples will be discarded after analysis. All 
data will be stored on a secure, password protected computer and only researchers will 
have access to the data. The results of this study may be reported in professional journals 
or presented at meetings; however, you will not be identified. 
 
RISKS 
There is a moderate risk for developing adverse effects due to NSAID use. Potential risks 
and side effects include: ulcers, bleeding, or holes, which may develop without warning, 
in the stomach or intestine; constipation; diarrhea; gas; sores in mouth; excessive thirst; 
headache; dizziness; lightheadedness; drowsiness; difficulty falling asleep or staying 
asleep; burning or tingling in the arms or legs; cold symptoms; ringing in the ears; hearing 
problems. Serious side effects include: changes in vision; feeling that the tablet is stuck in 
your throat; unexplained weight gain; sore throat, fever, chills, and other signs of infection; 
blisters; rash; skin reddening; itching; hives; swelling of the eyes, face, lips, tongue, throat, 
arms, hands, feet, ankles, or lower legs; difficulty breathing or swallowing; hoarseness; 
excessive tiredness; pain in the upper right part of the stomach; nausea; loss of appetite; 
yellowing of the skin or eyes; flu-like symptoms; bruises or purple blotches under the skin; 
pale skin; fast heartbeat; cloudy, discolored, or bloody urine; back pain; difficult or painful 
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urination. In the event you experience these symptoms, you may request to stop or the 
researchers will stop your trial.  
 
There is a low probability that you experience a more serious risk during this study. Serious 
risks include, but are not limited to, heat illness and cardiac events. There is a risk of 
developing an exertional heat illness (for example, heat exhaustion and heat stroke) while 
exercising in a thermal environment. In the event that you experience symptoms of heat 
exhaustion, (nausea, vomiting, dizziness, etc.) you may request to stop or the researchers 
will stop your trial. In the case that you are suffering from a heat stroke, your trial will be 
immediately stopped and ice/cold water immersion will be available. Ice/cold water 
immersion is the best method available to quickly decrease the body’s Tc to a safe limit. 
The probability of developing a heat stroke during this study is minimal. We will 
continuously monitor Tc and cease the cycling protocol if and when you reach a Tc of 40°C 
(104°F) and/or when you begin to experience any of the symptoms mentioned above.  
 
As with any exercise, there is a small risk of a cardiac event due to an undetected cardiac 
condition. Heart rate will be monitored continuously and blood pressure will be monitored 
every 15 minutes to help ensure your safety. All investigators are American Red Cross 
AED, CPR Professional Rescuer and First Aid certified. 
 
Other risks of this study are general risks associated with exercise, such as muscle or tendon 
strains. Cycling is a low impact exercise and should minimize the risk of developing a 
muscle or tendon injury. There is no known risk for consuming the sugar solution.  
 
Risks of drawing blood include temporary discomfort from the needle stick, bruising, 
tenderness and infection. Fainting could also occur. OSHA guidelines will be followed to 
minimizing these risks. Investigators will abide by all OSHA guidelines and will be able 
to act if there is an emergency or other medical issue during the study.  
 
PARTICIPANT SAFETY 
In the event you experience a heat stroke there will be a cold/ice water tub available for 
immersion. Ice water immersion is the fastest and safest method to cool the body to a safe 
Tc. In the event that you experience a sudden stop in your heart, there is access to an 
Automated External Defribillator (AED), room 316 of the Public Health Research Center. 
All investigators are trained to use an AED and in CPR. If you experience any medical 
issues such as a heat illness or cardiac event as a participant in this study, the investigators 
will provide appropriate immediate care and you will be referred for additional medical 
treatment if necessary. However, in the event you suffer from a research related injury, 
there will be no financial compensation from the investigators or the University of South 
Carolina to assist with medical fees.   
 
The investigators will terminate your participation in the study, without your consent, if 
you suffer any symptoms or conditions that the investigators believe make it inadvisable 
for you to continue in the study. In the case of a trial being terminated due to adverse 
symptoms an incident report will be completed and given to the physician overseeing the 
study. In the case of trial termination due to mild symptoms (dizziness, nausea, headache, 
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etc.) the participant may choose to continue the trial at another date. However, the 
participant cannot continue until the physician has reviewed the incident report and deems 
it appropriate for the participant to continue with the study. In the case of a more severe 
incident (for example, heat stroke) the participant will not be allowed to continue in the 
study. 
 
PARTICIPANT PAYMENT 
As a participant in this study, you will have the opportunity to earn $100.00. Participants 
will be paid $20.00 at the completion of each trial, for a total of $80.00 ($20.00 x four 
trials). Upon completion of the fourth trial, each participant will be given $20.00 if he or 
she follows all study instructions and provides maximum effort during all exercise trials. 
 
BENEFITS 
Participating in this study will increase your awareness of personal hydration behaviors. 
Each participant will receive a personalized hydration protocol that includes fluid and 
electrolyte needs during exercise. The primary investigator will also be available to discuss 
the individual reports and answer any specific questions the participant has in regards to 
fluid and electrolyte needs during exercise. 
 
The information from this study will be helpful for competitive athletes as well as 
recreational athletes and athletic trainers regarding the use of NSAIDs in hot, humid 
environments.    
 
VOLUNTARINESS 
Participation is voluntary. You may decide not to participate at all, or to stop participating 
at any time, for any reason without negative consequences. Participants wishing to 
withdraw voluntarily from the study should notify the primary investigator (Dawn 
Emerson) by phone or email. Your participation, non-participation and/or withdrawal will 
not affect your grades or your relationship with your professors, college(s), or the 
University of South Carolina. 
 
QUESTIONS 
If you have any questions, please feel free to ask at any time. You should contact Dawn M. 
Emerson at (cell) (XXX) XXX-XXXX or (email) mintond@mailbox.sc.edu or Dr. Mark 
Davis at (office) (XXX) XXX-XXXX or (email) mard@mailbox.sc.edu if you have any 
questions or if you believe that you have suffered a research related injury.  
 
If you have any questions about your rights as a research subject contact, Lisa Marie 
Johnson, IRB Manager, Office of Research Compliance, University of South Carolina, 901 
Sumter Street, Byrnes 515, Columbia, SC 29208, Phone: (803) 777-7095 
or LisaJ@mailbox.sc.edu.  The Office of Research Compliance is an administrative office 
that supports the USC Institutional Review Board.  The Institutional Review Board (IRB) 
consists of representatives from a variety of scientific disciplines, non-scientists, and 
community members for the primary purpose of protecting the rights and welfare of human 
subjects enrolled in research studies. 
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SIGNATURES 
I have read the contents of this Consent Form.  The purpose of this study, procedures to be 
followed, risks and benefits have been explained to me. I have been allowed to ask 
questions, and my questions have been answered to my satisfaction. I have been told whom 
to contact if I have additional questions. I agree to participate in this study, knowing that I 
may withdraw at any time. I have been given a copy of this Consent Form to keep for my 
reference. 
 
_______________ 
Date 
______________________________ _____________________________ 
Signature of Participant    Name (Please Print)   
------------------------------------------------------------------------------------------------------------
I have explained and defined in detail the research procedure in which the participant has 
agreed to participate and have offered him a copy of this informed consent form.  
_______________ 
Date 
______________________________ _____________________________ 
Signature of Investigator   Name (Please Print)
 219 
 
APPENDIX B. HEALTH AND INJURY HISTORY QUESTIONNAIRE 
Instructions:  Complete the following questions the best of your knowledge/ability. Let 
the investigator know if you need further explanation. 
Part 1.  Participant Information 
Name: ________________________   Age: ______  Participant #: _____ 
Part 2. Physical Activity Readiness Questionnaire© (Canadian Society for Exercise 
Physiology) 
 Yes No 
1. Has your doctor ever said that you have a heart condition and that 
you should only do physical activity recommended by a doctor? 
    
2. Do you feel pain in your chest when you do physical activity?       
3. In the past month, have you had chest pain when you were not doing 
physical activity? 
    
4. Do you lose your balance because of dizziness or do you ever lose 
consciousness?  
    
5. Do you have a bone or joint problem (for example, back, knee or hip) 
that could be made worse by a change in your physical activity? 
    
6. Is your doctor currently prescribing drugs (for example, water pills) 
for your blood pressure or heart condition? 
    
7. Do you know of any other reason why you should not do physical 
activity?  
    
 
Part 3.  Medical History Explain “yes” answers below. (American Medical Society for 
Sports Medicine, American Orthopedic Society for Sports Medicine, American Heart Association, 
and American College of Sports Medicine) 
  Yes No 
8. Have you had a medical illness or injury since your last check up or 
sports physical? 
    
9. Do you have an ongoing chronic illness?      
10. Have you ever passed out during or after exercise?      
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11. Have you ever been dizzy or fainted during or after exercise?      
12. Have you had a medical illness or injury since your last check up or 
sports physical? 
    
13. Have you ever had pain, discomfort, tightness, or pressure in your 
chest during or after exercise? 
    
14. Do you get tired more quickly than your friends do during exercise?     
15. Have you ever had racing of your heart or skipped heartbeats? 
  
    
16. Have you had high blood pressure or high cholesterol?      
17. Have you ever been told you have a heart murmur?      
18. Has a physician ever denied or restricted your participation for sports 
or for any heart problems? 
    
19. Have you ever had a head injury or concussion?       
20. Have you ever been knocked out, become unconscious, or lost your 
memory? 
    
21. Have you ever had an unexplained seizure?     
22. Have you ever had numbness or tingling in your arms, hands, legs, 
or feet? 
    
23. Have you ever become ill from exercising in the heat?     
24. Do you cough, wheeze, or have trouble breathing during or after 
activity?   
    
25. Do you have diabetes?     
26. Do you have asthma or other lung disease?     
27. Do you smoke?     
28. Do you have or think you may have any bleeding disorders? 
 
    
29. Have you had any other problems with injury, surgery, pain or swelling 
in muscles, tendons, bones, or joints? 
    
If yes to question 29, check appropriate blank and explain below.   
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__ Head __ Elbow   __ Hip __ Foot     __ Upper Arm 
__ Neck __ Forearm __ Thigh __ Ankle     __ Shoulder      
__ Back __ Wrist __ Knee __ Shin/Calf     __ Finger  
__ Chest __ Hand  
Explain “Yes” answers here:   
   
   
30. Do you have, or think you may have, any of the following conditions? Check 
all that apply.  
  Nausea, vomiting, or other gastrointestinal disorders  
  
Obstructive disease of the gastrointestinal tract, such as diverticulitis 
or inflammatory bowel disease  
  A history of disorders or impairment swallowing or of the gag reflex  
  Any gastrointestinal surgery  
 Explain “Yes” answers here:   
   
   
31. Do you get frequent muscle cramps when exercising?   Yes   No 
32. Do you or someone in your family have sickle cell trait or disease?   Yes   No 
33. Have you ever experienced an exertional heat stroke or other 
significant heat illness?   Yes   No 
34. Are you currently taking any prescription medications, pills, or an 
inhaler?  
For example: Albuterol, Prednisone, Naproxen, etc. 
  Yes   No 
Explain “Yes” answers here:   
   
   
35. Are you currently and regularly taking any non-prescription (over-
the-counter) medications or pills?  
For example: Bayer, Prilosec, NyQuil, etc.   
  Yes   No 
Explain “Yes” answers here:   
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36. Are you currently and regularly taking any vitamins, supplements, 
or other substances?  
For example: multi-vitamin, iron, diet pills, energy drinks, protein 
powder, etc.   
  Yes   No 
Explain “Yes” answers here:   
   
   
*FEMALES ONLY*   
37. Is your menstrual cycle regular?     Yes   No 
38. Are you on birth control?   Yes   No 
39. Are you currently on your period?   Yes   No 
40. What is the date of your last period? 
  
 
I hereby state that, to the best of my knowledge, my answers to the above questions are 
complete and correct. 
 
_________________________        __________________________ ____________  
Signature of Participant   Printed Name of Participant  Date 
 
 
University of South Carolina 
Athletic Training Program 
Blatt PE Center 
Columbia, SC 29208
 223 
 
APPENDIX C. TAKE HOME INSTRUCTIONS 
C.1. First Trial Email to Participants 4 Days Prior to Data Collection 
Dear __________________,  
Thank you for participating in our study.  
Starting _____________ we ask you to begin recording your diet and physical activity. 
First, you must initiate your account. 
You will need to register on FoodProdigy.  Use this online system to record all your daily 
intake of food and drinks as well as exercise and physical activity. This will allow us to 
look at your current habits throughout the study and mimic these for each trial. If you 
wish, you can receive a more detailed report of your information at the conclusion of the 
study.  
                                              
To get started:  
1.    Go to www.foodprodigyonline.com/ui/registration and type in your email address.  
2.    Enter a unique Password.  
3.    Enter this Subscription ID: ______________________  
4.    Go to www.foodprodigyonline.com. Use the email and password you registered with 
to log in to this account.  
                                                      
Use the FoodProdigy™ program to enter your diet and exercise information for 4 days. 
At the conclusion of the 4th day send your report to our co-investigator - Dr. Toni Torres-
McGehee - using FoodProdigy. You will see a link that states e-mail Toni Torres-
McGehee.  
We recommend you save a copy of the report for yourself so you can refer back to it. 
 
Remember things to avoid during this time: 
Red meat  
Prescription or non-prescription NSAIDs 
Strenuous exercise 
 
If you have any questions regarding FoodProdigy or completing the diet/activity log in 
general, please feel free to contact myself or Dr. Torres-McGehee. 
 
Please to arrive to the lab on ______________ at _______________ to pick up your 
pre-trial information. Attached to this email are directions to the Public Health 
Research Center. 
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Contact us immediately if you must reschedule your appointment or if you have any 
questions or concerns.   
 
Sincerely, 
Dawn M. Emerson 
 
Toni M. Torres-McGehee 
Associate Professor/Graduate AT Program Director 
University of South Carolina 
Blatt PE Center 218 
Columbia, SC 29208 
 
C.2. Reminder Email to Participants to Register and Complete Diet/Activity Log 
 
Dear _________________, 
 
This is a reminder to register for FoodProdigy and begin today to record your daily diet 
and physical activity. You may stop recording ______________ and then send your 
report to Dr. Torres-McGehee. 
 
Please let me know if you have any questions regarding FoodProdigy or your daily 
diet/activity log. 
 
Sincerely, 
Dawn M. Emerson 
 
C.3. Subsequent Trials Email to Participants 4 Days Prior to Data Collection 
Dear __________________,  
Starting _______________ we ask you to begin recording your diet and physical 
activity.  
You must remember your login information for FoodProdigy 
(www.foodprodigyonline.com).  Use the FoodProdigy program to enter all your daily 
intake of food and drinks as well as exercise and physical activity for 4 days. You will 
need to overwrite/clear your previous entries.  
At the conclusion of the 4th day send your report to our co-investigator - Dr. Toni Torres-
McGehee - using FoodProdigy. You will see a link that states e-mail Toni Torres-
McGehee. 
Remember things to avoid during this time: 
Red meat  
Prescription or non-prescription NSAIDs 
Strenuous exercise 
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If you have any questions regarding FoodProdigy or completing the diet/activity log in 
general, please feel free to contact myself or Dr. Torres-McGehee. 
 
Please to arrive to the lab on ______________ at _______________ to pick up your 
pre-trial information. 
Attached to this email are directions to the Public Health Research Center. 
Contact us immediately if you must reschedule your appointment or if you have any 
questions or concerns.   
 
Sincerely, 
Dawn M. Emerson 
 
Toni M. Torres-McGehee 
Associate Professor/Graduate AT Program Director 
University of South Carolina 
Blatt PE Center 218 
Columbia, SC 29208 
 
C.4. Pre-Data Collection Take Home Instructions 
Thank you for participating in our research investigation! 
 
Arrive to the lab on ______________________________, at your scheduled time 
________________. 
What should I wear? 
Athletic shorts, a t-shirt, socks, and a pair of athletic shoes 
Optional things I can bring? 
Change of clothes and a towel for after exercising 
A computer, book, or other material to use while you rest 
What should I eat or drink before I come?  
About 2 hours before coming to the lab you should eat a small meal (bagel, 
peanut butter and jelly, etc.)  
We also ask that you arrive hydrated by drinking water  
What things should I avoid during this time? 
Alcohol   Non-prescription medications 
Energy supplements  Dehydrating behaviors (sauna, diuretics, etc.) 
Exercise   Changes in your sleep or eating habits 
What else do I need to do? 
Attached to this letter is: 
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1. An envelope with 2 pills 
 Take 1st pill at __________ 
 Take 2nd pill at ___________  
Directions for taking pills: 
 Take each pill with a glass of water 
 Do NOT take with food 
2. A bag with a fecal test kit 
 Collect one fecal sample before you come to the lab 
Directions:  
Take card out of the bag and open the card. Apply a THIN smear of specimen 
on ONE window.  
 
Do NOT cover 
the entire 
window. 
Close the card and place back in bag. Throw away used stick. 
 
3. A parking pass that you MUST bring with you to park at the Public Health 
Research Building. Use the handicap spaces on the left side of the parking lot 
behind the building. 
 
Please contact us immediately if you need to reschedule your appointment or if you have 
any questions or concerns.   
 
Sincerely, 
Dawn M. Emerson 
 
C.5. Post-Data Collection Take Home Instructions 
We have a few things for you to complete after you leave the lab today.  
1. Continue recording your diet and activity using the online program until you 
collect your next fecal sample.  
 
2. Using your fecal take home test kit, please collect your first fecal sample after 
leaving the lab 
Directions:  
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Take card out of bag and open the card. Apply a THIN smear of specimen 
to the SECOND window.  
 
Do NOT cover the 
entire window. 
Do NOT pull the tab or alter the card in any other way. Close the card and 
place back in bag 
 
3. At the time of your fecal sample, complete the Gastrointestinal Symptom Index 
attached to this letter. 
 
4. Return the fecal test kit and questionnaire by placing both items in the bag.  
Return the bag on __________________ at _________________. At this time 
you will receive your payment. 
 
Please contact us immediately if you need to reschedule your appointment or if you have 
any questions or concerns.   
 
Thank you for your participation, 
Dawn M. Emerson
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APPENDIX D. GASTROINTESTINAL SYMPTOM INDEXES 
D.1. GI Symptom Index during Exercise 
Are you CURRENTLY experiencing GI symptoms? 
0 No problem at all 
1  
2  
3  
4  
5  
6  
7  
8  
9 Worst it has ever been 
 
Reflux/Heartburn Left abdominal pain/stitch 
Belching Right abdominal pain/stitch 
Bloating Loose stool 
Stomach pain/cramps Diarrhea 
Vomiting Dizziness 
Nausea Headache 
Intestinal cramps Muscle cramps 
Flatulence Urge to urinate 
Urge to defecate  
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D.2. GI Symptom Index Pre- and Post-Exercise 
Participant Number: ____  Trial Number: ____   Date: ______________ Time: ____________ 
Directions: Please circle the number that corresponds to symptoms you are currently experiencing. 
 
 No 
problem 
at all 
        
Worst it 
has ever 
been 
Reflux/Heartburn 0 1 2 3 4 5 6 7 8 9 
Belching 0 1 2 3 4 5 6 7 8 9 
Bloating 0 1 2 3 4 5 6 7 8 9 
Stomach pain/cramps 0 1 2 3 4 5 6 7 8 9 
Vomiting 0 1 2 3 4 5 6 7 8 9 
Nausea 0 1 2 3 4 5 6 7 8 9 
Intestinal cramps 0 1 2 3 4 5 6 7 8 9 
Flatulence 0 1 2 3 4 5 6 7 8 9 
Urge to defecate 0 1 2 3 4 5 6 7 8 9 
Left abdominal pain/stich 0 1 2 3 4 5 6 7 8 9 
Right abdominal pain/stich 0 1 2 3 4 5 6 7 8 9 
Loose stool 0 1 2 3 4 5 6 7 8 9 
Diarrhea 0 1 2 3 4 5 6 7 8 9 
Dizziness 0 1 2 3 4 5 6 7 8 9 
Headache 0 1 2 3 4 5 6 7 8 9 
Muscle cramps 0 1 2 3 4 5 6 7 8 9 
Urge to urinate 0 1 2 3 4 5 6 7 8 9 
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APPENDIX E. DATA COLLECTION PROCEDURE CHECKLISTS 
 
E.1. Information Session 
 
30 minutes prior to participant arrival 
□ Set out: 
o Informed Consent Form 
o Second ICF signature sheet 
o Information Session sheet 
o Health and Injury History Questionnaire 
o Serving Size document 
o Pens 
o Computer 
 Ensure internet access 
 Logon to FoodProdigy 
o Stethoscope and BP cuff 
o If doing V̇O2max Test 
 Tanita scale 
 See V̇O2max Procedures 
 
Participant arrival 
□ Provide participant with ICF and second signature sheet 
□ Primary investigator reviews ICF and answers any questions 
□ Gather signed participant ICF 
□ Instruct participant to complete Health and Injury History Questionnaire 
□ Review information on diet/physical activity logging, show FoodProdigy online 
program 
o Review serving size document and give copy 
□ Assess participant’s resting HR and BP 
□ Gather participant’s self-reported height 
o Convert to cm (1 foot = 30.48 cm) 
□ If scheduled/able conduct V̇O2max test 
□ If not, schedule V̇O2max test 
□ Gather general information about available days/times to conduct data collection 
□ Provide Take Home Instructions if applicable 
 
E.2. V̇O2max Testing 
 
(30 minutes prior to participant arrival) 
□ Ensure room is at appropriate thermoneutral temperature 
□ Obtain equipment:
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o Bike  
o Heart rate strap 
o Heart rate monitor 
o RPE scale 
o Metronome 
o Pen 
o Tanita scale 
o “Information Session” sheet 
o Water bottle for after test 
□ Ensure Monark is working (batteries in computer), pedals, break system, etc. 
 
Participant Arrival 
□ Ensure participant is dressed appropriately 
□ Verbally inquire/verify participant has not eaten immediately before coming, 
received an appropriate amount of sleep and has not performed strenuous exercise 
within 24 hours 
□ Request participant remove shoes and socks 
o Take weight measure 
□ Give participant HR strap and ensure working 
□ Allow participant to sit and rest while you complete the following: 
□ Briefly explain the purpose of the test in layman terms 
o Aerobic fitness level 
o Measurement of the maximal amount of oxygen one can consume 
o Relative measure of the amount of endurance work one can perform 
o Done in all professional endurance athletes 
o Describe range of values for V̇O2 max and what our criteria is 
o Encourage your subject to ask questions before you move on 
□ Explain the cycling protocol 
o Cycle to complete exhaustion (physical fatigue) 
o Minutes per stage 
o Incremental increases in resistance 
o Speed should be constant throughout the study (50rpm) 
o Describe the physiological measurement including heart rate and RPE 
 Rate of perceived exertion (RPE) 
• Describe this chart very clearly to participant  
 ‘During the exercise test we want you to pay close attention to 
how hard you feel the exercise work rate is. This feeling should 
reflect your total amount of exertion, and fatigue, combining all 
sensations and feelings of physical stress, effort and fatigue. 
Don’t concern yourself with factors such as leg pain, shortness 
of breath or exercise intensity, but try to concentrate on your 
total inner feeling of exertion. Try not to underestimate or 
overestimate your feelings of exertion. Be as accurate as you 
can.’ - ACSM 
o Repeat: Cycle to complete exhaustion (physical fatigue) 
□ Explain termination criteria 
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o Onset of angina or angina-like symptoms 
o Signs of poor perfusion: lightheadedness, ataxia, pallor, nausea, cold and 
clammy skin 
o Failure of HR to increase with increasing exercise intensity 
o Participant requests to stop 
o Failure of testing equipment 
o Participant cannot keep up cadence (50 RPM) during stage 
□ Encourage your subject to ask questions about this section before you move on 
□ Assess participant’s resting HR and blood pressure 
 
Running the V̇O2max test 
□ Position participant on bike 
o Seat height (5-10 degrees knee flexion at bottom position) 
o Handle bar setting 
o Make sure participant is comfortable before starting! 
o Record corresponding seat and bar height/position 
□ Explain clearly to subject that he/she will follow the metronome beeps for the 
cadence  
□ Ensure bike is set to 0 kp and allow participant to warm up for 2 minutes at set 
cadence 
□ Increase resistance (kp/watts) every 2 minutes as corresponding on the 
Information Sheet 
□ Record heart rate and RPE at the end of each stage 
□ You may provide encouragement to the participant, but this must be consistent 
between participants!  
 
Ending V̇O2 max Test 
□ Once participant reaches termination criteria, immediately record heart rate, RPE, 
and time 
□ Immediately decrease/remove resistance 
□ Allow participant to actively cool down for 3-5 minutes 
□ Monitor heart rate to ensure it decreases appropriately 
□ Provide water to participant 
 
Criteria for reaching V̇O2 max 
□ Maximal heart rate within 10 beats of age-predicted max heart rate 
□ RPE > 17 
 
Calculate V̇O2max on data sheet 
Must be between ~ 40-50 ml/kg/min for males based on age and 31-40 ml/kg/min for 
females based on age and cycling vs running*  
 
E.3. Pre-Trial Appointment 
 
30 minutes before participant arrival 
□ Prepare Pre-Trial Take Home Instructions 
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o Fill out report time and date 
o Envelope with 2 pills 
o Fill out time to take each pill 
o Bag with fecal occult blood test and two sample collection sticks 
o Dated parking pass 
 
Participant arrival 
□ Thoroughly review Take Home instructions with participant 
□ Answer any questions 
 
E.4. Post-Trial Appointment 
 
15 minutes before participant arrival 
□ Obtain participant payment 
□ Fill out receipt book 
 
Participant arrival 
□ Obtain fecal occult blood test and GI Symptom Index 
□ Give participant money 
□ Have participant sign receipt book and provide participant with receipt 
□ Verify next trial appointment 
 
E.5. Data Collection Session 
 
60-90 minutes before participant arrival 
□ Verify chamber is set to appropriate temperature 
o Thermal: 35°C/95°F, 30% RH 
 If 32.5 then set humidity to 50% 
o Thermoneutral: 15°C/59°F, 30%RH  
 If in room 317 check temperature 
□ Set out following equipment: 
o Blood collection  
 Label 2 pink 6ml tubes for each blood time point (8 total) 
• Participant #, Trial #, pre 
• Participant #, Trial #, 80 min 
• Participant #, Trial #, post 
• Participant #, Trial #, 3hr post  
 
 
 
 
 Styrofoam cooler 
• Fill ¾ with ice 
o Gloves 
o Sugars 
  
#1 
Trial 1 
3hr Post 
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o Urine volume containers and 3 cups 
 Label cups:  
• Participant #, trial #, pre 
• Participant #, trial #, post 
• Participant #, trial #, 3hr post 
o 3 gallon cooler 
 Fill with ice and water 
o 1 water bottle with cap, 1 water bottle without cap 
o Graduated cylinder for water 
o 3rd pill 
o White plastic container with ice for urine 
o HR monitor and strap 
o Stop watch 
o RPE chart 
o GI symptom chart 
o GI Symptom Index  
o Refractometers 
 2 clinical, 1 pen, and 1 digital 
o Pens and sharpies 
o Clipboards 
o Pre Post Data Collection sheet and Cycling Protocol sheet 
o 2.0ml microtubes 
 Label 4 urine tubes 
• Participant #, Trial # 
 Label minimum 2 plasma tubes for each blood time point 
(minimum 8 total) 
• Participant #, Trial #, pre 
• Participant #, Trial #, 80 min 
• Participant #, Trial #, post 
• Participant #, Trial #, 3hr post  
o Distilled water 
o Disposable pipettes 
o Kestrel environmental monitor 
o Rectal temperature probe and reader 
o Tanita scale 
o Ice chest and tarp 
 Fill chest with ice and place with tarp in men’s or women’s 
locker room 
□ Bike 
o Calibrate Computrainer See Procedures OR 
o Calibrate Monark See Procedures 
o Set bike up to participant’s previously determined set-up 
□ Set up Kestrel in chamber (or room 317) to verify environment 
□ Calibrate refractometers 
o Clinical refractometers 
#6 
Trial 2 
#4 
Trial 3 
#1 
Trial 2 
3hr post 
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 Using a disposable pipette, put 2 drops of distilled water onto 
prism 
 Close cover plate 
 Hold up to light 
 Adjust the correcting screw to make light/dark boundary 
coincide at 1.000 
o Pen refractometer 
 Turn Pen on 
 Using a cup of distilled water, place end of pen into water 
• Ensure prism is covered by water 
 Wait for reading 
 If not 0, press ZERO to calibrate 
o Digital refractometer 
 Turn refractometer on 
 Using disposable pipette, pipette distilled water on prism 
 Wait for reading 
 If not 0, press ZERO to calibrate 
□ Check centrifuge and set up if necessary 
□ Prepare sugar solution 
o 5g lactulose, 5g sucrose, 2g mannitol powder mixed with 150ml water 
□ Prepare water to be consumed during exercise 
o 3.5ml/kg every 15 minutes 
o Measure from 3 gallon cooler into graduated cylinder 
o Pour into designated water bottle 
o Set aside bottle without cap to be used to refill participant bottle 
 
Participant arrival 
□ Confirm participant 
o Consumed a light breakfast and water 
o Consumed 2 pills at assigned times 
o Dressed appropriately 
o Inquire if participant has been logging diet/activity and collected 1 fecal 
sample 
□ Primary investigator inserts venous catheter and takes 2 6ml vials for pre-trial 
measure 
□ Give participant HR strap and ensure monitor is reading HR 
□ Give participant 3rd pill to consume with water 
□ Participant complete GI Symptom Index 
□ Assess pre-trial HR and BP 
□ Provide participant with urine cup and rectal probe 
o Instruct participant to provide pre-trial urine sample into cup, and to 
completely void bladder the rest of the way into the toilet 
o Instruct participant to insert rectal probe approximately 10cm past the anal 
sphincter (to marked line on probe) 
□ Measure urine specific gravity using clinical refractometer to ensure participant is 
< 1.020 
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□ Measure participants pre-trial body mass 
o Shirt and shorts 
o NO shoes and socks 
□ Measure pre-trial core body temperature  
□ Provide participant with sugar solution and instruct to consume within 5 minutes 
□ Explain fluid consumption during trial 
o “You will be provided with a designated amount of water in a bottle. We 
have superficially measured out this amount of water for you in order to 
ensure you maintain hydration. You are to consume the entire contents of 
the bottle, (their specific volume) ml, every 15 minutes. We encourage 
you to drink a little bit throughout the entire 15 minutes and to not wait till 
the end to consume the whole amount. At the end of each 15 minute 
increment we will provide you with more water.” 
o Answer any questions regarding this 
□ Take participant into chamber and orient him/her to the bike and room 
□ Explain cycle exercise 
o “Based on your VO2max test you will need to bike at an intensity that 
elicits a HR at their HR corresponding to 70% VO2max. We have set up the 
bike for you. This display shows your rpm and time. Here is the HR 
monitor. You will bike at this workload and HR for 80 minutes. Every 15 
minutes we will ask you RPE (show scale) GI symptoms (explain scale), 
take BP and refill your water bottle. We will have the probe plugged into 
the monitor so we can continuously monitor your core temperature and we 
can also continuously monitor your HR. At the end of the 80 minutes we 
will collect 2 6ml vials of blood.” 
o Answer any questions up to this point. 
o “At the end of 80 minutes we will ask you to finish the last 10 minutes of 
the cycle exercise in an ‘all-out effort’. Consider it a sprint to the finish. 
You want to go as fast and far as you can in 10 minutes.” 
o Answer any questions up to this point. 
□ Record environment on Data Collection Cycle Protocol sheet 
o Check environment post-cycle, if different record on sheet 
 
□ Co-investigators may run analysis and spin blood during cycle protocol 
o Follow Blood Mapping for appropriate procedures on handling, preparing, 
and freezing blood and plasma samples 
o Analyze urine samples with refractometers and record on Pre Post Data 
Collection sheet 
 
Cycle Protocol 
□ Instruct participant to get on bike 
o Ensure participant is comfortable on the bike 
□ Allow participant to warm-up for 3 minutes 
o Answer any questions at this point and ensure their comfort 
o Check core temperature and HR are being monitored 
□ At 2.5 minutes measure time point 0 
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o Core temperature 
o HR 
o BP 
o RPE 
o GI symptoms 
□ Begin 70% VO2max/HR portion 
o 5 minutes record core temperature, HR, RPE, and GI symptoms 
 Remind participate to consume fluids 
o 10 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 15 minutes record core temperature, HR, BP, RPE, and GI symptoms 
 Refill water bottle with designated fluid volume 
o 20 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 25 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 30 minutes record core temperature, HR, BP, RPE, and GI symptoms 
 Refill water bottle with designated fluid volume 
o 35 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 40 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 45 minutes record core temperature, HR, BP, RPE, and GI symptoms 
 Refill water bottle with designated fluid volume 
o 50 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 55 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 60 minutes record core temperature, HR, BP, RPE, and GI symptoms 
 Refill water bottle with designated fluid volume 
o 65 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 70 minutes record core temperature, HR 
 Remind participate to consume fluids 
o 75 minutes record core temperature, HR, BP, RPE, and GI symptoms 
 Refill water bottle with designated fluid volume 
o 80 minutes record core temperature, HR, RPE, and GI symptoms 
 Take blood sample 
• Flush catheter with saline 
 Record starting distance 
o 85 minutes record core temperature, HR 
o 90 minutes record core temperature, HR, BP, RPE, and GI symptoms 
 Record end distance 
□ Allow participant to actively cool down for 5 minutes 
o Take post-cycle blood measure 
 Flush catheter 
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o Allow to consume fluid and refill bottle if necessary 
o Monitor and record HR and core temperature 
□ At end of 5 minutes remove from bike 
□ Instruct participant to towel off any sweat and remove shoes and socks 
□ Weigh participant 
□ Allow to rest for 10 minutes 
o Record HR and core temperature 
o Instruct to complete post- GI Symptom Index 
□ Provide urine cup and urine volume container 
o Instruct participant to provide small sample in urine cup 
o Instruct participant to completely void urine into the large urine container 
 “Please Do NOT void into the toilet/urinal”  
o Place urine volume container in white tub with ice 
□ Participant may remove rectal thermometer 
o If participant chooses to remove it, remind them a final core temperature 
must be taken at the end of the 3 hours 
□ Participant may change clothes at this point 
o Instruct them to take care to not pull out the catheter  
o Instruct them to complete this as efficiently as possible to avoid an 
extended period in the locker room/restroom 
□ While participant is gone 
o Prepare fluid to be consumed during rest (provide amount enough ½ hour) 
□ Once participant returns 
□ Once finished participant rests for 3 hours 
o Remind participant to consume fluids regularly to promote hydration and 
urine volume 
o Instruct participant that any time he/she needs to void urine it must be 
done in the urine volume container 
o He/she is permitted to work, read, or watch something to occupy 
themselves over the next 3 hours; however, he/she cannot leave and 
should not be up being active 
□ Every 1 hour venous catheter should be flushed and water bottle refilled 
□ Approximately ten minutes before the end of the rest 
o Provide GI Symptom Index 
o Review Post-Trial Take Home Instructions 
 Provide GI Symptom Index 
 Set up return appointment 
o Obtain 2 6ml vials of blood 
 Remove catheter 
o Weigh 
o Core temperature (unless not inserted, then must reinsert and measure at 
end of rest) 
□ At end of rest 
o Obtain urine sample in urine cup and void any remaining urine into urine 
volume container 
o Instruct participant to remove rectal probe 
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□ Answer any questions and finalize session 
 
Post-trial  
□ Centrifuge all blood 
o Follow Blood Mapping 
□ Record total urine volume  
o Pipette aliquots of urine into the 4 microtubes to be frozen 
□ Record total fluid volume consumed 
□ Ensure all blood and urine samples are in freezer and appropriately labeled 
□ Ensure all biohazard/sharps are appropriately disposed of 
□ Clean all equipment 
o Water bottles 
o Wipe down bike 
o Rectal probe 
o Counters and tables 
o Cooler and cylinder (end of day) 
□ Put away all equipment 
o Kestrel 
o Scale 
□ Ensure data sheets are all in box 
□ Turn off all equipment and lock up all labs 
 
Miscellaneous 
□ Avoid providing food unless participant absolutely is in need of food. In these 
instances, attempt to provide non-sucrose containing foods 
 
In Case of Emergency 
□ Immediately notify primary investigator if not currently involved with incident 
□ Cardiac 
o Call 911, obtain AED from room 317 
o Begin CPR 
□ Exertional heat stroke 
o Confirm heat stroke 
 CNS dysfunction and core temperature above 104°F/40°C 
o Immediately remove from environmental chamber and into locker room 
o Lay out tarp and place participant on tarp 
o Turn on cold water in shower 
o Dump ice over participant 
o Monitor core temperature and HR 
□ As soon as possible, call supervising physician 
o Dr. Brian Kiesler  
□ Notify supervising faculty advisor  
o Dr. Mark Davis 
□ Complete incident report.  
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APPENDIX F. ADDITIONAL TABLES AND FIGURES 
 
 
Figure F.1. Male Mean Core Temperature during Cycling and Rest for Experimental Conditions 
No significant differences between conditions at any time point
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Figure F.2. Female Mean Core Temperature during Cycling and Rest for Experimental Conditions 
No significant differences between conditions at any time point.
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Figure F.3. Mean Core Temperature during Cycling and Rest for Gender. 
aSignificant difference between gender (P < 0.05).  
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Figure F.4. Mean IL-6 Pre-, Post-, and 3 Hours Post-Cycling for Males. 
N = 4. Significant main effect for each condition (P < 0.04). aSignificantly greater than pre (P = 0.014) and 3 hr 
post (P = 0.038). bSignificantly greater than pre (P = 0.042).
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Figure F.5. Mean IL-6 Pre-, Post-, and 3 Hrs Post-Cycling for Females. 
N = 3. Significant main effect for Control (P = 0.022) and Npx (P = 0.017). aSignificantly greater than 3 hr (P = 
0.046). bSignificantly greater than pre (P = 0.015). 
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Table F.1. Fluid Volume and Urine Volume for Gender by Experimental Conditions 
(M + SD) 
  Fvol (L)  Fvol (ml/kg)  Uvol (L) 
 Exercise Total  Exercise Total  
Aggregate        
Males 1.7 + 0.7a 2.5 + 1.3a  19.0 + 6.5 27.5 + 11.9  1.1 + 0.6 
Females 1.1 + 0.5 1.7 + 0.7  16.3 + 5.9 24.1 + 7.2  0.9 + 0.4 
Control        
Males 1.3 + 0.5 1.9 + 0.7  14.1 + 3.4 20.3 + 5.7  1.2 + 0.8 
Females 1.0 + 0.3 1.5 + 0.6  14.4 + 5.5 22.8 + 8.0  1.1 + 0.5 
Npx        
Males 1.9 + 1.0b 2.8 + 1.8  20.7 + 8.8 30.8 + 16.8  1.3 + 0.6 
Females 0.9 + 0.5 1.4 + 0.7  12.1 + 5.0 20.1 + 7.1  0.8 + 0.5 
Heat        
Males 1.7 + 0.7 2.5 + 1.2  18.8 + 5.3 27.4 + 10.1  1.1 + 0.6 
Females 1.4 + 0.4 1.9 + 0.7  20.7 + 4.6 27.2 + 6.1  0.8 + 0.3 
HeatNpx        
Males 2.0 + 0.6a 3.0 + 1.4  22.5 + 5.4 32.0 + 12.8  0.9 + 0.1 
Females 1.3 + 0.5 1.9 + 0.9  17.9 + 5.9 26.4 + 7.4  0.7 + 0.3 
        
aSignificantly higher than females (P < 0.05). bApproached significance (P = 0.055). 
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Figure F.6 Mean Systolic BP Pre-, Post-, and 3 Hrs Post-Exercise for Experimental Conditions by Gender. 
Significant main effect over time (F2,40 = 37.0, P < 0.001) for males (a) and females (b). aSignificantly higher than 
female Npx post (F1,10 = 8.5, P = 0.017). bSignificantly higher than female NpxHeat post (F1,10 = 5.8, P = 0.043). 
cSignificantly higher than female Heat 3 hrs (F1,10  = 6.9, P = 0.028). 
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Table F.2. Diet and Exercise Overall and for Gender (M + SD). 
  Aggregate (N = 22) Males (N = 14) Females (N = 8) 
Calories (kcal) 1522.2 + 388.0 1660.1 + 379.6b 1280.9 + 281.8 
Protein (g) 67.3 + 21.6 75.9 + 19.6b 52.3 + 16.6 
Fat (g) 48.1 + 19.9 51.4 + 22.9 42.3 + 12.5 
Carb (g) 194.5 + 62.7 206.7 + 73.0 173.0 + 32.9 
Sodium (mg) 2401.1 + 759.2  2650.9 + 853.7b 1964.0 + 180.0 
Exercisea 260.4 + 78.9 226.0 + 29.1 303.5 + 105.0 
    
N = number of logs reported (22/44). aBased on calories burned during activity 24 hrs 
prior to data collection. All reported activity categorized as low-sedentary. 
bSignificantly greater than females (P < 0.04). 
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Table F.3. Rate of Perceived Exertion during Cycling for Gender by Experimental Condition (M + SD) 
Cycle 
time 
(min) 
Aggregate 
 
Control 
 
Npx 
 
Heat 
 
NpxHeat 
Male Female  Male Female  Male Female  Male Female  Male Female 
0 8 + 2a 10 + 2  8 + 2 9 + 2  8 + 3 10 + 3  8 + 3 10 + 3  7 + 1b 9 + 2 
15 9 + 3a 11 + 2  10 + 3 12 + 1  10 + 2 11 + 3  8 + 3 11 + 2  9 + 3 11 + 2 
30 10 + 3 12 + 2  11 + 4 11 + 2 
 11 + 2 11 + 3  9 + 3 12 + 1  10 + 3 12 + 2 
45 11 + 3 12 + 2  11 + 3 13 + 1  12 + 2 11 + 3  10 + 2 12 + 1  11 + 3 12 + 2 
60 11 + 2 12 + 2  11 + 3 12 + 1  12 + 2 11 + 3  11 + 2 12 + 2  12 + 2 12 + 1 
75 12 + 2 12 + 2  12 + 3 13 + 2  12 + 3 12 + 3  11 + 2 13 + 1  11 + 2 12 + 2 
80 12 + 2 13 + 2  12 + 2 14 + 2  12 + 3 13 + 2  12 + 2 13 + 1  12 + 2 13 + 2 
90 19 + 2a 18 + 2  19 + 2 18 + 2  20 + 1 18 + 2  19 + 2 18 + 2  19 + 2 18 + 2 
               
No significant difference between experimental conditions within gender. aSignificantly different than females (P < 0.03). 
bSignificantly less than females (P = 0.03). 
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Table F.4. Distance and Max Heart Rate during Cycling for 
Gender by Experimental Condition (M + SD) 
  Distance (miles)  Max HR (bpm) 
Aggregate    
Males 3.2 + 0.7  177.2 + 17.1 
Females 2.8 + 0.9  177.2 + 15.0 
Control    
Males 3.4 + 0.8  175.0 + 16.6 
Females 2.9 + 0.9  176.6 + 12.7 
Npx    
Males 3.5 + 0.7  179.5 + 15.1 
Females 3.0 + 1.0  172.2 + 15.5 
Heat    
Males 3.0 + 0.7  176.3 + 20.2 
Females 2.7 + 1.0  179.6 + 17.6 
NpxHeat    
Males 3.0 + 0.8  178.0 + 20.3 
Females 2.5 + 0.9  180.2 + 17.2 
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Table F.5. Mean, Maximum, and Serious (> 4) Gastrointestinal Symptom Scores for Experimental Conditions 
Condition 
Upper  Lower  Systemic 
Max Mean + SD Serious  Max Mean + SD Serious  Max Mean + SD Serious 
Control            
Pre 2 0.1 + 0.1b -  2 0.0 + 0.1 -  1 0.1 + 0.1f - 
Post 2 0.2 + 0.2 -  2 0.1 + 0.1 -  8 0.9 + 0.9 6% 
3hr Post 5 0.2 + 0.3 3%  3 0.2 + 0.2d,e -  5 0.7 + 0.7j 6% 
Day Postk - - -  5 0.3 + 1.0 3%  2 0.2 + 0.5 - 
Npx            
Pre 2 0.1 + 0.1 -  1 0.0 + 0.1 -  2 0.2 + 0.3 - 
Post 2 0.1 + 0.2 -  2 0.0 + 0.1 -  7 0.6 + 0.6g 5% 
3hr Post 2 0.0 + 0.1 -  1 0.0 + 0.1 -  2 0.1 + 0.2 - 
Day Postk - - -  4 0.2 + 0.8 -  - - - 
Heat            
Pre 0 0.0 + 0.0a -  1 0.0 + 0.0 -  3 0.2 + 0.3 - 
Post 2 0.3 + 0.3c -  2 0.1 + 0.1 -  8 0.7 + 0.9h 3% 
3hr Post 1 0.0 + 0.1a -  2 0.1 + 0.1 -  6 0.4 + 0.6 3% 
Day Postk 6 1.3 + 2.5 18%  6 1.9 + 2.4 6%  6 1.3 + 2.2 5% 
NpxHeat            
Pre 2 0.1 + 0.2 -  1 0.0 + 0.0 -  5 0.3 + 0.6 3% 
Post 2 0.2 + 0.3 -  1 0.0 + 0.1 -  3 0.3 + 0.4i - 
3hr Post 4 0.1 + 0.2 -  2 0.1 + 0.1 -  3 0.2 + 0.2 - 
Day Postk 3 0.1 + 0.6 -  7 0.7 + 2.1 12%  2 0.1 + 0.5 - 
aSignificantly less than Heat post (Z = -2.3, P < 0.019). bSignificantly greater than Heat pre (Z = -2.1, P = 0.038). cSignificantly 
greater than Npx post (Z = -2.2, P = 0.027). dSignificantly greater than Npx 3hr (Z = -2.0, P = 0.048), HeatNpx 3hr (Z = -2.4, P = 
0.014). eSignificantly greater than Control pre (Z = -2.4, P = 0.016), post (Z = -2.1, P = 0.039). fSignificantly less than post (Z = -
2.4, P = 0.018), 3hr post (Z = -2.2, P = 0.026). gSignificantly greater than 3hr (Z = -2.1, P = 0.035). hSignificantly greater than pre 
(Z = -2.0, P = 0.042). iSignificantly less than Control post (Z = -2.0, P = 0.046). jSignificantly greater than Npx 3hr (Z = -2.4, P = 
0.018), Heat 3hr (Z = -2.0, P = 0.042). kVarying sample size (n = 3-5) and not included in Wilcoxon analysis. 
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Table F.6. Mean and Serious (> 4) Gastrointestinal Symptom Scores for Experimental 
Conditions during Exercise 
 
Condition Upper  
 Lower  Systemic 
Mean + SD Serious  Mean + SD Serious  Mean + SD Serious 
Control 0.3 + 0.6 1%  0.4 + 0.8 -  0.3 + 0.4 10% 
Npx 0.4 + 0.7 1%  0.1 + 0.3 -  0.2 + 0.3 10% 
Heat 0.6 + 1.0 3%  0.3 + 0.6 -  0.1 + 0.3 7% 
NpxHeat 0.3 + 0.9 2%  0.3 + 0.7 -  0.0 + 0.8a 1% 
         
aSignificantly less than Control (Z = -2.0, P = 0.046).  
